<center>Comprehensive Invited Review</center>

Oxygen in metabolic dysfunction and its therapeutic relevance

Amaya Lopez-Pascual [1,2], Paul Trayhurn [3,4], J. Alfredo Martínez [1,5,6,7], Pedro González-Muniesa [1,5,6 ✉]

[1] University of Navarra, Department of Nutrition, Food Science and Physiology, Centre for Nutrition Research, School of Pharmacy and Nutrition, Pamplona, Spain

[2] Lund University, Neuroendocrine Cell Biology, Lund University Diabetes Centre, Malmö, Sweden

[3] University of Liverpool, Obesity Biology Unit, Liverpool, United Kingdom

[4] The University of Buckingham, Clore Laboratory, Buckingham, United Kingdom

[5] IdiSNA Navarra's Health Research Institute, Pamplona, Spain

[6] CIBERobn Physiopathology of Obesity and Nutrition, Centre of Biomedical Research Network, ISCIII, Madrid, Spain

[7] IMDEA Food, Madrid Institute for Advanced Studies, Precision Nutrition and Cardiometabolic Health, Madrid, Spain

✉ Correspondence to Dr Pedro González-Muniesa, Centre for Nutrition Research/Department of Nutrition, Food Science and Physiology, Universidad de Navarra, Edificio de Investigación, C/ Irunlarrea 1, Pamplona 31008, Navarra, Spain; Tel.: +34 948 425 600 Ext.: 806650. E-mail: pgonmun@unav.es

Running title: Oxygen in metabolic dysfunction

Reviewing Editors: Alberto Bindoli, Enrique Cadenas, Luca Giordano, Jörg Hänze, Thomas Kietzmann, Michele Samaja and Junji Yodoi

Abstract

Significance: In recent years, a number of studies have shown altered oxygen partial pressure at a tissue level in metabolic disorders, and some researchers have considered oxygen to be a (macro) nutrient. Oxygen availability may be compromised in obesity and several other metabolism-related pathological conditions, including sleep apnea-hypopnea syndrome, the metabolic syndrome (which is a set of conditions), type 2 diabetes, cardiovascular disease and cancer.

Recent Advances: Strategies designed to reduce adiposity and its accompanying disorders have been mainly centered on nutritional interventions and physical activity programs. However, novel therapies are needed since these approaches have not been sufficient to counteract the worldwide increasing rates of metabolic disorders. In this regard, intermittent hypoxia training and hyperoxia could be potential treatments through oxygen-related adaptations. Moreover, living at high altitude may have a protective effect against the development of abnormal metabolic conditions. In addition, oxygen delivery systems may be of therapeutic value for supplying the tissue-specific oxygen requirements.

Critical Issues: Precise *in vivo* methods to measure oxygenation are vital to disentangle some of the controversies related to this research area. Furthermore, it is evident that there is a growing need for novel *in vitro* models to study the potential pathways involved in metabolic dysfunction in order to find appropriate therapeutic targets.

Future directions: Based on the existing evidence, it is suggested that oxygen availability has a key role in obesity and related comorbidities. Oxygen should be considered in relation to potential therapeutic strategies in the treatment and prevention of metabolic disorders.

I.   Introduction

Oxygen is a member of the chalcogen group in the periodic table, and is a highly reactive nonmetal that readily reacts with other elements to form oxides. By mass, it is the third-most abundant element in the universe, after hydrogen and helium. At standard temperature and pressure, two atoms of the element bind to form dioxygen (O_2), a colorless, odorless, gaseous element (206). Two centuries ago, scientists began to realize that there was an element in the air that was essential for life; something that could be depleted with a flame enclosed in a chamber ("phlogiston theory"), with severe consequences for small rodents inside the chamber (215, 369). Joseph Priestley is credited with these experiments as he published first, but, at the same time Carl Wilhelm Scheele was undertaking similar studies (215). Indeed, both scientists had communicated the experiments with Antoine Lavoisier, who disproved the combustion theory when he discovered the chemical significance of the oxidation and named the element "oxygen" from the Greek roots ὀξύς oxys- "acid" and γενής -genes "producer" (206).

During the Hadean eon (4,600–3,800 million years ago), before life existed on earth, oxygen levels in the atmosphere were nearly zero (1 part in a million), and gradually in the subsequent 1,500 million years the first cells developed systems for energy metabolism under anoxic conditions (Figure 1A) (215, 369). The first form of aerobic respiration was possible due to the disproportionate amount of H_2O_2 in the atmosphere, early catalase enzymes leading to the avoidance of the harmful products as hydroxyl radicals. What is termed the "Great Oxidation event" was the transition that occurred around 2,500 million years ago from the anoxic environment of the early Earth to an "oxic" atmosphere, whereby there was a rise of oxygen in the atmosphere to up to 2% (215, 369).

Throughout evolution, living organisms have been required to adapt to changes in atmospheric concentrations of carbon dioxide, nitrogen and oxygen. Fluctuations in the levels of these elements have occurred multiple times throughout the evolution of the atmosphere of the Earth. Nearly 4,000 million years ago the Earth's atmosphere was composed of a ratio of $CO_2:N_2:O_2$ of 98:1.9:0, and today this ratio is 0.03:79:21 (35, 369). This progressive change from an atmosphere lacking oxygen to one relatively rich in the element has been accompanied by a substantial increase in the complexity of living organisms (Figure 1B) (35).

The increased presence of oxygen produces a more efficient energy supply by aerobic metabolism, this generating 16–18 times more adenosine triphosphate (ATP) per hexose sugar than anaerobic metabolism (369). The higher energy supply generated by aerobic metabolism allowed hundreds of new reactions, and therefore new metabolites, to emerge (206, 369). Once oxygen became more abundant aerobic respiring bacteria were able to thrive, including the ancestors of mitochondria (206), thereby increasing cellular complexity. The increasing content of oxygen in the atmosphere is paralleled by an increase in oxygen-rich protein domains such as the extracellular domains of

3

transmembrane proteins (2). Thus the compartmentalization of eukaryotic cells and the allocation of cellular respiration to mitochondria could have evolved as a mechanism to protect oxygen-rich protein domains (369). Through the development of complex compartmentalization, multiple processes including signaling and different biochemical conditions could also be controlled in different parts of the cell, which in turn, may have led to the emergence of multiple cell types within the same "greater" organism (with over 200 different cell types in the adult human body) (2, 101, 410).

Even though oxygen is essential for life in most organisms, its associated metabolic products may become toxic (369). The paramagnetic characteristic of O_2 renders a barrier to chemical reaction since organic donors have to experience a slow spin inversion to donate electrons. This spin restriction is avoided by the electronically excited singlet oxygen ($^1O_2$), making it vastly more reactive than ground state oxygen (206). Over 95% of all the oxygen we breathe is reduced by a very efficient system to $2H_2O$, but a small proportion produces the superoxide anion radical ($O_2 \cdot -$) (293). Superoxide can be subject to dismutation producing hydrogen peroxide (H_2O_2), which can also react with reduced transition metals to form a hydroxyl radical ($\cdot OH$) (376). These intermediates, reactive oxygen species (ROS), may lead to a serious threat to cells as they can interact easily with organic compounds damaging cellular components (316). ROS oxidize redox-reactive cysteine (Cys) residues of proteins producing reactive sulfenic acid ($-SOH$) which can form disulfide bonds with closely located cysteines ($-S–S-$) or suffer additional oxidation to sulfinic ($-SO_2H$) or sulfonic ($-SO_3H$) acid (316). For this reason, organisms should avoid their overproduction through oxygen reduction using paramagnetic transition metals and organic substances with reactive sites (206). Nevertheless, there are other enzymes responsible for minimizing the effects of an excess of ROS production such as catalases, glutathione peroxidases and superoxide dismutases. These enzymes involved in counteracting ROS toxicity are thought to have evolved before the rise in oxygen levels that allowed for aerobic respiration (206, 369).

Energy homeostasis is a key aspect of the metabolic regulation involved in the adaptation to different circumstances (410). Among the regulatory changes, some of the most important are increases in the capacity of tissues to carry out oxidative metabolism together with the availability of oxygen itself (105). Oxygen is just as important for organisms (aerobic) as the other nutrients that they oxidize to generate energy. The average human has an intake of 713 g of food (in a diet of 3,420 Kcal/day as an average energy consumption in developed countries — according to FAO) and 1,696 ml (g) fluid per day (396). Thus, the total weight of food and fluid intake is 2,409 g. Assuming an average food density of 1 g/cm^3 (fat has a lower density, while protein is usually greater) equivalent of that of water, a standard human consumes 2.4 l of nutrients per day.

On the other hand, a standard 70 kg-adult, when resting, averages 12 breaths per minute, with each inhalation (and exhalation) moving about 500 ml of air into the lungs (136). This means 6 l of inhaled air per minute for a standard 70 kg-person (86 ml/kg/min of air). More specifically, an average person inhales approximately 8,640 l of air gas mixture per day — despite variations with the physical activity level. This totals 1,810 l of pure oxygen per day. Making an analogy with the iceberg paradigm, 99.87% corresponds to oxygen while the rest corresponds to what we have commonly accepted as the food pyramid, representing a mere 0.13% of our daily consumption — considering the approximate volume of the components when they are to enter the body (Figure 1C). In terms of weight, the amount of classical nutrients (fluids and food) and oxygen (density 1.429 g/l at standard pressure and room temperature) consumed is similar (oxygen is 51.77% while classical nutrients and fluids represent 48.23% of the total weight).


Figure 1. The importance of oxygen. (A) Summary of oxygen accumulation during the history of the Earth. Estimated changes in the oxygen concentration in Earth's atmosphere over the last 4.000 million years. **(B)** Evolution of organisms (below) in time of their approximate appearance on Earth, which implies higher cellular complexity. **(C)** Iceberg paradigm: illustrative iceberg representation of the importance of considering oxygen as a nutrient. Iceberg tip contains the volume of classical nutrients included in the food pyramid: fluids and food. The underwater part represents the volume of oxygen inhaled by a standard human being. The expression "tip of the iceberg" illustrates a small part of a larger, unconsidered but vital nutrient. In terms of weight, the amount of fluids and food (48.23% of weight) and oxygen (51.77% of weight) consumed is similar.

The maintenance of an adequate supply of oxygen requires the coordinated operation of the three major systems involved in oxygen transport: respiratory, cardiovascular, and blood (299). Oxygen is recognized as a critical factor for respiration, and key metabolic processes and low levels of oxygen are characteristic of certain tissues under normal conditions as well as in pathological situations (385, 386). In this regard, the normal oxygen levels range from 14.5% pO_2 in the lung alveoli to 3–10% in most of the peripheral tissues (53).

This raises important questions about the use of the term "normoxia", which is almost universally applied to refer to the highest oxygen availability at sea level (21% oxygen as inspired) as well as with reference to normal oxygen levels for each tissue. Some authors have proposed the use of "physiological hypoxia", "physioxia", or "physoxia" to define the oxygen concentration at which tissues respond to maintain their preferred oxygen level (242). In this sense, hypoxia-response elements could regulate cellular processes at various oxygen levels in different tissues, hindering the overall analysis of oxygen homeostasis. On the other hand, from a pathological point of view hypoxia could be considered when oxygen levels are below the physiological conditions for a given tissue. This detrimental hypoxia may be found in a wide variety of diseases, such as ischemia, cancer and obesity (92, 347, 385). Conversely, recent work has shown that mitochondrial disease models display tissue hyperoxia and that disease pathology can be reversed by normalization of excess oxygen (17, 169, 170).

Cellular responses to low oxygen levels are mediated by specific transcription factors, particularly by hypoxia inducible factor-1 (HIF-1). Two other key HIFs are evident, namely HIF-2 and HIF-3, but HIF-1 has received considerably more attention. HIF-1 is, an oxygen-labile DNA binding transcriptional activator responsible for the induction of the expression of multiple genes involved in glucose uptake and anaerobic metabolism, mitochondrial function, angiogenesis, inflammation, proliferation and cell survival (35, 120, 348, 442). The activity of this transcription factor has been particularly studied in the context of cancer since hypoxia is a prominent characteristic of the tumor environment and is strongly associated with aggressive tumors (367). HIF-1 activates several hallmarks of cancer such as angiogenesis, cell proliferation, invasion and metastasis, and, therefore, has a crucial role in tumor survival and progression (302). Although the stabilization of the oxygen-responsive subunit of HIF-1, namely HIF-1α, usually involves a tissue hypoxic milieu (it is rapidly degraded in the presence of oxygen) due to decreased oxygen delivery and diffusion (occasionally combined with increased oxygen consumption), the stabilization of HIF-1α can also be triggered by non-hypoxic stimuli as discussed in the following sections.

The present review focuses on the complexity of oxygen delivery and sensing, the relevance of this element in the cellular stress antioxidant system, oxygen's role in metabolic disorders as well as

oxygen-related therapeutic approaches. Over the last few decades, effort has been devoted to understanding the role of oxygen in metabolic disorders at a cellular level. The stabilization and consequent activity of HIF-1 in metabolically active tissues has been associated with metabolic diseases (120). However, the mechanism by which hypoxia pathways are involved in the progression of metabolic impairment is still unclear. Due to the considerable complexity of metabolic dysfunction and the side-effects of current treatments, there has been a growing interest in developing new therapeutic approaches for metabolic diseases. In this sense, a wide-variety of oxygen-related therapies have been studied — as we discuss in the present review.

II.   Oxygen delivery

At sea level, 1 atmosphere (pressure unit) is equivalent to 760 mm of mercury (mmHg), and oxygen is 21% of dry air. Hence, the oxygen partial pressure (pO_2) of inspired air is around 160 mmHg at sea level. In the body, oxygen is transported by the blood to different organs producing a physiological distribution of the molecule in tissues (Figure 2). Thus, those tissues with lower than normal pO_2 can be considered as hypoxic from a molecular point of view (35).

| Blood flow									
Lung	**Liver**	**Intestine**	**Kidney**	**Muscle**	**Brain**	**WAT**	**Heart**	**Bone**	**Skin**
100 %	20 %	10-15 %	20 %	15-20 %	15 %	5-10 %	4-5 %	3-5 %	5 %
110 mmHg 14.5 %	40.6 mmHg 5.4 %	57.6 mmHg 7.6 %	72 mmHg 9.5 %	29 mmHg 3.8 %	33.8 mmHg 4.4 %	54 mmHg 7 %	40 mmHg 5.3 %	49 mmHg 6.4 %	24 mmHg 3.2 %

Oxygenation

Figure 2. Schematic illustration of human organ and tissue circulation and oxygenation. Upstream from the alveoli to downstream tissues. Normal values of blood flow distribution between organs at rest (percentage of cardiac output) and the partial pressure of oxygen (mmHg or equivalent percentage of total oxygen in the air). WAT: white adipose tissue.

In normal conditions, oxygen delivery by arterial blood flow to the capillaries in man is approximately 14 ml/kg/min, with 25% oxygen being exchanged between blood and tissues, the oxygen consumption being 3.5 ml/kg/min (172, 299). Changes in oxygen transport usually lead to hypoxic tissue environments. From a physiological standpoint this can be classified according to the origin in terms of cardiovascular, respiratory, blood or tissue defects (299): hypoperfusion, hypoxemia, anemia and histotoxicity. First, situations involving cardiovascular system defects usually cause extremely low blood flow or hypoperfusion (306). This defect can be local, as ischemic perfusion, or systemic, i.e.

7

reduced cardiac output. For example, in obesity, white adipose tissue (WAT) experiences a certain grade of hypoxia due to impaired perfusion (123). Also, in the inner regions of a tumor (53, 67, 286), and during acute myocardial infarction (343, 348), a perfusion deficit is experienced.

Secondly, conditions entailing the respiratory system, such as low inspired pO_2 (i.e. at high altitude) and breathing problems (i.e. pulmonary edema, ventilation-perfusion mismatch, apnea), lead to falls in arterial pO_2 producing hypoxemia (299). Concerning low inspired pO_2, high-altitude sickness is a shared term for the syndromes affecting non-acclimated travelers shortly after ascent to altitudes above 2500 m (recognized also above 1500 m), and encompasses the cerebral conditions of acute mountain sickness, high-altitude cerebral and pulmonary edema syndromes (22). Sleep apnea-hypopnea syndrome (SAHS) can be also classified in these respiratory problems which present hypoxemia and is associated with hypertension (hereafter arterial hypertension, unless otherwise stated), ischemia and metabolic dysfunction (79). Moreover, oxygen consumption is associated with resting metabolic rate through the metabolic equivalent classification or METs (172). This term refers to the oxygen consumption, where 1 MET is equivalent to 3.5 ml oxygen/kg/min, and it is used to quantify the physical activity intensity. Several studies have shown approximately 30% lower oxygen consumption, compared to the standard 1 MET, in both obese subjects with a mean BMI of 30 kg/m^2 (44) and extremely obese individuals with a mean BMI of 42 kg/m^2 (415). In a recently published bibliographic review, where this threshold is also discussed, the authors suggest an overestimation of resting oxygen consumption among coronary patients and the morbidly obese (104). Noteworthy is that this report provides information on lower oxygen consumption at rest in obesity and cardiovascular disease (CVD). In this regard, low oxygen consumption was associated with systemic inflammation in obese men with SAHS (223). The measurement of basal oxygen consumption is an easy to perform, non-invasive and affordable approach, which other than in the particular study, is not commonly used to differentiate between metabolically healthy individuals and those with metabolic disorders.

Thirdly, blood oxygen deficiency, or anemia, occurs when the concentration of hemoglobin, responsible for carrying oxygen through the blood to the tissues, and/or erythrocyte count, are lower than normal and insufficient to meet an individual's physiological needs (61). This means that fewer oxygen-binding sites are available to hold oxygen and is frequently caused by blood loss, iron and the deficiency of other nutrients' — vitamins A, B2, B9, and B12 — as well as inflammatory and infectious diseases (61). The adaptive response to anemia is erythrocytosis, an abnormal increase in the number of circulating erythrocytes (345). Erythrocytosis is defined by: (i) hemoglobin >18.5 g/100 ml in men, or 16.5 g/100 ml in women, for Caucasians; or (ii) hemoglobin or hematocrit >99th percentile of method-specific reference range for age, sex and altitude of residence; or (iii)

hemoglobin >17 g/100 ml in men or 15 g/100 ml in women for Caucasians (or the equivalent in other races and age groups) if associated with a documented and sustained increase of at least 2 g/100 ml from an individual's baseline value and cannot be attributed to the correction of iron deficiency (292). Finally, mitochondrial dysfunction associated with impaired oxygen utilization, or histotoxic hypoxia, could lead to reduced ATP production (1). This deficit is due to a disturbance of oxygen usage by cells and involves chemicals acting as poisons (cyanide, rotenone, antimycin A) as well as by inflammatory mediators (1, 200, 299). For example, rotenone — used as a broad-spectrum insecticide, piscicide, and pesticide, and naturally present in several plants — inhibits the complex I (NADH:ubiquinone oxidoreductase) of the mitochondrial respiratory chain in all cell types by inhibiting the ubiquinone-dependent oxidation of the mitochondrial NADH to NAD (353, 420). In cells, rotenone decreased the mitochondrial membrane potential, increasing ROS production and shifting respiration to a more anaerobic state that develops lactic acidosis (310). In the case of rotenone intoxication in humans, the inhibition of the mitochondrial respiratory chain led to severe metabolic acidosis (pH 6.76), reduced level of consciousness, coma and respiratory depression leading to respiratory arrest (420). In this regard, cyanides are found in certain seeds and fruit stones, while hydrogen cyanide is produced by the combustion of certain materials under oxygen-deficient conditions, such as in combustion engines and in tobacco smoke. Cyanide is a potent inhibitor of the cytochrome c oxidase (mitochondrial complex IV), decreasing oxygen consumption at the cellular level (111). This disruption of electron transport also induces cellular redox imbalance and excessive ROS production (116). On the other hand, antimycin A — a secondary metabolite produced by *Streptomyces* bacteria and the active ingredient in Fintrol, a chemical piscicide — is a mitochondrial complex III inhibitor that completely inhibits oxygen consumption in the respiratory chain (171). Noteworthy, the expression of alternative oxidase (AOX) from the ascidian *Ciona intestinalis*, confers resistance to antimycin A and cyanide, bypassing the cytochrome segment of the respiratory chain (116, 135, 375). AOX also inhibits the mitochondrial membrane hyperpolarization, and the superoxide overproduction induced by acute hypoxia in pulmonary artery smooth muscle cells, avoiding the subsequent pulmonary vasoconstriction in mice (366). In this regard, a chemically modified RNA encoding a humanized AOX has been recently generated as a therapeutic route (115). Lastly, inflammatory mediators such as nitric oxide and oxygen radicals have been suggested to play a role in the impairment of ATP production, resulting in a form of histotoxic hypoxia (1, 224).

III.   Oxygen sensing

Organisms need oxygen sensing mechanisms to allow a fast response to changes in pO_2, thereby maintaining intracellular oxygen homeostasis. Oxygen sensor systems are able to sense oxygen

concentrations, initiating intracellular signaling cascades in response to altered pO_2 (94). The chemoreceptors of the central nervous system are located on the ventrolateral medulla, while the peripheral chemoreceptors are located in the carotid and aortic bodies. The specialized glomus cells in the carotid body sense even minor changes in arterial blood oxygen tension, eliciting afferent signals in the carotid sinus nerve (215). As Pittman has explained in detail, the aortic bodies are responsible for the cardiovascular response to respiratory-linked chemical factors in the arterial blood. On the other hand, the carotid bodies sense when the arterial pO_2 falls below 50 mm Hg, and consequently peripheral chemoreceptors increase ventilation as a stimulatory response to hypoxia. While the carotid bodies are not sensitive to hypoperfusion or anemia because they have high blood flow, aortic bodies are sensitive as their perfusion is lower. The inability of the respiratory chemoreceptors to sense changes in pO_2 elevation above 50–60 mmHg leads to a ventilatory unresponsiveness in hyperoxia (299). In addition, other stimuli such as plasma glucose and blood osmolality also trigger the carotid body, serving as a polymodal sensor involved in metabolic homeostasis (215). Besides these specialized chemoreceptors, each tissue has its own oxygen sensor and threshold to low pO_2, depending on its normal pO_2 (94).

At a cellular level, the adaptive response to low oxygen availability is primarily regulated through HIF-1, as noted above, a master regulator which mediates the transcriptional activity of multiple genes (45, 442). It is known that HIF-1 binding is associated mainly at genes with increased expression; however, HIF-1 downregulates gene expression indirectly by regulating transcriptional repressors and microRNAs (345). As noted earlier, HIF-1 is a heterodimer of a constitutively expressed HIF-1β subunit and an oxygen-regulated HIF-1α subunit, which under normoxic (normal oxygen concentration) conditions is hydroxylated at specific proline residues by prolyl hydroxylase domain proteins (Figure 3), which use oxygen and α-ketoglutarate as substrates and contain Fe^{+2} in their catalytic center (346). Hydroxylated HIF-1α interacts with the von Hippel-Lindau (VHL) protein, the substrate-recognition subunit of the E3 ubiquitin-protein ligase that targets HIF-1α for proteasomal degradation (77). Under hypoxic conditions, hydroxylation is inhibited and HIF-1α remains stable (128). The HIF-1α subunit contains two transactivation domains: an amino-terminal transactivation domain that lies within the oxygen-dependent degradation domain, and a carboxy-terminal transactivation domain. The cAMP response element-binding (CREB)-binding protein (CBP) and p300, two transcriptional co-activators, interact with the carboxy-terminal transactivation domain of HIF-1α to induce transcription of HIF-1 target genes (128, 183).

HIF-1α transcriptional activity is negatively regulated in an oxygen-dependent manner by a factor inhibiting HIF-1 (FIH)-dependent asparaginyl hydroxylation, which blocks the interaction between HIF-1 and the coactivators CBP and p300 (183, 347). Thus, in hypoxic conditions this hydroxylation

is also reduced, allowing the interaction of HIF-1 with coactivators, thereby leading to the transactivation of target genes (128). The HIF-1α and HIF-1β proteins both contain basic helix-loop-helix motifs that bind DNA in the hypoxia-response elements (HREs: 5'–A/GCGTG–3') and, finally, cause subunit dimerization (45, 77). Additionally, HIF-1α activity may be classified by the type of interplay between itself and target genes or transcription factors (Table 1). Further complexity is generated by the existence of multiple HIF isoforms, with HIF-2 recently receiving more attention (70). The HIF-2α subunit has a similar amino acid sequence compared to the isoform 1, but acting in a different manner on phenotype upon inactivation (254). HIF-2 function is essential for modulating ventilatory sensitivity to hypoxia, erythropoiesis and vascularization (151, 345).


Figure 3. Oxygen-dependent and independent regulation of HIF-1. In normal oxygen conditions (normoxia), HIF-1α is subject to oxygen-dependent prolyl hydroxylation by PHDs, which allows for ubiquitylation by the VHL complex. FIH asparaginyl hydroxylation of HIF-1α blocks the interaction between HIF-1 and the CBP/p300 complex. Polyubiquitylated HIF-1α is targeted for degradation by the proteasome. Under low oxygen tension (hypoxia), PHDs are unable to catalyze the hydroxylation at HIF-1α proline residues leading to its stabilization. FIH is incapable to hydroxylate an asparagine residue of HIF-1α under hypoxic conditions, allowing for CBP/p300 recruitment. The stable subunit is translocated to the nucleus, where it binds to HIF-1β. The heterodimer recognizes the HRE core consensus sequence in target genes, binds to coactivators as CBP/p300 and initiates transcription. Non-hypoxic stimuli (e.g. pro-inflammatory molecules) increase the transcription of the HIF-1α gene by a PKC-dependent pathway. The translation into HIF-1α protein is enhanced by the activation of the PI3K/mTOR pathway.

CBP p300: CREB-binding protein and p300 complex; FIH, factor inhibiting HIF-1; HREs: hypoxia-responsive elements; mTOR: mammalian target f rapamycin; PHD: prolyl hydroxylase domain proteins; PI3K: phosphatidylinositol 3-kinase; PKC: protein kinase C; Ub: ubiquitin; VHL: von Hippel-Lindau protein.

Lopez-Pascual *et al.*

Table 1. Major target genes and transcription factors associated to HIF-1α.

HIF-1α activity	Gene symbol
Cooperates (TF)	*E2F7; E2F8; JUN; MTF1; NFKB1; SMAD4; SP7*
Interacts (TF)	*BHLHE41; COPS5; CREB3L1; ELL; ELOB; ELOC; HDAC4; HDAC5; HDAC6; HDAC7; HIF1AN; HIF3A; HNF4A; IRF1; KAT2B; KAT5; KDM3A; KDM4C; MAFG; MDM2; MTA1; MYC; NCOA1; NCOA2; NEDD8; PCGF2; PER1; PIAS3; PRKDC; RB1; RELA; SMAD3; SMARCA2; SMARCA4; SP1; STAT3; TET1; TP53; TP63; TRAF6; VHL; ZNF197*
Regulates (TF)	*APEX1; BHLHE40; CCND1; CEBPA; CTNNB1; ESR1; ESR2; ESRRG; EZH2; FOXM1; FOXO3; HDAC2; HEY1; HEY2; ID1; KDM4B; LOXL2; MTDH; MXI1; NEUROG3; NFAT5; NOTCH1; PARP1; POU5F1; PPARA; PPARG; PROX1; RAC1; RORC; RUNX1; SNAI1; SNAI2; SOX2; SOX9; SREBF1; TWIST1; ZEB1; ZEB2*
Interacts (gene)	*COMMD1; CPEB2; CUL2; DCUN1D1; DNAJB1; EAF2; EGLN1; EGLN3; FBXW7; FTCD; HEXIM1; HSP90AA1; HSP90AB1; HSPA1L; HSPA4; HSPA8; IKBKG; LINC01139; LRRK2; MAPK3; MCM3; MCM7; NAA10; NBN; NDN; OS9; OTUD7B; PGK1; PIN1; PLD1; PLD2; PRKN; PSMA7; PSMC3; PSMD10; PTBP1; PTK6; RACGAP1; RACK1; RBM38; RHBDF1; RHOBTB3; RPTOR; RWDD3; SAT1; SAT2; SENP1; SENP3; SHC1; SQSTM1; SRC; STUB1; SUMO1; TSGA10; TXNIP; UBXN7; USP19; USP20; USP7; VHLL; WWOX; XPO1; ZC3H12A*
Regulates (gene)	*ABCB1; ABCG2; ACAN; ADM; ADORA2A; AFP; AGR2; AGT; AK1; AKT1; ANG; ANGPT1; ANGPT2; ANGPTL4; APOE; AQP4; ARG1; AURKA; AXL; BAX; BBC3; BCL2; BCL2L1; BIRC5; BNIP3; BNIP3L; BSG; BTG2; CA9; CALCRL; CASP3; CCL2; CCL4; CCL5; CCN1; CCN2; CCR1; CCR5; CD44; CDH1; CDH2; CDKN1A; COL1A1; COX4I2; CP; CPT1A; CTSD; CXCL12; CXCL8; CXCR1; CXCR2; CXCR4; CYBB; DDIT4; DLL4; EDN1; EDN2; EDNRB; EIF4EBP1; ENTPD1; EPO; FABP4; FAM162A; FASN; FBXO32; FGF2; FLT1; FLT4; FN1; GAPDH; HK2; HMOX1; HOTAIR; IFNG; IGF2; IGFBP1; IGFBP3; IL10; IL1B; IL22; IL4; IL6; INHA; JAG1; KDR; KITLG; KLK3; KRT18; KRT19; LDHA; LEP; LGALS3; LIFR; LOX; MALAT1; MAPK1; MCL1; MDK; MIF; MIR101-1; MIR107; MIR146A; MIR17; MIR182; MIR20A; MIR20B; MIR21; MIR210; MIR27A; MIR29C; MIR373; MIR503; MMP1; MMP14; MMP2; MMP28; MMP3; MMP9; NDRG1; NOS2; NOS3; NOTCH3; NOTCH4; NOX4; NQO1; NT5E; OCLN; PCNA; PDGFC; PFKP; PGF; PKM; PLAU; PLAUR; PLIN2; PNMT; PROM1; PTGS2; PTPRB; SERPINE1; SLC2A1; SLC2A3; SLC2A4; SOCS3; SOD2; SOST; SPHK1; STC1; STIM1; TERT; TFRC; TGFB1; TGM2; TH; TIMP1; TLR4; TNF; TNFAIP6; TNFRSF12A; TRIM63; VEGFA; VEGFC; VIM; VLDLR*

HIF-1α cooperates with, interacts with or regulates proteins encoded by these genes. TF: transcription factor. HIF-1α also interacts with and regulates other genes. Data obtained from MatBase Matrix Family Library (Version 8.3, Genomatix Software GmbH, Munich).

The main adaptive molecular response to hypoxia is mediated through HIF-1-transcriptional control. A considerable number of molecular functions are associated with HIF-1, which can be classified in Gene Ontology (GO) terms (Table 2). Inferred from direct assay (biochemical or cell biological assay), and beyond oxygen homeostasis (158) and the response to hypoxia (29, 102, 139, 211, 421, 430), HIF-1 is associated with neuronal survival under conditions of oxidative stress (288), vascular endothelial growth factor production (102, 177) and transcriptional regulation (29, 193, 207, 210, 212, 252, 349, 351, 408, 421). However, other regulatory mechanisms appear to be involved in the hypoxic response, such as non-coding RNA and alternative splicing (314). When oxygen is available, most cells produce ATP via oxidative phosphorylation, but in hypoxic environments there is a shift to anaerobic metabolism for cellular energy production (12, 229, 442).

Table 2. Human HIF-1 associated Gene Ontology terms.

GO term	Evidence
Axonal transport of mitochondrion	IMP (201)
Cellular response to hypoxia	IDA (133, 201, 411)
Cellular response to interleukin-1	IEP (168)
mRNA transcription by RNA polymerase II	IC (389)
Negative regulation of gene expression	IMP (422)
Negative regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway	IDA (275)
Oxygen homeostasis	IDA (152)
Positive regulation of angiogenesis	IC (101)
Positive regulation of blood vessel endothelial cell migration	IMP (422)
Positive regulation of chemokine production	TAS (60)
Positive regulation of chemokine-mediated signaling pathway	IC (398)
Positive regulation of endothelial cell proliferation	IC (101)
Positive regulation of erythrocyte differentiation	IC (337)
Positive regulation of gene expression	IDA (240, 338)
Positive regulation of glycolytic process	IC (336)
Positive regulation of hormone biosynthetic process	IDA (337)
Positive regulation of nitric-oxide synthase activity	TAS (146)
Positive regulation of pri-miRNA transcription by RNA polymerase II	IMP (209)
Positive regulation of receptor biosynthetic process	IMP (398)
Positive regulation of transcription from RNA polymerase II promoter in response to hypoxia	IDA (200)
Positive regulation of transcription, DNA-templated	IDA (29, 197, 336)
Positive regulation of vascular endothelial growth factor production	IDA (101)
Positive regulation of vascular endothelial growth factor receptor signaling pathway	IC (101, 168)
Regulation of gene expression	IDA (202)
Regulation of transcription from RNA polymerase II promoter in response to oxidative stress	IDA (336, 390)
Regulation of transcription, DNA-templated	IDA (184, 402)
Regulation of transforming growth factor beta 2 production	IMP (419)
Response to hypoxia	IDA (29, 101, 402)
Response to iron ion	IEP (236)
Signal transduction	IMP (419)
Transcription by RNA polymerase II	IMP (313)
Vascular endothelial growth factor production	IDA (168)

Gene Ontology (GO) term and reference with evidence codes defined by the GO Consortium: Inferred from direct assay (IDA); inferred from expression pattern (IEP); inferred from mutant phenotype (IMP); inferred by curator (IC); traceable author statement (TAS). Data obtained from MatBase Matrix Family Library (Version 8.3, Genomatix Software GmbH, Munich).

Apart from increasing the expression of genes encoding glycolytic enzymes, HIF-1 leads to the reduction in mitochondrial oxygen consumption via pyruvate dehydrogenase kinase I (PDK-1), B-cell

Lopez-Pascual *et al*.

lymphoma 2 interacting protein 3 (BNIP3), and Beclin-1 and autophagy protein 5 (ATG5) among others (344). This results from the PDK-1-mediated inhibition of the Krebs cycle (286), BNIP3-regulated reduction of mitochondrial biogenesis as well as Beclin-1 and ATG5-induced autophagy (356). Regarding transcriptional activation, HIF-1 mediates cellular responses to hypoxia by regulating glucose uptake and anaerobic metabolism, mitochondrial function, angiogenesis and inflammation, as well as cell proliferation and survival (35, 241, 348, 442). To identify the functional annotations associated with the genes directly regulated by HIF-1α or interacting with it (listed in table 1), Web-based Gene Set Analysis Toolkit (WebGestalt) was used to cluster these genes according to GO term categories of biological process and molecular function (Figure 4).


Figure 4. Functional annotation clusters of HIF-1 regulated genes. Only the top 10 enriched categories are reported. Data obtained from Web-based Gene Set Analysis Toolkit (WebGestalt) and clustered according to GO term categories of (**A**) biological process and (**B**) molecular function. ROS: reactive oxygen species.

WebGestalt runs an over-representation analysis using the GO functional database categories of biological process and molecular function for a certain organism — in this case humans. Each GO

annotation describes the function of a particular gene and includes an evidence code to indicate how the annotation to a particular term is supported. As explained by the GoConsortium, evidence codes fall into six general categories: experimental, phylogenetic and computational evidence, author statements, curatorial statements and automatically generated annotations. Then, WebGestalt enrichment analysis statistically evaluates the over- (or under-) representation of a known fraction of genes in a particular GO term, or pathway, found among the set of input genes (244). Hence, if a statistically significant number of genes from the known set are present in the gene list, it may indicate that the gene function (GO term) or pathway plays a role in the biological condition under study (184). Among the enriched categories identified by gene clustering (Benjamini-Hochberg FDR<0.05; top 10 categories), the biological processes with the highest gene content per GO branch include response to oxygen levels, ROS, metabolic process and regulation of vasculature development (Figure 4A), while the enriched categories for molecular function comprise the binding of protein tyrosine kinase, growth factor receptor and chaperone (Figure 4B) highlighting the role of HIF-1α in oxidative and metabolic pathways.

IV.   Crosstalk between inflammation and hypoxia pathways

Even though most studies on HIF-1 activity have been conducted under hypoxic stress, this transcription factor has also been found to be up-regulated in inflammatory and oxidative conditions, such as arthritis, diabetes and obesity (92). In this context, the activation of HIF-1could be triggered by non-hypoxic stimuli such as LPS (31, 271), cytokines (6, 134, 204, 398, 413), growth factors and vascular hormones (143, 321, 389, 434). For example, ROS could lead to a stabilization of HIF-1α under normoxia (34, 41, 258, 309, 321). Furthermore, a ChIP assay revealed that the activation of HIF-1 led to a transcriptional regulation in adipocytes treated with a conditioned medium from LPS-activated macrophages (224). In this sense, the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway is activated via several stimuli such as growth factors, cytokines and stress conditions (168, 428), and is involved in numerous cellular functions including proliferation, adhesion, migration, invasion, metabolism, and survival (181).

A.   *Non-canonical activation of HIF-1*

The mechanistic target of rapamycin kinase (mTOR, also known as mammalian target of rapamycin), a well-known phosphorylation target of the PI3K/AKT pathway (181, 443), is involved in the onset and progression of diabetes, cancer and ageing, for example (443). Furthermore, HIF-1α levels are also regulated by different signaling cascades — the phosphatidylinositol 3-kinase (PI3K) and the mitogen-activated protein kinase (MAPK) cascades (24). Hence, the PI3K target AKT has been

suggested to either activate or inactivate HIF-1α stabilization, translation or coactivator recruitment by several downstream proteins such as glycogen synthase kinase-3 (GSK3) and mTOR, among others (186). For instance, the AKT target GSK3 is known to directly phosphorylate HIF-1α, thereby contributing to destabilization in response to long-term hypoxia (186). mTOR is a central regulator of many core metabolic processes leading to anabolic mechanisms including through HIF-1 (74, 411, 425). Moreover, several studies have demonstrated a mTOR-dependent activation of HIF-1 in an oxygen-independent manner (143, 224, 271, 347, 389, 411). The molecular basis of this non-canonical activation of HIF-1 is related to the activation of the PI3K/AKT/mTOR pathway, known to increase HIF-1α protein levels by increased translation (201, 271, 389, 434) even in normoxic conditions (77, 120, 164, 181, 258) (Figure 3).

In an oxygen-independent mechanism, an enhancement of *HIF1A* gene transcription has been suggested through the activation of protein kinase C (PKC) (77, 284, 426), which might occur by stimulating specific transcriptional regulatory elements, such as Sp1, to bind the *HIF1A* promoter (31, 77, 284). PKC regulates a wide variety of cellular functions including cell proliferation, cell death, gene transcription and translation, altered cell shape and migration, regulation of ion channels and receptors, regulation of cell-cell contact and secretion, and is, in turn, activated by diacylglycerol and calcium ions through a variety of signals such as hormones (adrenalin and angiotensin), growth factors (epidermal growth factor and insulin), and neurotransmitters (dopamine and endorphin) (253).

In addition, mTOR is also involved in the modulation of oxidative stress in hypoxia through the thioredoxin interacting protein (TXNIP) (419). This protein is induced by, and promotes, cellular oxidative stress by inhibiting thioredoxin — an antioxidant enzyme — reducing capacity and is in turn inversely regulated by ROS levels (8, 368). In hypoxic conditions, *TXNIP* gene expression is regulated in a biphasic manner whereby *TXNIP* shows an initial rapid down-regulation that may serve as an adaptive mechanism to increase glucose uptake under conditions of compromised oxidative phosphorylation, followed by an increase under prolonged hypoxia (419). This initial decrease of TXNIP in response to hypoxia results in enhanced insulin-stimulated AKT and downstream signaling in human myotubes (124). Thus, TXNIP is involved in the regulation of metabolic homeostasis thereby further linking oxidative stress and hypoxia pathways.

Moreover, the existing evidence indicates that nitric oxide (NO) influences HIF-1 signaling. However, complex mechanisms involving both positive and negative regulation of HIF signaling by NO have been described (40). NO can affect HIF-1 activation at multiple levels via several mechanisms (28). Briefly, regulatory capacities depend on NO concentration: lower NO leads to HIF-1α degradation, but high NO levels stabilize HIF-1 in normoxia, mimicking the hypoxia response (28, 280).

B.   *HIF and NF-κB crosstalk*

Many of the stimuli that induce HIF-1 in normoxia are known to activate other transcription factors such as nuclear factor κB (NF-κB) (398). The activation of the canonical NF-κB pathway triggers a rapid and reversible inflammatory and immune response, while a slower and irreversible developmental response classically occurs through the non-canonical pathway (359). The NF-κB family of transcription factors exist either as homo- or heterodimers and consists of five members — p50, p52, p65 (RelA), c-Rel, and RelB — which share an N-terminal Rel homology domain responsible for DNA binding to κB sites within the promoters/enhancers of target genes, regulating transcriptional activity (142). Some dimers are more prevalent than others and are mainly sequestered in the inactive form in the cytoplasm, inhibited by members of the IκB family (inhibitor of NF-κB) (398). When the signaling cascade is activated, IκB proteins are phosphorylated, ubiquitinated and degraded through the proteasome, resulting in NF-κB release and translocation into the nucleus (74). The transactivation domain necessary for the positive regulation of gene expression is present only in p65, c-Rel, and RelB, while p50 and p52 may repress transcription unless associated with a transactivation domain-containing NF-κB family member or other proteins capable of coactivator recruitment (142). The NF-κB transcription factor is known for its central role in the immune response (canonical pathway), especially in inflammatory processes present in cancer, muscular dystrophy, obesity, insulin resistance, and atherosclerosis (20, 142). NF-κB is involved in immune cell differentiation and maturation processes by the activation of the non-canonical pathway (359), known for coordinating metabolic stress responses to overnutrition (165).

Moreover, several studies demonstrate crosstalk between the NF-κB and HIF-1 signaling pathways and direct targets of both transcription factors (74). Direct targets of the NF-κB and HIF-1 transcription factors obtained from the MatBase Matrix Family Library were used for query (Version 8.3, Genomatix Software GmbH, Munich). Then, we compared NF-κB direct targets (of the five family members) with those of HIF-1 (α and β), 292 and 233 genes respectively, and found 78 overlapping genes (Figure 5A). The list of shared genes directly regulated or interacting with NF-κB and HIF-1 were further analyzed in WebGestalt to evaluate the enriched functional annotations. Among the top enriched GO term categories of biological process were reactive nitrogen species (RNS) and ROS metabolic processes, response to oxygen levels and regulation of vasculature development (Figure 5B), suggesting a contribution of these genes regulated by both transcription factors in oxygen and oxidative stress-related pathways. Furthermore, NF-κB activation could lead to transactivation of HIF-1 target genes in normoxia (224, 398).

Lopez-Pascual *et al.*

Figure 5. Functional annotation clusters of overlapping HIF-1 and NF-κB regulated genes. Only the top 10 enriched categories are reported. **(A)** Venn diagrams showing the overlap between HIF-1 and NF-κB regulated genes. **(B)** Analysis of overlapping HIF-1 and NF-κB regulated genes: GO term categories of biological process calculated by Web-based Gene Set Analysis Toolkit (WebGestalt). RNS: reactive nitrogen species; ROS: reactive oxygen species.

V. Cellular stress and antioxidant defense

The antioxidant system is responsible for managing the ROS naturally present in cells, which are involved in a number of physiological processes — through growth factor signaling, inflammation

18

and/or hypoxia, or immune responses (125, 440) — that produce desired cellular responses (including activation, cell survival, proliferation, stress adaptation, cell motility, vasodilation, and angiogenesis), lately named by Sies and Jones as oxidative eustress (154, 352, 362). However, large quantities of ROS can lead to cellular damage in lipids, membranes, proteins and DNA, contributing to the development of metabolic diseases or cell death — also defined as oxidative distress (313, 362). The major endogenous sources of ROS are the mitochondrial respiratory chain, NADPH oxidases, monoamine oxidase (MAO), nitric oxide synthases (NOS), the Fenton reaction, cytochrome P450 oxidases, xanthine oxidoreductase, peroxidases, and peroxisomal β-oxidation (56, 113, 179, 362). Mitochondria are a major source of cellular ROS as superoxide and hydrogen peroxide are mainly produced by these organelles, due to either a reduced NADH pool, or a high protonmotive force and a reduced coenzyme Q pool (260). Mitochondrial sodium import and interaction with phospholipids have a role in attenuating potential ROS production and injury upon cardiac reperfusion while promoting an adaptive ROS production during acute hypoxia (146). Mitochondrial oxidative phosphorylation is uncoupled when protons — translocated to the intermembrane space by respiratory complexes of the electron transport chain — return to the mitochondrial matrix independently of ATP synthase (proton leak) thereby generating heat instead of ATP (192). The process of proton leak increases the respiration rate and is a mechanism for energy dissipation (36). Mitochondrial uncoupling proteins (UCPs) are involved in the proton leak and in the control of mitochondrial ROS production. The adaptive thermogenesis that occurs in brown adipose tissue (BAT) is unambiguously mediated by UCP1; however, the functional role of the other UCPs, UCP2 and UCP3, has not been clearly established (36, 192). UCP2 has been associated with the control of ROS production (13) and to the modulation of insulin sensitivity (322). In WAT of mice fed a high-fat diet (HFD) for 15 weeks, *Ucp2* expression was decreased and HIF-1α was induced in normoxia (202). Also, *Ucp2* decreased in WAT and BAT of mice expressing a stable HIF-1α (176). Recently, a ChIP assay performed on adipocytes in a pro-inflammatory medium revealed that HIF-1α suppressed the enrichment at *Ucp2*, which was actually down-regulated in pro-inflammatory conditions (224). In hyperglycemia, pancreatic β-cells increase both superoxide and UCP2 production, leading to a decrease in ATP production and, consequently, to reduced ATP-dependent insulin secretion (36, 192, 322). On the other hand, UCP3 appears to be involved in promoting fatty acid oxidation, preventing mitochondrial damage from lipotoxicity (36). Thus, UCP1 mediates adaptive thermogenesis in BAT, while a role for UCP2 and UCP3 in the control of cellular redox status has been shown (36, 192). In this sense, a cardioprotective role of UCP-mediated uncoupling by means of reducing ROS production has been demonstrated (4, 327). Thereby, mild mitochondrial uncoupling is a well-known cytoprotective strategy under

conditions of oxidative stress, including obesity, diabetes and ischemia-reperfusion injury (4, 36, 37, 192, 327).

Recently, NAD/NADH and NADP/NADPH pools have been also identified as cellular redox homeostasis regulators (196, 427). Similarly, redoxins (including peroxiredoxins, thioredoxins and glutaredoxins) have been characterized as electron donors, acting as redox catalysts (43, 137, 153, 362). Moreover, the Nrf2-Keap1 pathway is considered very relevant as a transcriptional antioxidant response (93, 362, 440). The intracellular distribution of these molecules is highly compartmentalized, maintaining cellular redox status in a wide range of subcellular organelles (137, 427). Therefore, ROS levels must be perfectly regulated in the cell environment.

Some rapid modifications in metabolic flux can be determined by the redox state within cells; when this situation is maintained over time, the oxidative stress triggers mitochondrial dysfunction (293, 313). Thus, it is well established that the production of ROS is both necessary, and at the same time potentially hazardous, for normal cell function. Modulation of the different antioxidant systems could cause either beneficial or adverse effects, depending on the context (56, 110, 336). Several studies showed that a high antioxidant intake increased blood pressure, prevented statin-induced c-HDL elevation, enhanced the oxidative stress and blocked the enhanced insulin sensitivity produced by acute exercise, increased the risk of breast cancer and raised mortality (401). Other studies have confirmed that a high intake of antioxidants do not show any beneficial effects in cancer patients (333).

Moreover, many cell stressors (free fatty acids, hypoxia, high glucose) that lead to ROS generation and the subsequent oxidative stress (110, 313) could induce endoplasmic reticulum (ER) stress (129, 318), affecting protein synthesis, folding and transport, and several cellular signaling processes — mainly those related with calcium (126). Likewise, many characteristics of metabolic disease that induce inflammatory signaling could also induce ER stress (129). The ER stress and downstream activation of the molecular pathways managing the unfolded protein response (UPR) seem to be closely related to inflammation, and indicate a conserved mechanism whereby ER stress is intimately connected to host-cell defense (129, 318). ROS are upstream of the UPR, but not necessarily upstream of ER stress, suggesting that ROS may also be involved in solving an early stage of ER dysfunction by activating the UPR (278). Also, hypoxia-derived ROS is known to specifically activate UPR pathway-promoting energy and redox homeostasis, enhancing cellular survival (218).

Under normal conditions, the three canonical UPR sensors — PKR-like eukaryotic initiating factor alpha kinase (PERK), activating transcription factor-6 (ATF6) and inositol requiring enzyme 1 (IRE1) — are capped by BiP/GRP78 chaperone and remain inactive (126, 154, 278, 334). When proteins are misfolded or an overload of protein synthesis machinery prevails, proteins accumulate in the ER and BiP dissociates, allowing oligomerization of PERK and IRE1, translocation of ATF6 to Golgi and ER

signaling (126, 278). Hence, a number of pathways are involved in the UPR initiation, reflecting the extremely important role of ER stress and the complexity of the cellular response. Specifically, hypoxia induces protein misfolding as a consequence of the need for oxygen to form disulphide linkages, which leads to ER stress and the activation of UPR (80). Moreover, UPR downstream pathways are linked to a wide range of processes. One such pathway involves IRE1 as an ER stress sensor, which increases the production and secretion of inflammatory cytokines as a downstream consequence (156). However, all three branches of UPR are at some level involved in inflammatory signaling (278).

If proper ER function is not achieved, or if the stress continues, the UPR may also initiate apoptotic pathways through the activation of C/EBP homologous protein (CHOP) downstream of IRE1 and PERK pathways (80, 334). ER stress can trigger autophagy, an essential homeostatic process whereby the cell breaks down its own components to help maintain a balance between the synthesis, degradation and subsequent recycling of cellular products, most likely via PERK and IRE1α pathways (80, 334). Recent reports have shown that the failure of autophagy-dependent control of immune-cell homeostasis can contribute to inflammation and insulin resistance (281).

Finally, the aging process has also been associated with the accumulation of cell damage over a lifetime, promoted mostly by increased mitochondrial dysfunction-derived ROS (36, 56). The free radical theory of aging proposes that free radicals produce oxidative damage to cellular components, with the accumulation over time contributing to aging (36, 336, 409). Despite an increase in overall lifespan, age-related diseases such as neurodegenerative disorders, diabetes and CVD are major causes of mortality and morbidity worldwide (336). However, studies in both *C. elegans* and *Drosophila* refute the free radical theory of aging due to a lack of association between increased ROS and lifespan, and indeed free radicals could even lengthen it (50, 336, 409). Antioxidants play a critical role neutralizing ROS, but the association with lifespan is complex.

VI.   Metabolic dysfunction

A close interaction between AT, liver, pancreatic islets, muscle and immune cells generates an environment for continuous and dynamic interactions between immune and metabolic responses (155). This coordinated regulation of metabolic and immune responses is beneficial in certain conditions, since the organism needs to organize and redistribute its energy resources to block anabolic signaling pathways (38). However, this network becomes detrimental in the presence of continuous nutrient overload (281). Currently, the nutritional and lifestyle habits in Western countries (also known as the Occident world) strongly promote metabolic excess and have established a worldwide problem with chronic metabolic diseases.

The metabolic dysfunction is characterized by a wide variety of disorders commonly found in metabolically active tissues including the pancreas, arteries, liver, fat and skeletal muscle, to name key examples (Figure 6). Although explained in more detail below, hyperlipemia is associated with hypercholesterolemia and lipotoxicity in several tissues and leads to the excessive accumulation of lipids in the abdominal cavity (visceral adiposity). Atherosclerosis is also related to hyperlipemia and involves immune cell infiltration in the atherosclerotic plaque, strongly linked to hypertension.


Figure 6. Overview of metabolic dysfunction. Based on epidemiological and biological data discussed in the text, the figure illustrates the dysfunction in metabolically active tissues associated with metabolic disorders.

Likewise, the metabolically altered WAT is infiltrated with macrophages. Thus, metabolically impaired tissues produce pro-inflammatory molecules able to promote insulin resistance. At the same time, hyperglycemia, as a result of metabolic dysfunction in pancreatic β-cells, leads to impaired insulin secretion and diabetes. Although not included in current diagnostic criteria of the metabolic syndrome, non-alcoholic fatty liver disease (liver steatosis) is a trait of this syndrome from a pathophysiological point of view, and a determinant of the development and progression of metabolic disorders.

The immune response triggered in metabolic disorders involves the integration of many complex signals in different cells and organs, and is characterized by a low-grade chronic inflammation, usually called metaflammation (157), and which refers to metabolically triggered inflammation. This condition is mainly initiated by an excess of nutrients that favors the storage of energy, disrupting metabolic

homeostasis (318). Individual tissues and cells are effectors of the immune response when an inflammatory state is chronically established. In turn, responsiveness to certain inflammatory mediators (vasoactive amines, vasoactive peptides, complement components, lipid mediators, cytokines, chemokines and proteolytic enzymes) is almost ubiquitous, but these have distinct effects in different cell types (243).

Immune responses to cellular stress through NF-κB signaling such as the production of antimicrobial factors, phagocytosis, leukocyte recruitment, and adaptive immunity could also involve HIF-1 activity (74, 92, 241). For instance, phagocytes lacking HIF-1α are unable to eliminate bacterial loads (92). In hypoxic and inflamed tissues, HIF-1α also stimulates ATP generation in myeloid cells to increase antibacterial activity, and to prevent neutrophil apoptosis (90, 92, 241). Moreover, after pathogen phagocytosis, oxygen is needed in the production of ROS — a process called respiratory burst — to lyse and kill microbes (90). The resident macrophages constitute 10–15% of the cellular content of most tissues and are responsible for monitoring the tissues, primarily in relation to host defense and the removal of apoptotic bodies. When tissues are under stress or dysfunction, these resident macrophages are activated and a pro-inflammatory response is initiated (166). Therefore, the immune response has a physiological role in restoring tissue homeostasis, and an inability to resolve the dysfunctional condition establishes a mild chronic inflammatory disease state (341). Metabolic organs under stress conditions dysregulate the production of classical cytokines — particularly tumor necrosis factor alpha (TNF-α), interleukin 1β (IL-1β) and interleukin 6 (IL-6) — and of proteins involved in vascular hemostasis and angiogenesis such as plasminogen activator inhibitor 1 (PAI-1). The production of factors involved in glucose homeostasis, an example being adiponectin (ADIPOQ), and in immune cell recruitment, such as monocyte chemotactic protein 1 (CCL-2, also known as MCP-1) (377) — which are closely related to MetS, CVD and type 2 diabetes (T2D) (255) — is also dysregulated. Despite the fact that IL-6 is generally considered to participate in pro-inflammatory signaling, genetic inhibition of *Il6* expression has been reported to lead to insulin resistance and liver inflammation in mice, and IL-6R blocking drug-therapy increased body weight and resulted in dyslipidemia in humans, suggesting a dual role of this molecule in metabolism (340). In this sense, the IL-6 produced by skeletal muscle seems to have beneficial effects on metabolism energy sensing during exercise as (311); nevertheless, the chronic elevation of IL-6 could contribute to the development of insulin resistance (91).

A.   *Metabolic disorders and methylation*

In recent years, epigenetic regulation of gene expression has become evident, leading to increasing scientific interest in metabolic disease (48, 332). In this regard, DNA methylation is one of the most

Lopez-Pascual *et al.*

widely studied epigenetic modifications, and has been used as a biomarker in metabolic diseases such as obesity, CVD and insulin resistance, since it controls the cell phenotype by altering the production of regulatory proteins (48, 235, 246, 332). The methylation of CpG islands in the promoter region of the long interspersed nucleotide element 1 (*LINE1*) retrotransposon, the only active, autonomous transposable element in humans, has been widely used as a marker of global DNA methylation (404). As a general rule, higher levels of DNA methylation used to be related to lower gene expression (320). However, in some metabolic disorders, both DNA hypo- and hypermethylation are present. For instance, previous studies found that *LINE1* promoter methylation (measured in blood cells unless stated otherwise) was inversely associated with BMI and HOMA-IR in healthy women (300), with body fat mass in healthy young adults (234), with CVD in overweight and diabetic subjects (54), with myocardial infarction risk in a case-control cohort (132) and with metabolic risk markers in the WAT of MetS subjects (392). In contrast, it was positively associated with weight loss (107) and insulin sensitivity (232) in blood cells from obese subjects. However, other authors suggested that there is no association (88, 436), or even a positive connection (52, 269, 319, 393), between *LINE1* methylation and metabolic markers. The disparities in the direction of the outcomes might be related to differences in gender and race/ethnicity, as previously evidenced (436).

The gene methylation pattern of pro-inflammatory molecules was previously linked with metabolism-related pathological conditions. For example, *IL6* methylation was increased 6 months after weight loss (269) and 12 months after bariatric surgery (190). However, it was also positively correlated with obesity features in MetS subjects (52), and with women's obesity (261), but not significantly when associated with lifestyle (437). Moreover, *TNF* methylation increased a year after bariatric surgery (190). Despite that, other studies on *TNF* methylation have shown a decrease after a weight loss intervention (47, 71), a negative correlation with waist circumference in healthy young individuals (234), a positive association with adiposity (145), and no association with BMI (261).

Regarding *SERPINE1* methylation, a positive association with weight loss (269) and waist circumference (52) was found, as well as a negative association with obesity and CVD markers in MetS subjects (220). Besides, lower *TNF* promoter methylation was previously correlated with higher circulating TNF-α levels (145). In addition, aging is commonly associated with higher systemic levels of pro-inflammatory factors, such as CRP, IL-6 and TNF-α (294). Previous studies have described a link between DNA methylation and the aging process (65, 127, 223, 231, 329, 370). Nevertheless, aging-induced differential methylation occurs mostly without changes in gene expression (370).

Furthermore, resting oxygen consumption was associated with a hypomethylation in a CpG island in the promoter region of *IL6* as well as an increase in circulating IL-6 in obese subjects with SAHS (223). Concerning SAHS, DNA methylation patterns were associated with sleep severity in adults

24

(64). In children with SAHS, an epigenetic dysregulation of vascular function is suggested through endothelial NOS hypermethylation (185), and of inflammation through the hypermethylation of the forkhead box P3 (FOXP3) gene in those individuals with higher systemic inflammation (188). However, a prospective study designed to evaluate the epigenetic mechanism involved in SAHS (233) showed that FOXP3 methylation, or its expression, is not altered in adults with OSA, whatever their inflammatory status (337). In this sense, it could be hypothesized that in the context of metabolic disorders, beyond transcriptional regulation, low oxygen consumption and hypoxia might be associated with levels of pro-inflammatory cytokines via epigenetic marks (Figure 7).


Figure 7. Hypothesis of hypoxia-induced epigenetic regulation. The low oxygen consumption (air breathed) and tissue hypoxia might be associated with the levels of pro-inflammatory molecules via epigenetic marks. Specifically, DNA methylation changes in the promoter region of pro-inflammatory coding genes are proposed in this schematic diagram; however other epigenetic mechanisms cannot be excluded.

At a molecular level, DNA methylation marks can be removed by an active demethylation mechanism involving a family of DNA hydroxylases (TET proteins), or a passive demethylation process (inhibition of the maintenance methyltransferase, DNMT1), during cell division (208). In the active mechanism, the enzymes removing methyl groups from DNA and histones are included in the superfamily of 2-oxoglutarate-dependent dioxygenases, enzymes that are dependent on molecular oxygen as a co-substrate and ferrous (Fe^{+2}) iron as a catalyzing cofactor (330). Therefore, by this mechanism hypoxia could induce hypermethylation. Moreover, methylation is modified by ROS with important implications in the pathogenesis of metabolic disorders such as CVD, obesity and diabetes

(83, 186). For example, ROS directly affect methylation by oxidation or hydroxylation of nucleotides, as well as indirectly, by means of modifying the activity and recruitment of methyltransferases and TET proteins (186). On the other hand, the hypoxic phenotype is at least partially mediated by DNA methylation alterations, depending on both the modulation of the universal methyl donor S-adenosylmethionine availability and the regulation of enzymes involved in DNA methylation and demethylation by HIF-1 and 2 (49). Thus, many epigenetic regulators are affected by hypoxia and ROS, but their effects might be tissue-specific and could involve many other physiopathological aspects.

B. *Metabolic syndrome*

The metabolic syndrome (MetS) is a cluster of interconnected factors with a common low-grade, chronic pro-inflammatory state and is highly prevalent in Western countries, where more than 25% of adults are said to suffer from the condition (277). These factors are hyperglycemia, elevated blood pressure, hypertriglyceridemia, low levels of high-density lipoprotein cholesterol levels (c-HDL), and central adiposity; the latter can be measured by waist circumference and body mass index (BMI) (131). Many international organizations and expert groups have defined the MetS (Table 3). Nevertheless, a major problem with some definitions is apparent in terms of the applicability to different ethnic groups, especially when trying to define central adiposity according to waist circumference cut-offs (5). As a result, the prevalence of MetS varies and depends on the criteria used in different definitions, as well as the composition (sex, age, race and ethnicity) of the population studied. Despite this variance, there is enough evidence indicating that MetS is a risk factor for CVD and T2D (257, 417).

Recently, other disturbances have been related to the MetS, such as respiratory disorders, liver disease, arthritis, fertility disorders, psychological disturbances and cancer (57, 318). A link between MetS and respiratory disorders has been observed in several studies, not only sleep apnea but also lung function impairment, pulmonary hypertension and asthma (15). Sleep apnea, or SAHS, is characterized by recurrent episodes of apnea-hypopnea due to the occlusion of the upper airways with pharyngeal soft tissue, resulting in intermittent hypoxemia (79, 84). The carotid body senses the lack of oxygen and activates the sympathetic nervous system, clearing the airways and producing reoxygenation (346). This sequence is repeated with each apnea event, leading to oxidative stress and inflammation (79, 250). In this sense, hypoxia-reoxygenation in SAHS contributes to ischemia-reperfusion injury (79). SAHS is associated with hypertension (89), insulin resistance (381) and obesity (331). In the general population, SAHS is evident in approximately 6-13% of adults; however, this proportion is dramatically enhanced in those with MetS, around 60% MetS patients exhibiting the condition (86).

Lopez-Pascual *et al.*

Table 3. Criteria for definitions of the metabolic syndrome (MetS) in adults

	ATPIII (2001)	AHA/NHLBI (2004)	IDF (2005)	IDF-AHA/NHLBI (2009)
Criteria required	Any ≥ 3	Any ≥ 3	WC mandatory, plus ≥ 2	Any ≥ 3
Waist circumference	≥102 cm (men) ≥88 cm (women)	≥102 cm (men) ≥88 cm (women)	≥94 cm (men) ≥80 cm (women)	≥94 cm (men) * ≥80 cm (women) *
High-density lipoprotein	<40 mg/dl (men) < 50 mg/dl (women)	<40 mg/dl (men) < 50 mg/dl (women)	<40 mg/dl (men) < 50 mg/dl (women)	<40 mg/dl (men) < 50 mg/dl (women)
Triglycerides	≥150 mg/dl	≥150 mg/dl	≥150 mg/dl	≥150 mg/dl
Blood pressure	≥130/85 mmHg	≥130/85 mmHg	≥130/85 mmHg	≥130/85 mmHg
Blood glucose	≥110 mg/dl ‡	≥100 mg/dl	≥100 mg/dl	≥100 mg/dl

ATPIII: Adult Treatment Panel III; AHA/NHLBI: American Heart Association/National Heart, Lung, and Blood Institute; IDF: International Diabetes Federation; IDF-AHA/NHLBI: Harmonized definition of IDF and AHA/NHLBI. *Waist circumference (WC) according to population and country-specific definitions, these values for Caucasian population. Any criterion is also met when there is a drug treatment specific for reducing the clinical condition. ‡ ATPIII has changed the cut-off for blood glucose in 2003 by matching with harmonized definition.

Another metabolic disorder closely related to MetS and SAHS is non-alcoholic fatty liver disease (NAFLD), which is characterized by an accumulation of triglycerides in hepatocytes (250, 390). The severe progression of NALFD is steatohepatitis, which presents ballooning degeneration and inflammation, and is a major cause of cirrhosis and hepatocellular carcinoma (250). The high prevalence of NAFLD — up to 30% — is associated with the MetS (78, 109, 371). Finally, other disorders related to the MetS should be mentioned. About 10% of all cancer deaths among non-smokers are related to obesity; specifically breast, colon, endometrium, kidney and esophagus cancer are each associated with obesity and a sedentary lifestyle (57, 140). On the other hand, metabolic disorders have been associated with psychological features such as depression and neurodegenerative pathologies (Alzheimer's and Parkinson's diseases), since both pathologies share a dysregulation of inflammation and oxidative stress (156).

It is emphasized that recent studies indicate that increased adiposity does not always translate into metabolic dysfunction (121), and between 10 and 34% of obese individuals are considered metabolically healthy obese (MHO) since the excess in body weight is not accompanied by other metabolic disturbances (32). Despite the lack of relevant comorbidities and MetS clustering in MHO subjects, a similar risk of CVD and all-cause mortality has been observed (264), along with the risk of

T2D (32), to that for unhealthy obese. However, there is a lack of information on the underlying mechanisms that make a difference between the healthy and unhealthy obese (259).

1.   Obesity

The worldwide epidemic of obesity represents one of the greatest threats to global human health: world data from 2016 indicate that over 650 million adults are obese (13% world population), and over 1,300 million are overweight (39%). Moreover, the obesity epidemic is also affecting children and adolescents as the prevalence of childhood (5-19 years old) overweight/obesity is now over 18% (378). The complex physiopathological processes leading to obesity reflect environmental and genetic interactions, since not all individuals exposed to an environmental factor develop the same grade of obesity (140). The mutual gene-environmental interactions result in multi-factorial obese phenotypes (147).

The main feature of obesity is the excessive accumulation of lipid in white adipocytes as a result of a positive energy balance associated with overnutrition and sedentarism. WAT, as an endocrine organ, is responsible for the production of many secreted factors, both lipid and protein (adipokines),with systemic effects encompassing many different physiological and pathological functions (3, 16, 197, 209, 255). At the tissue level, obesity is characterized by a mild, chronic inflammatory state in metabolically active tissues including adipose, heart, liver and muscle, which induces a stress response characterized by increased levels of pro-inflammatory molecules (33). The immune cells present in WAT receive stress signals from the adipocytes, which are unable to store all the nutrients provided following overnutrition (9). Some chemotactic molecules are involved in the recruitment of immune cells (MCP-1), while others are able to differentiate macrophages to the M1 phenotype (IL-6, TNF-α) which is generally considered pro-inflammatory (20, 157, 281, 318).

Several mechanisms have been proposed to explain the initial cause of the inflammatory processes during obesity, including oxidative and ER stress, and WAT hypoxia (117, 281, 318). The oxidative stress is associated with impaired mitochondrial capacity which could lead to a defect in oxygen consumption (60% lower in the WAT of obese individuals), regulated by WAT blood flow which is also lower in obese subjects (40% reduction) (122, 205). In this sense, an inability to preserve tissue perfusion might be related to the hyperplasia and hypertrophy of WAT. Notwithstanding the lower perfusion, some authors have reported a higher abdominal WAT pO_2 (4-34% increase) in obese subjects, while others showed lower abdominal WAT pO_2 (15-25% reduction) in obese/overweight subjects (68, 205). Moreover, a recent study reported a 25% lower pO_2 in subcutaneous abdominal WAT in unhealthy obese subjects — with prediabetes and high intrahepatic triglyceride levels — compared to MHO (12% reduction vs lean) and healthy lean subjects (68). On the other hand, the pO_2

of WAT was found to be lower in obese rodents (6% in lean *vs.* 2% in obese mice) (72, 121, 388). Importantly, obese WAT immunostaining with pimonidazole (a chemical marker of hypoxia) revealed the co-localization of hypoxic regions and infiltrated macrophages (318). The lowered oxygen consumption in (mouse) obese WAT leads to a metabolic switch from aerobic to anaerobic metabolism (203, 387). But the range of metabolic changes resulting from low oxygen availability in WAT extends well beyond the augmentation of glycolysis. Data from microarray studies have shown that over 1,000 genes are hypoxia-sensitive in human adipocytes (384, 385).

As noted above, WAT exhibits high levels of hypoxia in obese rodents (106, 155, 315). Mechanistic studies have shown that the activation of hypoxia signaling stimulates glucose transport in adipocytes through the GLUT1 facilitative glucose transporter (372, 387). However, hypoxia induces an impairment in insulin sensitivity in adipocytes, so that insulin-stimulated glucose uptake is compromised (317, 399, 432). Moreover, it is also known that the inhibition of hypoxia signaling in HFD mice improves WAT dysfunction and insulin resistance by enhancing insulin secretion, and reducing macrophage infiltration and inflammation (174, 176, 187, 287, 360, 373). Furthermore, some authors have suggested that HIF-1 overexpression is involved in the inhibition of cellular respiration in BAT, since it is accompanied by a decrease in thermogenesis (176). However, to date there is no conclusive data of whether the inflammatory, or the hypoxic, cascade occurs first in the molecular events in obesity and its related comorbidities (317). On the other hand, the genetic inhibition of oxygen sensing proteins that leads to a pseudohypoxia state, showed a preventive effect on WAT inflammation, insulin resistance and weight gain in HFD mice (312), as well as improved glucose tolerance and less WAT macrophage infiltration (239); it also suppressed lipolysis and promoted benign WAT expansion (245).

2. Cardiovascular disease

The Global Burden of Disease study of 2015 estimated that there were 422.7 million cases of CVD, this being the most common cause of death worldwide with nearly 18 million people dying from the disorder (31% global deaths) (326). Coronary artery disease and cerebrovascular disease are the most common forms of CVD. The underlying pathological process of CVD is atherosclerosis which is a chronic inflammatory disorder in which cholesterol progressively accumulates in the large and medium-sized arteries, causing stenosis (138). This progression begins with endothelial activation and inflammation, that presumably originates from the high circulating levels of low-density lipoprotein cholesterol (c-LDL) which accumulates in the intima (the inner layer of the artery) (138). These c-LDL particles are prone to oxidation by enzymatic attack by myeloperoxidases, lipoxygenases and ROS, and this is a key factor in early atherogenesis. The accumulation of oxidized c-LDL also drives

29

the recruitment of immune cells, which increases the pro-inflammatory response and provokes the formation of a fibrous cap. Over time this atherosclerotic plaque becomes a more complex lesion with a necrotic core, covered by a fibrotic layer (138, 154, 213). The plaque growth contributes to lumen stenosis and ischemia, which activates hypoxia signaling (200, 348). Moreover, thrombosis can be produced by a plaque rupture, and this material may block the lumen or become an embolus which clots in a distal point (138).

Atherosclerosis can be explained in similar molecular terms as obesity, as both involve a pro-inflammatory process, oxidative stress and hypoxia pathways. In endothelial cells, the activation of NF-κB induces the transcription of cell adhesion proteins such as intracellular cell adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), as well as chemokines and cytokines — including IL-1β, IL-6, and TNF-α — involved in the atherogenic process (20, 114). Prolonged pro-inflammatory cytokine production leads to the generation of ROS and other oxidative stress molecules, which are major contributors in the development of cardiovascular-related traits such as ischemia/reperfusion injury, hypercholesterolemia and endothelial dysfunction (376). Moreover, the ER stress, also present in CVD, occurs in endothelial cells as a result of an excessive demand for protein synthesis and is aggravated by increased ROS and hyperlipidemia. (154). During the recruitment of macrophages to the atherosclerotic plaque, lipid transporters contribute to the removal of the excessive cholesterol accumulated in the vessel walls. This process triggers the UPR-dependent activation of inflammatory pathway (80, 278).

3. Diabetes

The number of people worldwide with T2D was more than 350 million in 2015 and is projected to rise to 439 million by 2030 (approximately 8% of the world's total adult population). Diabetes is a chronic degenerative disease characterized by insulin resistance, a pathological condition in which insulin becomes less effective at lowering blood glucose levels and which results in long-term complications affecting the eyes, kidneys and nervous system; it is also known to increase the risk of CVD and some types of cancer (63, 178, 262). The pro-inflammatory cytokines produced by metabolically impaired tissues, such as liver and AT, may promote insulin resistance in the tissues where they are produced or in distant tissues and organs, e.g. vessel walls, skeletal and cardiac muscle (85). Over-supply of nutrients — including glucose and fatty acids — as well as hypoxia are associated with β-cell damage, leading to impaired β-cell insulin secretion in T2D (110). Accumulating evidence points to a role for oxidative stress in both processes. Skeletal muscle is the largest insulin-sensitive organ in humans; consequently, insulin resistance in this tissue has a major impact on glucose homeostasis in the body

as a whole. Impaired mitochondrial function might contribute to insulin resistance via altered metabolism of fatty acids, which, in turn, may lead to ROS generation (293).

It is known that β-cells have a very low level of antioxidant systems, and are therefore particularly vulnerable to oxidative stress, which is central in the development of insulin resistance (85, 110). In response, β-cells increase insulin production dramatically, which may generate ER stress (85, 283). Concretely, the IRE1 and PERK arms of UPR are involved in the ER stress associated with obesity and glucose intolerance (278, 283). Moreover, WAT hypoxia in obesity may lead to marked insulin resistance through multiple routes. For example, alterations in the production of adipokines linked to insulin sensitivity such as adiponectin (markedly reduced under hypoxia) could drive insulin resistance in WAT (383). Similarly, lactate release is increased under hypoxic conditions, and could lead to the induction of insulin resistance in skeletal muscle (384).

VII.   Oxygen measurements

Given the critical importance of oxygen in aerobic organisms, it is essential to be able to monitor and measure its levels. In fact, some of the controversy and inconsistencies found in studies analyzing the role of oxygen in metabolism, seem to be related to the different measurement methods employed. In this context, most available techniques to directly measure oxygen levels are limited to the surface areas of a tissue. Thus, selecting the appropriate technique is based on applicability to the experimental model and the nature of the information pursued.

A.   *Electrochemical sensors*

Oxygen polarographic (Clark) electrodes are considered as the reference method for measuring oxygen tension in permeabilized cells and isolated mitochondria (53, 99, 363), due to the following advantages: good reproducibility and accuracy, low deviation between each sensor, and the high detection resolution (99). These electrodes contain a noble metal (e.g. silver, gold, platinum) which reduces oxygen due to a negative polarizing voltage (53). While oxygen is reduced at the cathode surface, the amount of oxygen diffusing through the permeable membrane increases, closing the circuit and emitting a current proportional to the amount of oxygen at the measurement point (99, 335, 363). However, these electrochemical sensors have major drawbacks such as reliability, invasiveness and heterogeneity (53, 99). The reliability is challenged by the oxygen consumed by the electrode itself, although this mainly affects those situations in which there are either small samples or oxygen-deficient tissues (418). Hence, the measurement over time in a specific region is not possible and the tissue oxygen tension should be rather greater than the electrode oxygen consumption. Regarding the invasiveness, the use of a needle potentially damages a tissue. Finally, the sensor measures only one

single point and does not reflect the heterogeneity of oxygen distribution in a tissue as a whole, thereby lowering the reproducibility between investigators and laboratories.

B.   Optic fibers

Systems based on optic fibers are another method to measure tissue, and isolated mitochondria, oxygen levels using a fluorescent dye, usually ruthenium chloride or porphyrin platinum, in a sol-gel coating on the sensor tip (53, 99, 418). The oxygen quenches the light emitted by the fluorescent dye in tissues in proportion to the oxygen tension (53, 418). The advantages of this technique are: (i) the possibility of continuous measurement since the oxygen is not consumed during the process, (ii) the option to measure in multiple sites at the same time, (iii) the ability to work under highly different levels of oxygen and areas of application, as well as in hostile environmental conditions (418). However, this approach can be invasive and the fiber tip is fragile (99).

Nowadays, the Seahorse X and the OROBOROS oxygraphy-2K analyzers, which are optic fiber-based techniques, are among the preferred methods to measure oxygen consumption and for the study of mitochondria in cell cultures (87, 230). However, these techniques can only be applied in cell culture and isolated mitochondria assays, and still do not provide an *in vivo* analysis. In order to overcome the problems of the fiber tip and to measure in larger areas, a combination of the optical sensor with a dialysis technique has been developed to monitor tissue oxygen levels *in vivo*. The microdialysis catheter is inserted 6-8 cm lateral from the umbilicus to extract interstitial fluid as an artificial blood vessel (122). The exchange of gases is measured by an optoelectronic unit in the catheter made of an oxygen-sensitive membrane connected to a computer for data collection (402).

C.   Pulse oximetry

A frequently used method for hemoglobin oxygen saturation (sO_2) is near-infrared spectroscopy (pulse oximetry). This optical technique applies light transmission and absorption principles to dynamic changes in biological molecules bound to oxygen (99). Based on the Beer-Lambert law, the visible light in the near infrared region (700–3,000 nm) easily passes through biological tissues. This technique is unable to measure tissue pO_2, but provides peripheral sO_2 instead, which results from the balance between oxygen delivery and consumption (53).

D.   Hypoxia imaging

Other methods may be used to measure relative oxygenation by the imaging of hypoxic areas, most often through labelling the oxygen content in a tissue. Electron paramagnetic resonance spectroscopy (EPR) offers the unique capability to detect unpaired electrons (53), which can be used to measure tissue oxygenation. ERP involves the use of an external probe (most commonly lithium

phthalocyanine) consisting of either implantable paramagnetic particles, or soluble probe molecules (nitroxides) that physically interact with, but do not consume, oxygen (374). The interaction of two paramagnetic species, molecular oxygen and the probe, gives the signal that allows pO_2 to be determined (53, 374). The advantages of EPR comprise continuous readouts of the same sample, site specificity and accuracy (53). However, the limited range of detection (10–100mm Hg pO_2), high cost, lack of evidence against toxicity (implantation or injection of paramagnetic material) and the low sensitivity-safety ratio (10 mm from the surface) result in it not being commonly employed in clinical practice (53, 99). Moreover, this method requires imaging by positron emission tomography (PET) scanning, a technique based on the detection of anti-parallel 511 keV photons emitted during the annihilation of positrons with electrons.

PET radiotracers (compounds labelled with short-lived positron-emitting radionuclides) are injected or inhaled to reach the target to be detected with a ring-shaped array of photoelectric crystals by the PET scanner (53). Despite newer radiotracers having been developed, the limited sensitivity (anatomical resolution of 4-8 mm^3) and the cost make it difficult to apply this approach for indirect oxygen measurements (53, 99). In essence, magnetic resonance imaging (MRI) techniques using perfluorinated contrast agents (fluorine) could be used for quantifying tissue oxygen levels (335) with better resolution than PET imaging (53). MRI is based on the paramagnetic properties of oxygen dissolved molecules affecting the relaxation rate of the contrast agent, which is used to either monitor the pO_2 levels or create an organ oxygen distribution map (99). However, this technique is high-priced and requires patient cooperation (53).

E. *Indirect methods*

Lactic acid (2-Hydroxypropanoic acid) is generated in tissues from pyruvic acid under anaerobic conditions. Lactate determination is an indirect measurement of oxygen availability that can be made by basic analytic methods (colorimetry, spectrophotometry, fluorometry, voltammetry, MRI and chromatography) or by biosensing techniques (electrochemical, electrochemiluminescence, fluorescence and microband lactate biosensors) (305). The authors of the aforementioned review (305) support the use of biosensing methods pointing out that they are better than traditional analytic methods, as they are very simple, sensitive, selective, disposable, automated and give rapid results. However, more simple, accurate, reliable and cheap lactate biosensors are needed. Thus, lactate biosensors are promising devices for clinical analysis of several metabolic disorders related to hypoxia. Lastly, indirect calorimetry is regarded as the gold standard to estimate resting energy expenditure, by measuring oxygen consumption and carbon dioxide production. Heat production from substrate oxidation is estimated from measures of oxygen consumption and carbon dioxide production using

Weir's equation: 3 heat output (Kcal) = $3.9 \times$ oxygen consumed (l)+1.11 x carbon dioxide produced (l; 1 Kcal =4.186 kJ), where in a balanced diet it is considered that 1 l of O_2 consumed equals to 4.825 Kcal (195, 325). The most common indirect calorimetry device is the metabolic cart, which captures exhaled gas using a canopy, facemask or mouthpiece with a nose clip connected to oxygen and carbon dioxide analyzers (195). These systems are relatively inexpensive and easy to use, but measurements can be influenced by subject anxiety and hyperventilation (325). Indications for indirect calorimetry can be clinical conditions altering resting energy expenditure, and patients with a lack of predictive equations for their particular situation.

VIII.   *In vitro* experimental models of metabolic disease

The interplay between the different pathways together with gene-environment interactions make the study and treatment of metabolic diseases particularly difficult. Common metabolic disorders are polygenic, involving complex gene-gene and gene-environment interactions, producing multi-factorial phenotypes. For the correct study of every single disease, the cell biology and physiology, the interaction with other cell types and the specific milieu should each be well-understood. Thus, there is a profound need for adequate experimental models of each metabolic disease, including the pathways affected, in order to study the possible causes and potential therapeutic targets (7, 279, 295, 297, 403). Animal models for the study of the physiopathology of metabolic disorders represent an important tool in research, as they provide information under relatively controlled conditions. However, such studies have some ethical and economic limitations (279, 295, 297). For this reason, *in vitro* models have emerged as the favored choice for many mechanistic investigations (279, 297).

A.   2D-Cell culture models

One example is adherent 2D cultures and these are defined by a cell monolayer attached to a plastic surface and have the main advantage of simple handling and low-cost maintenance. However, the major drawback is the lack of reproducibility of the *in vivo* tissue conditions (180). The absence of different cell-type interactions makes it necessary to develop new culturing techniques. In co-cultures, different cell types are grown together in the same environment allowing the study of cell-cell communication (290). Co-cultures can be divided into direct and indirect types, depending on the contact between the cultures (mixed or with a physical barrier) (180). The main short-coming of co-cultures is the inevitable inclusion of variables that require a higher experimental design than unique cell-type 2D cultures.

B.   3D-in vitro approaches

Novel methods of tissue engineering are critical for relating the results of *in vitro* studies to *in vivo* conditions. Spheroids and organoids have recently been developed as a 3D approach relying on spontaneous morphogenesis in cell aggregates (289). These three-dimensional tissue cultures are a fast-growing method for investigating cell biology that could be helpful in increasing the range of *in vitro* models in human medicine (99, 226). Spheroids are multicellular aggregates of microscopic tissues with a modifiable composition and biological properties which may be of considerable interest in diverse applications due to the micro-environment generated being similar to that of tissues *in vivo* (189, 226). Thus, this approach could be useful for mimicking the physiopathological conditions on the way to complex organ-like structures (99, 189). The study of spherical cellular aggregates provides insight into variations between the surface of the spheroid and its core (189). However, this also implies a serious limitation due to insufficient oxygen diffusion towards their cores (99).

C.   Novel experimental models

Further along the direction of mimicking real tissues, organoids have been presented as an approach for organ-like culturing of *in vitro* studies and *in vivo* transplantation (226). Organoids are characterized by a group of organ-specific cells that are developed from stem cells or organ progenitors (99, 226). Hence, organoids are promising new tools in the arsenal for developing strategies for organ replacement, the modeling of many diseases, drug discovery, and safety screening studies (226, 289). However, the organoid approach faces important challenges, such as controlling the organoid micro-environment including extracellular matrix composition, stiffness, and architecture and managing the cellular heterogeneity in each specific organoid system, as well as providing the appropriate oxygen and nutrient supply for each particular cell type within the organoid (99, 189, 226). Nevertheless, reliable and accurate animal models are still the best choice for bridging *in vitro* mechanistic investigations with clinical application, despite ethical and economical barriers.

IX.   Therapeutic approaches

With regard to the clinical management of the MetS, the primary goal is to reduce the risk factors comprising the syndrome. The first emphasis is on the mitigation of the underlying modifiable factors (diet, habits, physical activity) through lifestyle changes. These low-risk treatments are based on lifestyle alterations such as dietary modification and exercise to produce an energy deficit as the first-line choice. When this approach is not enough, drug therapy is considered in order to maintain the cardiovascular and diabetes risk as low as possible. However, due to the side effects of current drug therapies, and the risks derived from surgical treatments, there has been a growing interest in

developing novel therapeutic approaches for metabolic diseases. In this sense, new strategies applying genetic data (specific targets coming from pharmacogenetic and nutrigenetic screening), antibodies or vaccines against mediators (ghrelin, IL-6, IL-1, IL-1β), bioactive compounds, gene therapy, RNA interference technologies and oxygen therapy have all been considered (73, 85, 117, 119, 236). Oxygen-related therapies include a wide-variety of approaches, such as intermittent hypoxia (IH) and chronic hypobaric hypoxia (altitude), hyperoxia exposure and oxygen delivery strategies; these will be discussed next.

A.   *Intermittent hypoxia*

Although the detrimental effects of severe hypoxia on a variety of physiological outcomes have been established, there are a number of intervention studies that employ IH due to some health-promoting effects as a result of adaptation. The protocols for IH commonly used in experimental research normally refer to normobaric hypoxia in cycles along time. However, the protocols vary in terms of the severity of hypoxia, duration of episodes, the number of hypoxia/reoxygenation cycles, and the pattern in both time and cumulative duration of exposure. Generally speaking, IH protocols considered to provide beneficial outcomes are defined by episodes of mild hypoxia (10–14% oxygen) that are short in duration (15 seconds to 4 minutes), small in number (around 10 episodes), and have a short length of exposure (up to 1 hour) — although these milder protocols may also have some inherent risks (236).

1.   Functional principle

IH therapy, besides having been found in obese WAT to be probably linked to lower oxygen perfusion (121), has been suggested as a putative treatment for obesity and related risk factors (182, 249, 263, 308). Several beneficial metabolic responses to IH have been reported including reductions in body weight, cholesterol, glycemia and insulin resistance. IH protocols have been used as a treatment for different pathologies such as respiratory disorders, CVD, inflammation and neurodegeneration. The underlying mechanisms of the putative benefits of IH may involve the enhancement of angiogenesis, increased satiety through sympathetic activation, enhanced mitochondrial enzymatic activity and enhanced glucose uptake due to the translocation of glucose transporters (263, 394). Moreover, IH could improve cardiometabolic risk by reducing blood pressure via RNS production, which would lead to endothelial relaxation and adaptive responses for NO production (237).

The potential mechanisms of IH are summarized in Figure 8. In this context, IH could be considered as a therapeutic strategy to manage some metabolic-related disorders such as SAHS, possibly due to the reduction in the number of apneas by sustained hypercapnia, and CVD, associated with the

adaptation to hypoxic stress and the molecular consequences of the remodeling of the cardiovascular system (263). In rodents, the PI3K/AKT pathway has been suggested to be involved in IH-induced cardioprotection (247). In this sense, current evidence suggests that regular exercise-induced adaptations to ROS handling, through redox signaling, including antioxidant and oxidative damage repair systems, contribute to the beneficial effects of regular exercise (311). The intermittent factor provides a preconditioning role to both exercise and hypoxia.


Figure 8. Schematic flow chart showing the potential mechanisms of intermittent hypoxia on cardiovascular, metabolic and neurodegenerative disorders. NO: nitric oxide; ROS: reactive oxygen species; EPO: erythropoietin. Adapted from Mateika, JH. and Komnenov D. 2017 and Quintero, P. *et al*. 2010.

It should be noted that SAHS patients suffer from cycles of IH and hypercapnia, which differs from IH therapies due to the hypocapnia (365). In SAHS patients, hypoglossal nerve activity could be a therapeutic target as this nerve is responsible for a decrease in pharyngeal dilator muscle tone and ultimately the collapse in apnea episodes; it has been suggested that IH might benefit SAHS patients through reduction in hypoglossal activity (237). Furthermore, IH could have a neuroprotective effect via increased angiogenesis and ROS-dependent endothelial adaptation, as well as ischemia-preconditioning (236). Another way to benefit from a hypoxic stimulus without undergoing the detrimental effects of a prolonged exposure to hypoxia is IH training, consisting of physical activity under hypoxic conditions (for short periods) remaining at normoxic conditions for the rest of the time,

Lopez-Pascual *et al*.

which has been suggested as a weight loss approach (394). Obesity, in turn, is the most important risk factor for SAHS development, and both conditions would benefit from weight loss and physical activity (11, 391). Finally, it has been suggested that IH training induces specific molecular adaptations at the muscle level which are not achieved by exercising under normoxic conditions (394).

2. Experimental evidence

Regarding the specific effects of IH on the MetS and its components, several studies of obese subjects treated with normobaric IH training found greater weight loss (191, 266), decreased body fat (414), improved cardiometabolic fitness (118) and lowered systolic pressure (191) over a medium-term period (4-8 weeks). Also, in healthy young men IH training for 4 weeks increased lean mass (18), attenuated the acute exercise-induced lipid peroxidation (19), decreased triglyceride levels and improved glucose tolerance (141). Another trial reported that pre-diabetic subjects (males and females) exposed to IH training for 3 weeks improved glucose tolerance and blood insulin (post-oral glucose tolerance test) (356), as well as respiratory and cardiovascular parameters (355). In short-term trials (3-5 nonconsecutive days), T2D males who followed a continuous exercise program of sixty minutes in hypoxic conditions improved insulin sensitivity (227, 228). In healthy males exposed to 10 successive days of IH training, a decreased postprandial glucose response and reduced cholesterol levels were observed (76). Finally, an investigation conducted in obese men treated with normobaric hypoxia for 10 consecutive nights showed an improvement in insulin sensitivity (199), although this only involved a small sample size.

On the other hand, a study performed in well-trained healthy men with normobaric IH high-intensity training for 4 weeks found an impairment in insulin sensitivity compared with training in normoxia (198). The level of specific adipokines was not changed following an IH training protocol of 13 weeks in obese men with SAHS (118), which could be in line with a recent short-term study (3 sessions) performed in healthy men exposed to IH (without exercise) that showed an improvement in respiratory plasticity in an inflammation-independent manner (23). Also, a study performed with healthy men under 10 days of normobaric hypoxia treatment (1 h/day, without exercise) found no changes in inflammatory markers (307). Moreover, over a longer period of time (8 months), no differences were shown in body weight and metabolic markers between obese individuals (males and females) in IH training and exercising under normoxic conditions (108).

Nevertheless, further studies are needed to identify the hypoxic protocol that best provides the amelioration of metabolic disorders by means of changing the hypoxia intensity/amount of oxygen, normo- or hypobaric pressure, number and duration of episodes, combination with exercise, and total protocol length in terms of the number of exposure days (236, 249). Besides, it seems likely that the

responses to exercise may vary across individuals and clinical conditions (82). Hence, a comprehensive examination of the metabolic responses to IH should be undertaken for both healthy subjects and those suffering from the MetS and associated comorbidities. The selection of the proper protocol will depend on the appropriate identification of biomarkers of the pathological features.

B. *Hypobaric hypoxia*

Studies of short-term exposure to environmental altitude, or as simulated with hypobaric hypoxia, have suggested a positive effect on insulin sensitivity and appetite reduction (422), and seem to be similar to those of normobaric IH (263). Certain studies have reported beneficial effects of a short-term geographical altitude exposure for subjects that already have MetS (130, 133, 267, 342).

1. Potential benefits

The available evidence shows that hypobaric hypoxia may have potential effects on metabolic disorders (148, 182) since it has been associated with weight loss and appetite reduction (217, 400), higher arterial sO$_2$ (303), lower adiposity and increased serum adiponectin levels (272), along with improved lipid metabolism (133). Chronic exposure to altitude has been associated with a lower prevalence of metabolic disorders in permanent populations living at very high- to extreme altitudes (Figure 9) (21, 81, 221, 222, 405, 406, 423, 424). Moreover, research conducted in Tibetans (358) showed that BMI decreased with increasing altitude (for each 1,000 m ascent the BMI was reduced by 1.43 kg/m^2). Also, previous studies have reported lower fasting glycemia (55, 216) and better glucose tolerance (296) at high altitude. However, some of these studies are descriptive and just reported prevalence, and hence the cause-effect relationship is still unclear. Moreover, the underlying mechanisms of the inverse association between altitude and glycemia remain uncertain (422).

Despite some studies reporting less ischemic heart disease, inconclusive data concerning blood pressure are evident as a higher prevalence of hypertension was associated with the very high altitudes (over 3,000 m) in highlanders of India (275); however, the evidence seems to support lower blood pressures in subjects who reside at altitude (10, 148, 285). In addition, living at high altitude reduces the mortality rate from ischemia (95), stroke (96) and coronary heart disease (96, 97), while the mortality from chronic obstructive pulmonary disease increases (95). Despite most studies being adjusted for multiple factors, exposure to altitude could influence the central nervous system by a regulatory role on appetite — at least in short-time exposures. Nevertheless, the direct effect of prolonged altitude exposure on appetite remains unknown. Basal metabolic rate and sympathetic activation in highlanders seems to be similar to those living on the coast, even if normalized to fat-free mass (424). Leptin and noradrenaline could be influencing the changes in energy expenditure and food

39

Lopez-Pascual *et al*.

Figure 9. Association between altitude and metabolic disorders. Studies are listed by increasing altitude level. m: meters; HR: Hazard ratio; OR: odds ratio; Diabetes T2: type 2 diabetes; c-HDL: high-density lipoprotein cholesterol.

40

intake at high altitude, since they increase energy expenditure via sympathetic nerve activity, even in acclimatized subjects (148, 285, 406). In addition, leptin levels were increased in participants who lost weight at very high altitude compared to those at sea level (285). Finally, the beneficial effects of ROS production, oxidative eustress — mainly through cellular signaling (362) — might explain the effect of altitude on metabolic disorders. In this sense, controlled ROS production due to altitude could exert several beneficial effects (394) through oxidative eustress and the physiological adaptation needed to breathe an adequate amount of oxygen at several hundred meters above sea level.

2.   Scientific rationale

As noted earlier, the highest concentration of oxygen occurs at sea level, where the pO_2 is approximately 160 mmHg (21 kPa), corresponding to 21% oxygen. The arterial pO_2 is approximately 13 kPa, with almost 100% of oxygen being available at 0 meters of altitude (Baillie lab, University of Edinburgh). This atmospheric pO_2 means roughly 98% of arterial sO_2. For every 500 m in elevation the arterial pO_2 is reduced by 1 kPa, at the same time the arterial sO_2 decreases by around 1% and the oxygen availability falls by 7%. A reduction in arterial pO_2 by more than 1 kPa, and/or an arterial sO_2 below 95%, is considered hypoxemia (270). Therefore, we could assume that those subjects who permanently live at moderately high altitude (above 500 m) experience a certain degree of hypoxemia. Chronic hypobaric hypoxia exposure is more pronounced in studies including participants living above 1,500 m, which means 3 kPa less than those at sea level and an arterial sO_2 of 77%. This situation leads to various physiological changes following adaptation to chronic hypoxemia.

The available evidence suggests a potential preventive effect of living at altitude, but other possible explanations apart from reduced oxygen availability cannot be dismissed, since at high altitude there is lower pressure, temperature and humidity (Figure 10) (240, 412). In this regard, previous studies have found higher rates of obesity at higher temperatures (395, 431). Moreover, other factors such as genetic polymorphisms for the adaptation to very high and extreme altitudes could be involved in the lower prevalence of metabolic disorders, at least in Andean, Ethiopian and Tibetan highlanders (30, 159, 397). In this respect, some of the genetic variants that could contribute to human adaptation to altitude are linked to hypoxic adaptation (159), while others are related to the antioxidant system and lung function (397). Antioxidant adaptation is needed as hypobaric hypoxia is known to induce oxidative stress, which in turn contributes to endothelial damage and vascular remodeling (291). It is emphasized that we should be cautious in generalizing the effects on highlanders to populations living at moderate to high altitudes.

The emergence of COVID-19 infection in 2020 has aroused interest in relation to geographic factors in the transmission of the causative virus (SARS-CoV-2). In the midst of the crisis some authors have observed that an epidemiological trend has emerged in relation to high altitude populations exhibiting attenuated rates of transmission with limited COVID-19 infection severity (175). However, the potential contribution of ethnic genetic variations in the expression of angiotensin-converting enzyme 2 (ACE2), a protein recently associated with COVID-19 pathogenesis and

Figure 10. Altitude levels and associated atmospheric conditions. Classification based on the balance between the benefits and risks of altitude. The cutoff point between high, very high and extreme altitude may differ among studies. This limit is set by the manifestation of the first symptoms of high-altitude sickness (includes cerebral syndromes of acute mountain sickness, high-altitude cerebral and pulmonary edema syndromes). The death zone is over 8,000 meters, where the availability of oxygen is insufficient to sustain human life for a prolonged time span.

mortality, has been recognized. Thus, further studies are needed to analyze the potential protective effect of altitude against COVID-19 infection, especially in relation to altitude adaptation polymorphisms in highlanders.

C. Hyperoxia

Oxygen therapy, originally pioneered by Thomas Beddoes in Bristol (UK) at the end of the 18th century, has been used in clinical practice for the treatment of various disorders such as chronic obstructive pulmonary disease, ulcers in diabetic patients and cerebral ischemia, in addition to acutely in medical emergencies, such as for resuscitation and anaphylaxis, as well as for the treatment of chronic lung disease (117, 386). There are two different hyperoxia treatments depending on the pressure: hyperbaric oxygen therapy (HBOT) and normobaric oxygen therapy (NBOT). The administration of 100% oxygen at normal pressure (1 atmosphere absolute, ATA) or NBOT is indicated at any state which produces hypoxemia, in order to recover blood oxygen levels. HBOT corresponds to 100% oxygen with an atmospheric pressure equal or greater than 1.4 (usually 2.4–2.8 ATA) and it is already approved by the US Food and Drug Administration (FDA) for medical use in specific situations (Table 4).

Table 4. Indications for Hyperbaric Oxygen Therapy

FDA approved uses of HBOT	Beneficial effect
Air or gas embolism	Resorption and elimination of the emboli
Carbon monoxide poisoning	Prevention of delayed neurological sequelae
Gas gangrene	Bacteriostatic properties
Crush injury	Counteract of cognitive impairments
Decompression sickness	Reduction in bubble size, correction of hypoxia
Arterial insufficiency	Improvement of oxygen tension around the wound
Severe anemia	Increase in blood oxygenation
Intracranial abscess	Prevention of anaerobic bacterial growth
Necrotizing infections	Reduction of tissue hypoxia
Osteomyelitis	Bacteriostatic effects
Delayed radiation injury	Promotion of wound healing
Compromised grafts and flaps	Enhance vascularization
Acute thermal burn injury	Reduction of edema, improved healing
Sudden hearing loss	Reverse hypoxia in the cochlear apparatus

FDA: Food and Drug Administration

1.   Current indications of HBOT

The European Committee for Hyperbaric Medicine (ECHM) evaluated the FDA indications, categorizing them according to the strength of recommendation and level of evidence, at a consensus conference in 2016 (238). HBOT is administered in a chamber or through an endotracheal tube, masks or head hoods, with a duration varying from 45 minutes for carbon monoxide poisoning, to several hours in decompression disorders (380). The indications approved by the FDA that are categorized by the ECHM as being strongly recommended — of critical importance for final outcome of the patient/quality of practice/future specific knowledge — with a moderate level of evidence, unless otherwise stated, are outlined hereunder grouped by the etiology of each disease.

Carbon monoxide poisoning, arterial gas embolism and decompression sickness are characterized by an alteration in blood gases. Carbon monoxide poisoning has acute toxic effects, as well as a high risk for delayed neuropsychological sequelae (256). Given these potentially life-threatening effects, the ECHM recommends HBOT in case carbon monoxide poisoning causes one or more of these conditions: loss of consciousness at or before admission, clinical neurological, cardiac, respiratory or psychological symptoms or signs — as well as in pregnant women (238). Recently, a clinical practice

43

guideline also recommended HBOT for carbon monoxide poisoning (361). In this group of pathologies characterized by an alteration in blood gases, arterial gas embolism and decompression sickness are only supported by the ECHM in certain cases, with a moderate level of evidence (238).

Problematic wounds, anemia, radiation injuries, skin grafts, thermal wounds, traumatic injury and sudden deafness are defined by the presence of hypoxia, reduced irrigation of a tissue and insufficiency. When late radiation injuries occur, tissues suffer a progressive deterioration characterized by a reduction in the density of small blood vessels (reduced vascularity) and the replacement of normal tissue cells with dense fibrous tissue (fibrosis), until there is insufficient oxygen supplied to sustain normal function (25). HBOT promotes healing by increasing angiogenesis, cell proliferation and collagen formation, and prevents breakdown of irradiated tissue fields (25, 301). In traumatic brain injury, the brain and contiguous central nervous system structures suffer mechanical harm, with resultant ischemia, edema, compartment syndromes, and tissue necrosis — factors known to exacerbate secondary brain damage and ultimately to lead to neuron loss (39, 380). While surgery is a fundamental therapy for these injuries, the reduction of edema, protection from reperfusion damage, and enhanced wound healing are benefits of complementary HBOT (380). Lastly, for idiopathic sudden sensorineural hearing loss and tinnitus, treatment with HBOT remains recommended despite little knowledge on the mechanisms underlying the potential benefits (238, 364); but the benefits could be related to the etiology of the sudden deafness which has been suggested to result from a hypoxic event in the cochlear apparatus. Thus, HBOT might be able to reverse that oxygen deficit (27). The ECHM recommends HBOT for problematic wounds — moderate to low evidence, depending on the clinical aspects — and in particular cases of compromised skin graft and flaps — with a moderate to low level of evidence (238). Also, HBOT might help in the treatment of severe anemia and burn wounds, although with a low level of evidence (238).

Finally, infectious pathologies such as gas gangrene, intracranial abscess, necrotizing fasciitis and refractory osteomyelitis are suggested by the ECHM — with low evidence — to be treated with HBOT in conjunction with antibiotics and/or surgery to counteract the infectious agents (256, 380).

2. Clinical practice and experimental efficacy

In a recent meta-analysis of studies in critically ill patients in the first 24 h in ICU, it was concluded that hyperoxia treatment would lead to higher mortality (268). Furthermore, a meta-analysis with studies on acutely ill adults (66) concluded that a liberal oxygen therapy (above a peripheral sO_2 of 94-96%) increases mortality without improving other patient-important outcomes. Conversely, setting a "safe" peripheral sO_2 lower limit (avoiding a higher risk of death due to hypoxemia) is more difficult to establish. However, the authors support the conservative administration of oxygen therapy in

patients, and this is in line with a recent clinical practice guideline (361), which recommends oxygen therapy only when peripheral sO_2 falls below 89% for patients at risk of hypercapnia, or 90–92% for patients with stroke or myocardial infarction. On the other hand, the latter recommends stopping oxygen therapy when peripheral sO_2 reaches 96% because of increased mortality (around 1%) without any reduction in morbidity for higher values (disability, infection, length of stay, infarct size).

Therefore, and based on previous arguments, we think the guideline should be widened and thereby oxygen therapy should be started when peripheral sO_2 falls below 89% in patients at risk of oxygen-induced hypercapnia, or below 93% for other patients. Finally, oxygen therapy should be stopped when peripheral sO_2 achieves 96% in patients without hypercapnia and 92% in patients at risk of oxygen-induced hypercapnia.

Recent research has shown that oxygen therapy could improve other conditions such as wound healing, muscle regeneration, stroke recovery, traumatic brain injury, neurological damage, retrieval of surgical-related loss of cognitive function and migraine (26, 59, 103, 214, 301, 357, 379). However, excessive exposure to high oxygen — in time, or concentration — may lead to harmful effects. As discussed above, the main potential risk of oxygen therapy could be the imbalance between oxidative stress and antioxidant induction (282, 301, 364). After hours of higher oxygen exposure, the toxic effects of hyperoxia such as inflammation in the lungs, neurological damage, and ear and ocular injuries, could appear (301, 364).

Studies on hyperoxia treatment have provided evidence for an analogous beneficial effect to that found under acute hypoxia exposure on weight loss, glucose homeostasis and WAT inflammation (46, 117). Also nocturnal oxygen therapy improved exercise capacity, cardiac function, and cardiac sympathetic nerve activity in patients with heart failure and central sleep apnea (338, 382). Moreover, hyperoxia has been used in athletes as a support during training with an improvement in the oxygen transport capacity, lactate metabolism, power output and work tolerance (endurance) being shown (51). Hence, hyperoxia alone (117), or in combination with NO (276), has been suggested for the treatment of obesity and related disorders.

3.   Mechanisms of action

Physiologically, hyperoxemia results in vasoconstriction in the brain, heart and skeletal muscle, which decreases blood flow (364). The combination of peripheral vasoconstriction and increased vascular resistance leads to higher blood pressure (39, 364). This is sensed by pressure-sensitive receptors (baroreceptors) and causes a reduction in heart rate through para-sympathetic activity (354, 364). Furthermore, in order to prevent hypertension, blood flow is reduced (39). Hyperoxia also decreases carbon dioxide transport from tissues since hyper-oxygenated blood weakens the affinity of carbon

dioxide for hemoglobin (39, 75). The higher levels of tissue carbon dioxide together with the previously mentioned reduced blood flow lead to a hyperoxic hyperventilation phenomenon (39, 364). Finally, hyperoxemia increases ROS levels, leading to hyperventilation and hypocapnia, further contributing to vasoconstriction (39, 75). The administration of HBOT is known to increase the dissolved oxygen fraction in comparison with that of NBOT (364). Also, the increased pressure may have additional benefits, but the specific mechanism is unclear.

The molecular basis of oxygen therapy has been proposed as an adaptive response to compensate for increased oxidative stress (301) with the levels of antioxidant enzymes being increased when oxygen is present (364). The combination of oxygen therapy and exercise has a good rationale, as the exercise-induced ROS generation is also a powerful stimulus to activate antioxidant enzymes. Thus, both intermittent exercise and hypoxia-induced ROS generation result in increased activity of enzymatic antioxidants, which then results in increased resistance to oxidative challenges, including a wide variety of oxidative stress-related diseases (311).

In marked contrast, hyperoxia increases the production of both ROS and nitrogen species (301, 354). Moreover, animal studies showed neovascularization which increases the recruitment and differentiation of progenitor cells that could improve wound healing (301). These progenitors under HBOT have shown oxidative stress resistance through growth factors, which also help to regenerate the tissue (364). In parallel, HBOT has been shown to have a potential inhibitory effect on adhesion and inflammatory molecules (117). Overall, it is possible that hyperoxia therapy could have antioxidant and anti-inflammatory effects in various organs.

D.   Oxygen delivery systems

Whilst there are some investigations being conducted in relation to therapeutic approaches for metabolic diseases, the available strategies are not able to counteract the increasing rates of obesity and related disorders. Hence, novel therapies are needed, along with the personalization of treatments (119). In this sense, drug therapy against hypoxia signaling has been suggested to treat diverse disorders (200). Besides altered pO_2, obesity and associated comorbidities are characterized by increased oxidative stress and inflammation (117), which could be counteracted by novel agents (429). Therefore, the use of molecules with antioxidant activity could be a useful strategy to prevent the deleterious effects of ROS. Oxygenation strategies based on free or encapsulated oxygen carriers and oxygen-generating materials have been developed as tissue-engineered scaffolds to supply the tissue-specific oxygen-microenvironment requirements (99, 112).

1.   Hemoglobin-based oxygen carriers

Hemoglobin-based oxygen carriers (HBOCs) have been developed as chemically modified hemoglobin (acellular) or encapsulated hemoglobin inside oxygen carriers (cellular) (98, 173). To improve the half-life and stability of HBOCs, strategies such as cross-linking, polymerizing, coating, conjugating and complexation have been studied (99). The first generation of HBOCs was designed to avoid dissociation of hemoglobin tetramers into dimers by intramolecular or intermolecular crosslinked, polymer-conjugated and recombinant hemoglobin (173). Despite the substantial effort devoted on developing HBOCs, to date, acellular systems have been unsafe in humans. Especially concerning in relation to their use in clinical trials are induced hypertension, liver and pancreas damage, renal and neural toxicity and oxidative stress (42, 98, 298).

The second generation of HBOCs are based on co-assembly of hemoglobin with antioxidant enzymes — superoxide dismutase, catalase and rubrerythrin — to further stabilize and avoid inactive methemoglobin formation (173, 298). The cardiovascular system has been reported as the primary target of acellular HBOCs toxicity, with myocardial infarction, hypertension and death being the primary adverse events in clinical trials (339). Therefore, a third generation of HBOCs has been developed as cellular carriers by encapsulating hemoglobin inside several structures to protect tissue contact to HBOCs and avoid leakage, also prolonging the half-life in the circulation (298).

Generally, there are two main types of cellular HBOCs: liposome-encapsulated hemoglobin and polymer-encapsulated hemoglobin (173, 298). Although liposome-based strategies were found to have long vascular retention and stability (298), some defects still exist. For example, they are difficult to produce and expensive, and can activate the complement pathway and induce peroxidation (173, 298). On the other hand, polymer-encapsulated hemoglobin has generated greater interest due to the availability and lower price, broad variety and biocompatibility of polymers (173). Polyethylene glycol, poly(lactic acid), poly(glycolic acid) and their copolymers are the most applied polymers in the development of polymeric cellular HBOCs (298). Notwithstanding that some HBOCs have reached phase III clinical trials, reports of serious adverse events are the main reason for their being discontinued. Safety concerns about HBOCs-related vascular dysfunction characterized by hypertension, inflammation and oxidative stress have hindered further product

development and licensing (42). Thus, further studies on cellular HBOCs are warranted.

2.   Oxygen-releasing biomaterials

HBOCs have had less significant success in clinical trials than perfluorocarbons (PFCs), another artificial blood substitute that has been extensively studied. PFCs consist of fluorinated carbon chains which exhibit various properties that make them a highly suitable oxygen carrier for biological

applications (98). These properties are biocompatibility with living tissues given by the strength of C-F bonds, structural stability due to hydro- and lipophobic and self-assemble features in aqueous solution, the low polarizability and miscibility with non-polar gases, enabling PFCs to dissolve O_2 by physically capturing the molecules (98). Since PFCs can easily dissolve oxygen in aqueous conditions, PFC-containing gels are a promising solution for many of the limitations of current oxygen-related tissue engineering. PFCs have been used in a wide range of applications, including liquid ventilation, blood substitution, tissue preservation, wound healing, *in vitro* cell culture, and tissue engineering (439). PFCs were able to increase cell viability, promote cell differentiation, and maintain cell metabolism in various tissues and organs (98) and have been used as oxygen suppliers to preserve islets, brains, pancreas, hearts and kidneys (439). Nonetheless, their inability to provide a sustained release of oxygen may be a potential barrier for *in vivo* success (98).

Several PFC blood substitute products have been clinically tested and approved by different countries for specific applications (99). However, some products encountered setbacks in phase III clinical trials when patients experienced increased stroke risk and adverse neurological side effects (98). Hence currently, no PFC-based blood substitutes are approved for clinical use in any country — except Russia (439). Nevertheless, PFCs have overall shown greater clinical potential than other materials for oxygen delivery (98).

Alternate approaches have been experimentally used as oxygen-releasing biomaterials to provide adequate and sustained oxygen supply for engineered tissue both *in vitro* and *in vivo* by diffusion of entrapped, adsorbed oxygen or by chemical generation of oxygen (112). Some of these technologies are polymeric nanosponges, gas-filled microbubbles and microtanks for oxygen delivery. Experimental polymeric nanosponge-based formulations designed as oxygen delivery systems have been tested in cell cultures and in animal models (58, 100). In this regard, cyclodextrin nanosponges are biocompatible porous materials with adjustable release through ultrasound (439). Obtained by cross-linking a polymer with α- β- γ- cyclodextrins, these nanosponges have the capacity of encapsulating active molecules due to the cooperation of cyclodextrin cavities and cross-linker networks (58). With an average diameter of 400–550 nm, this material demonstrated an ability to reduce cell mortality during hypoxia and reoxygenation in a cardiac cell model *in vitro* (100) and possesses interesting potential for oxygen topical delivery in future medical applications (58). Nevertheless, the efficacy of the nanosponges delivering oxygen under hypoxic or anoxic conditions has not been examined yet (439).

Further, gas-filled microbubbles for oxygen delivery are biocompatible microparticles which showed a protective effect on rats with lung injuries through peritoneal perfusion (439). Another recent approach used polymeric hollow microspheres called microtanks, which can be hyperbarically loaded

with oxygen, and these showed promising results as oxygen carriers in relation to proliferation and metabolic rates in cells treated with anoxia, while cell viability and survival were improved in hypoxia-treated cell cultures (98, 99).

3.   Oxygen-generating materials

Oxygen-generating materials as peroxides and nano-structured particles, decompose in the biological environment to produce oxygen and, in some cases, byproducts (99). The poor stability of peroxides allows its decomposition to produce molecular oxygen when heated or when in contact with water (439). Oxygen generation by aqueous decomposition via the formation of hydrogen peroxide finally decomposes to produce molecular oxygen, and basic byproducts (439). Peroxides have been used to deliver oxygen to tissues and cells in several approaches such as *in vitro* cell culture and tissue preservation, where they have been shown to have the capacity to mitigate anaerobic glycolysis and preserve insulin release, increase cell survival and neovascularization (99, 112). Peroxides as oxygen delivery agents have low cost, easy storage, controlled generation of oxygen, and *in situ* release of oxygen (439). However, there is still no effective way to eliminate radicals generated during the decomposition of peroxides leading to cytotoxicity (112).

Materials at the nanoscale size are generally up to 100 nm in at least one dimension, a non-arbitrary threshold with physicochemical significance that makes a critical difference to their properties with respect to larger structures. In addition to size, the shape, elemental constitution and surface morphology strongly influence the reactivity of nanomaterials (50). These materials offer unique characteristics that offer considerable appeal for many types of application. The applications include nanomedicine, which is designed to overcome several issues as they provide nanosized solid structures that can target a treatment to a specific part of the body as well as preserving and masking a drug until the target is located. The administration of nano-structured particles has been shown to have therapeutic potential in nanomedicine due to better distribution and cellular uptake than other systems for delivering drugs; furthermore, the trans-excitation reactions make them able to take part in redox reactions (50, 328, 433).

Cerium oxide nanoparticles (CeO_2 NPs) are one of the most promising nanomaterials for antioxidant and anti-inflammatory pharmacological applications; they have been proposed for diverse therapies in pathological conditions such as neurodegenerative disorders, oxidative stress-related diseases, diabetes, chronic inflammation and cancer among others (50, 62, 150, 225, 429). The therapeutic potential is attributed first to the coexistence of two valence states (Ce^{3+} and Ce^{4+}) that provide the ability to mimic superoxide dismutase, behaving as efficient ROS scavengers (Ce^{3+} to Ce^{4+}) and changing to mimic catalase activity which reduces hydrogen peroxide releasing protons and O_2 (Ce^{4+}

49

to the initial Ce^{+3}) (Figure 11). Thus, this self-regenerative property renders this nanomaterial as a very valuable tool for the pharmacological treatment of oxidative-related disorders(50).

Despite the large number of studies reporting beneficial effects of CeO_2 NPs, there is also research indicating toxic and pro-inflammatory responses. As a consequence, the net health effects of nanoceria are still inconclusive, as several studies obtained contradictory findings about its biological activity (50, 429). Some


Figure 11. Mechanism of action of cerium oxide nanoparticles (CeO_2 NPs). The therapeutic potential is due to the coexistence of two valence states Ce^{3+} and Ce^{4+} that provide the free radical scavenging property and the self-regenerative capacity.

authors have reported beneficial properties of CeO_2 NPs on *in vitro* macrophage inflammation (150), smoke-related cardiomyopathy (274), oxidative stress in mesenchymal-derived β-cells (435), as well as ROS protection in neurons (69). Animal studies showed diverse useful properties of CeO_2 NPs in the treatment of many redox dysregulated states. For example, reducing adipogenesis by a decrease in plasma insulin, leptin, glucose and triglycerides (324), reducing macular degeneration (194) and cardiac dysfunction (273), attenuating hypoxia-derived lung damage (14), and alleviating liver ROS toxicity (149). In contrast, other experiments indicated an inability to counteract inflammation in human monocytes (161, 162), or even cell death through apoptosis and autophagy on this cell type (160), and oxidative stress and inflammation in lung, liver, kidney, heart, spleen and brain of mice (265). Moreover, the CeO_2 NPs were used to induce cytotoxicity and oxidative damage in tumor cells (251, 328), while they are able to protect non-malignant cells from chemotherapy (328).

Differences in biological targets (cell types and species), experimental design (preconditioning with inflammation/oxidants for treatment, or with the nanoparticles for prevention), nanoparticles (synthesis method, size, shape, chemical characteristics) and objectives of the studies could lead to these variations, making interpretation of the outcome and comparison between studies highly complex. Nevertheless, it has been suggested that the *in vitro* beneficial effects of these nanoparticles could differ due to diverse biochemical features, as lower pH was reported to lead them to behave as oxidants, thereby generating ROS (323). The different methods used to prepare the nanoparticles influences the relative proportion of surface charges (50). It is noted that the surface oxidation state of the CeO_2 NPs has been demonstrated to alter the accompanying enzyme-mimetic activity. Thus,Ce^{+3}charges at the nanoparticle surface are linked to the superoxide scavenging properties (144) and lower Ce^{+3}/Ce^{+4} ratios are less efficient (429).

X.   Concluding remarks and future perspectives

The discovery of how cells sense and adapt to oxygen availability, for which William Kaelin, Jr., Sir Peter Ratcliffe, and Gregg Semenza were awarded the Nobel Prize in Physiology or Medicine in 2019, revealed that the HIF pathway has a key role in modulating oxygen-sensitive gene expression and further evidenced the important role of oxygen in body homeostasis. At an early stage, Semenza identified both the HRE at the 3'-end of the erythropoietin (*EPO*) gene and the transcription factor acting on this site induced by low oxygen levels, namely HIF (350). Thereafter, Ratcliffe showed that HIF-1α levels were regulated by changes in protein stability (304). Kaelin's focus on the VHL tumor suppressor led to the discovery of a link between the HIF response and VHL-linked tumorigenesis (163), that subsequently was associated with a role of VHL in oxygen-dependent HIF-1α degradation (167). In the last two decades many other pieces of the puzzle of how oxygen is sensed and how cells respond to differing levels have been discovered and analyzed, which has led to recognition of the potential for pharmacological treatments and complementary therapies.

Some open questions for readers:

Should oxygen be considered as the 4th macronutrient (after proteins, lipids and carbohydrates) — or 5th if alcohol is included — as has recently been proposed (385, 386)? If so, how important is its purity (bearing in mind life in rural areas, as opposed to urban ones with contamination of the air through vehicle fumes, etc.)? Should the amount of antioxidants, and the percentage of macronutrients we consume, be correlated with our oxygen consumption? In our view, oxygen has to be considered as a very important factor in future lifestyle recommendations.

Will the measurement of oxygen consumption be included in strategies for the prevention of metabolic diseases, based on previous results (68, 223)? As mentioned above, measuring oxygen consumption is immediate, non-invasive and extremely cheap in comparison with many other measurements. Given the association of oxygen consumption and metabolic fitness, this additional measurement could be included in future intervention studies of metabolic disorders. If the efficacy in differentiating subjects at high metabolic risk and metabolically healthy individuals is proven, the measurement of oxygen consumption could be used in preventive care for metabolic diseases.

Should exposure to altitude be recommended for those genetically or phenotypically predisposed to develop the metabolic syndrome? Although high altitude living seems beneficial, very high and mainly extreme altitude have been linked with pernicious effects on metabolism. Therefore, which is the best altitude at which to live? Should altitude prescription be individualized, as with other therapies? Obviously, one cannot suggest living in a different city because of altitude, but perhaps a period in the mountains once or twice a year for shorter periods — as some sport professionals do — might be appropriate? Moreover, it would be interesting to study the potential benefit of locating residential

51

institutions (care of the elderly, those with chronic disease) at high altitude for population-based prevention strategies of chronic diseases — especially those that are metabolism-related.

Could hyperoxia or hypoxia be used to treat metabolic diseases? There is some indication that IH training could be beneficial for the adaptation of muscle to exercise in individuals suffering from the MetS and associated comorbidities. On the other hand, hyperoxia could be useful in clinical practice when peripheral sO$_2$ falls below 89% in patients at risk of oxygen-induced hypercapnia (or below 93% for other patients). In addition, oxygen therapy has been studied in a wide range of experimental conditions due to the potential adaptive response to increased oxidative stress. Nevertheless, an excess oxygen therapy may lead to detrimental effects. Thus, further studies are needed to evaluate the risks and benefits of treating with oxygen therapy. In this sense, alternative approaches have been experimentally analyzed, such as oxygen-delivery systems (free or encapsulated oxygen carriers and oxygen-generating materials) to supply tissues with their specific oxygen requirements. Consequently, additional research on novel oxygen-based therapeutic approaches for metabolic diseases are warranted.

Therefore, there are still many unknowns, including: the exact role of HIF-2 and particularly HIF-3, the relationship of the gut microbiota, the link between neurodegenerative diseases and oxygen, and the influence of HIFs in metal transportation.

Acknowledgments

Author Contributions

Conceptualization, A.L-P., J.A.M. and P.G-M.; Writing-Original Draft Preparation, A.L-P.; Review & Editing, A.L-P., P.T., J.A.M. and P.G-M.; Supervision, J.A.M. and P.G-M.; Funding Acquisition, J.A.M and A.L-P. All authors critically revised and approved the final version of the manuscript.

Author Disclosure Statement

The authors declare no conflicts of interest.

References

1. Aboul-Enein F and Lassmann H. Mitochondrial damage and histotoxic hypoxia: a pathway of tissue injury in inflammatory brain disease? *Acta Neuropathol* 109: 49–55, 2005.

2. Acquisti C, Kleffe J, and Collins S. Oxygen content of transmembrane proteins over macroevolutionary time scales. *Nature* 445: 47–52, 2007.

3. Aguilar-Valles A, Inoue W, Rummel C, and Luheshi GN. Obesity, adipokines and neuroinflammation. *Neuropharmacology* 96: 124–134, 2015.

4. Akhmedov AT, Rybin V, and Marín-García J. Mitochondrial oxidative metabolism and uncoupling proteins in the failing heart. *Heart Fail Rev* 20: 227–249, 2015.

5. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J-C, James WPT, Loria CM, and Smith SC. Harmonizing the Metabolic Syndrome. *Circulation* 120: 1640–1645, 2009.

6. Albina JE, Mastrofrancesco B, Vessella J a, Louis C a, Henry WL, and Reichner JS. HIF-1 expression in healing wounds: HIF-1α induction in primary inflammatory cells by TNF-α. *Am J Physiol Physiol* 281: C1971–C1977, 2001.

7. Aleixandre De Artiñano A and Miguel Castro M. Experimental rat models to study the metabolic syndrome. *Br J Nutr* 102: 1246–1253, 2009.

8. Alhawiti NM, Al Mahri S, Aziz MA, Malik SS, and Mohammad S. TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook. *Curr Drug Targets* 18: 1095–1103, 2017.

9. Alwarawrah Y, Kiernan K, and MacIver NJ. Changes in Nutritional Status Impact Immune Cell Metabolism and Function. *Front Immunol* 9: 1–14, 2018.

10. Anderson JD and Honigman B. The effect of altitude-induced hypoxia on heart disease: do acute, intermittent, and chronic exposures provide cardioprotection? *High Alt Med Biol* 12: 45–55, 2011.

11. Araghi MH, Chen Y-F, Jagielski A, Choudhury S, Banerjee D, Hussain S, Thomas GN, and Taheri S. Effectiveness of Lifestyle Interventions on Obstructive Sleep Apnea (OSA): Systematic Review and Meta-Analysis. *Sleep* 36: 1553–1562, 2013.

12. Aragonés J, Schneider M, Van Geyte K, Fraisl P, Dresselaers T, Mazzone M, Dirkx R, Zacchigna S, Lemieux H, Jeoung NH, Lambrechts D, Bishop T, Lafuste P, Diez-Juan A, Harten SK, Van Noten P, De Bock K, Willam C, Tjwa M, Grosfeld A, Navet R, Moons L, Vandendriessche T, Deroose C, Wijeyekoon B, Nuyts J, Jordan B, Silasi-Mansat R, Lupu F, Dewerchin M, Pugh C, Salmon P, Mortelmans L, Gallez B, Gorus F, Buyse J, Sluse F, Harris RA, Gnaiger E, Hespel P, Van Hecke P, Schuit F, Van

13. Veldhoven P, Ratcliffe P, Baes M, Maxwell P, and Carmeliet P. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. *Nat Genet* 40: 170–180, 2008.

    Arsenijevic D, Onuma H, Pecqueur C, Raimbault S, Manning BS, Miroux B, Couplan E, Alves-Guerra MC, Goubern M, Surwit R, Bouillaud F, Richard D, Collins S, and Ricquier D. Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. *Nat Genet* 26: 435–439, 2000.

14. Arya A, Sethy NK, Singh SK, Das M, and Bhargava K. Cerium oxide nanoparticles protect rodent lungs from hypobaric hypoxia-induced oxidative stress and inflammation. *Int J Nanomedicine* 8: 4507–4520, 2013.

15. Baffi CW, Wood L, Winnica D, Strollo PJ, Gladwin MT, Que LG, and Holguin F. Metabolic Syndrome and the Lung. *Chest* 149: 1525–1534, 2016.

16. Bai Y and Sun Q. Macrophage recruitment in obese adipose tissue. *Obes Rev* 16: 127–136, 2015.

17. Baik AH and Jain IH. Turning the Oxygen Dial: Balancing the Highs and Lows. *Trends Cell Biol* 30: 516–536, 2020.

18. Bailey DM, Davies B, and Baker J. Training in hypoxia: modulation of metabolic and cardiovascular risk factors in men. *Med Sci Sports Exerc* 32: 1058–1066, 2000.

19. Bailey DM, Davies B, and Young IS. Intermittent hypoxic training: implications for lipid peroxidation induced by acute normoxic exercise in active men. *Clin Sci (Lond)* 101: 465–475, 2001.

20. Baker RG, Hayden MS, and Ghosh S. NF-κB, Inflammation, and Metabolic Disease. *Cell Metab* 13: 11–22, 2011.

21. Baracco R, Mohanna S, and Seclén S. A Comparison of the Prevalence of Metabolic Syndrome and Its Components in High and Low Altitude Populations in Peru. *Metab Syndr Relat Disord* 5: 55–62, 2007.

22. Basnyat B and Murdoch DR. High-altitude illness. *Lancet* 361: 1967–1974, 2003.

23. Beaudin AE, Waltz X, Pun M, Wynne-Edwards KE, Ahmed SB, Anderson TJ, Hanly PJ, and Poulin MJ. Human intermittent hypoxia-induced respiratory plasticity is not caused by inflammation. *Eur Respir J* 46: 1072–1083, 2015.

24. Bel Aiba RS, Dimova EY, Görlach A, and Kietzmann T. The role of hypoxia inducible factor-1 in cell metabolism – a possible target in cancer therapy. *Expert Opin Ther Targets* 10: 583–599, 2006.

25. Bennett M, Feldmeier J, Hampson N, Smee R, and Milross C. Hyperbaric oxygen therapy for late

radiation tissue injury. *Cochrane Database Syst Rev* 5: CD005005–CD005005, 2012.

26. Bennett MH, French C, Schnabel A, Wasiak J, Kranke P, and Weibel S. Normobaric and hyperbaric oxygen therapy for the treatment and prevention of migraine and cluster headache. *Cochrane Database Syst Rev*, 2015.

27. Bennett MH, Kertesz T, Perleth M, Yeung P, and Lehm JP. Hyperbaric oxygen for idiopathic sudden sensorineural hearing loss and tinnitus. *Cochrane Database Syst Rev* 39: 777–792, 2012.

28. Berchner-Pfannschmidt U, Tug S, Kirsch M, and Fandrey J. Oxygen-sensing under the influence of nitric oxide. *Cell Signal* 22: 349–356, 2010.

29. Bhattacharya S, Michels CL, Leung MK, Arany ZP, Kung AL, and Livingston DM. Functional role of p35srj, a novel p300/CBP binding protein, during transactivation by HIF-1. *Genes Dev* 13: 64–75, 1999.

30. Bigham AW, Wilson MJ, Julian CG, Kiyamu M, Vargas E, Leon-Velarde F, Rivera-Chira M, Rodriquez C, Browne VA, Parra E, Brutsaert TD, Moore LG, and Shriver MD. Andean and Tibetan patterns of adaptation to high altitude. *Am J Hum Biol* 25: 190–197, 2013.

31. Blouin CC, Pagé EL, Soucy GM, and Richard DE. Hypoxic gene activation by lipopolysaccharide in macrophages: Implication of hypoxia-inducible factor 1alpha. *Blood* 103: 1124–1130, 2004.

32. Blüher S and Schwarz P. Metabolically healthy obesity from childhood to adulthood — Does weight status alone matter? *Metabolism* 63: 1084–1092, 2014.

33. Bondia-Pons I, Ryan L, and Martinez JA. Oxidative stress and inflammation interactions in human obesity. *J Physiol Biochem* 68: 701–711, 2012.

34. Bonello S, Zahringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, Kietzmann T, and Gorlach A. Reactive Oxygen Species Activate the HIF-1 Promoter Via a Functional NF B Site. *Arterioscler Thromb Vasc Biol* 27: 755–761, 2007.

35. Brahimi-Horn MC and Pouysségur J. Oxygen, a source of life and stress. *FEBS Lett* 581: 3582–3591, 2007.

36. Brand MD and Esteves TC. Physiological functions of the mitochondrial uncoupling proteins UCP2 and UCP3. *Cell Metab* 2: 85–93, 2005.

37. Brennan JP, Southworth R, Medina RA, Davidson SM, Duchen MR, and Shattock MJ. Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of KATP channel activation. *Cardiovasc Res* 72: 313–321, 2006.

38. Brestoff JR and Artis D. Immune regulation of metabolic homeostasis in health and disease. *Cell* 161: 146–160, 2015.

39. Brugniaux JV, Coombs GB, Barak OF, Dujic Z, Sekhon MS, and Ainslie PN. Highs and lows of

hyperoxia: physiological, performance, and clinical aspects. *Am J Physiol Integr Comp Physiol* 315: R1–R27, 2018.

40. Brüne B and Zhou J. Nitric oxide and superoxide: Interference with hypoxic signaling. *Cardiovasc Res* 75: 275–282, 2007.

41. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. *Cell Metab* 1: 409–414, 2005.

42. Buehler PW, D'Agnillo F, and Schaer DJ. Hemoglobin-based oxygen carriers: From mechanisms of toxicity and clearance to rational drug design. *Trends Mol Med* 16: 447–457, 2010.

43. Bunik VI. Redox-Driven Signaling: 2-Oxo Acid Dehydrogenase Complexes as Sensors and Transmitters of Metabolic Imbalance. *Antioxidants Redox Signal* 30: 1911–1947, 2019.

44. Byrne NM, Hills AP, Hunter GR, Weinsier RL, and Schutz Y. Metabolic equivalent: one size does not fit all. *J Appl Physiol* 99: 1112–1119, 2005.

45. Cai Z, Luo W, Zhan H, and Semenza GL. Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart. *Pnas* 110: 17462–17467, 2013.

46. Calzia E, Asfar P, Hauser B, Matejovic M, Ballestra C, Radermacher P, and Georgieff M. Hyperoxia may be beneficial. *Crit Care Med* 38: S559–S568, 2010.

47. Campión J, Milagro F, Goyenechea E, and Martínez J. TNF-alpha promoter methylation as a predictive biomarker for weight-loss response. *Obesity (Silver Spring)* 17: 1293–7, 2009.

48. Campión J, Milagro FI, and Martínez JA. Individuality and epigenetics in obesity. *Obes Rev* 10: 383–392, 2009.

49. Camuzi D, de Amorim Í, Ribeiro Pinto L, Oliveira Trivilin L, Mencalha A, and Soares Lima S. Regulation Is in the Air: The Relationship between Hypoxia and Epigenetics in Cancer. *Cells* 8: 300, 2019.

50. Caputo F, De Nicola M, and Ghibelli L. Pharmacological potential of bioactive engineered nanomaterials. *Biochem Pharmacol* 92: 112–130, 2014.

51. Cardinale DA and Ekblom B. Hyperoxia for performance and training. *J Sports Sci* 36: 1515–1522, 2018.

52. Carraro JCC, Mansego ML, Milagro FI, Chaves LO, Vidigal FC, Bressan J, and Martínez JA. LINE-1 and inflammatory gene methylation levels are early biomarkers of metabolic changes: association with adiposity. *Biomarkers* 21: 625–632, 2016.

53. Carreau A, Hafny-Rahbi B El, Matejuk A, Grillon C, and Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules

and hypoxia. *J Cell Mol Med* 15: 1239–1253, 2011.

54. Cash HL, McGarvey ST, Houseman EA, Marsit CJ, Hawley NL, Lambert-Messerlian GM, Viali S, Tuitele J, and Kelsey KT. Cardiovascular disease risk factors and DNA methylation at the LINE-1 repeat region in peripheral blood from Samoan Islanders. *Epigenetics* 6: 1257–1264, 2011.

55. Castillo O, Woolcott OO, Gonzales E, Tello V, Tello L, Villarreal C, Méndez N, Damas L, and Florentini E. Residents at High Altitude Show a Lower Glucose. *High Alt Med Biol* 8: 307–311, 2007.

56. Castro JP, Grune T, and Speckmann B. The two faces of reactive oxygen species (ROS) in adipocyte function and dysfunction. *Biol Chem* 397: 709–724, 2016.

57. Caterson ID. Prevention Conference VII: Obesity, a Worldwide Epidemic Related to Heart Disease and Stroke: Group III: Worldwide Comorbidities of Obesity. *Circulation* 110: e476–e483, 2004.

58. Cavalli R, Akhter AK, Bisazza A, Giustetto P, Trotta F, and Vavia P. Nanosponge formulations as oxygen delivery systems. *Int J Pharm* 402: 254–257, 2010.

59. Chaillou T and Lanner JT. Regulation of myogenesis and skeletal muscle regeneration: effects of oxygen levels on satellite cell activity. *FASEB J* 30: 3929–3941, 2016.

60. Chang EI, Chang EI, Thangarajah H, Hamou C, and Gurtner GC. Hypoxia, hormones, and endothelial progenitor cells in hemangioma. *Lymphat Res Biol* 5: 237–43, 2007.

61. Chaparro CM and Suchdev PS. Anemia epidemiology, pathophysiology, and etiology in low- and middle-income countries. *Ann N Y Acad Sci* 176: nyas.14092, 2019.

62. Charbgoo F, Ahmad M, and Darroudi M. Cerium oxide nanoparticles: green synthesis and biological applications. *Int J Nanomedicine* Volume 12: 1401–1413, 2017.

63. Chen L, Magliano DJ, and Zimmet PZ. The worldwide epidemiology of type 2 diabetes mellitus—present and future perspectives. *Nat Rev Endocrinol* 8: 228–236, 2012.

64. Chen Y-C, Chen T-W, Su M, Chen C-J, Chen K, Liou C, Tang P, Wang T-Y, Chang J-C, Wang C-C, Lin H-C, Chin C-H, Huang K-T, Lin M-C, and Hsiao C-C. Whole Genome DNA Methylation Analysis of Obstructive Sleep Apnea: IL1R2,NPR2, AR, SP140 Methylation and Clinical Phenotype. *Sleep* 39: 743–755, 2016.

65. Christensen BC, Houseman EA, Marsit CJ, Zheng S, Wrensch MR, Wiemels JL, Nelson HH, Karagas MR, Padbury JF, Bueno R, Sugarbaker DJ, Yeh RF, Wiencke JK, and Kelsey KT. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. *PLoS Genet* 5: e1000602, 2009.

66. Chu DK, Kim LH-Y, Young PJ, Zamiri N, Almenawer SA, Jaeschke R, Szczeklik W, Schünemann HJ, Neary JD, and Alhazzani W. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. *Lancet* 391: 1693–1705, 2018.

67. Chung AS, Lee J, and Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. *Nat Rev Cancer* 10: 505–514, 2010.

68. Cifarelli V, Beeman SC, Smith GI, Yoshino J, Morozov D, Beals JW, Kayser BD, Watrous JD, Jain M, Patterson BW, and Klein S. Decreased adipose tissue oxygenation associates with insulin resistance in individuals with obesity. *J Clin Invest* 130: 6688–6699, 2020.

69. Ciofani G, Genchi GG, Liakos I, Cappello V, Gemmi M, Athanassiou A, Mazzolai B, and Mattoli V. Effects of Cerium Oxide Nanoparticles on PC12 Neuronal-Like Cells: Proliferation, Differentiation, and Dopamine Secretion. *Pharm Res* 30: 2133–2145, 2013.

70. Coleman ML and Ratcliffe PJ. Angiogenesis: escape from hypoxia. *Nat Med* 15: 491–493, 2009.

71. Cordero P, Campion J, Milagro FI, Goyenechea E, Steemburgo T, Javierre BM, and Martinez JA. Leptin and TNF-alpha promoter methylation levels measured by MSP could predict the response to a low-calorie diet. *J Physiol Biochem* 67: 463–470, 2011.

72. da Costa RM, Fais RS, Dechandt CRP, Louzada-Junior P, Alberici LC, Lobato NS, and Tostes RC. Increased mitochondrial ROS generation mediates the loss of the anti-contractile effects of perivascular adipose tissue in high-fat diet obese mice. *Br J Pharmacol*: 3527–3541, 2017.

73. Czech MP, Aouadi M, and Tesz GJ. RNAi-based therapeutic strategies for metabolic disease. *Nat Rev Endocrinol* 7: 473–484, 2011.

74. D'Ignazio L, Bandarra D, and Rocha S. NF-κB and HIF crosstalk in immune responses. *FEBS J* 283: 413–424, 2016.

75. Dean JB, Mulkey DK, Henderson RA, Potter SJ, and Putnam RW. Hyperoxia, reactive oxygen species, and hyperventilation: Oxygen sensitivity of brain stem neurons. *J Appl Physiol* 96: 784–791, 2004.

76. Debevec T, Simpson EJ, Macdonald IA, Eiken O, and Mekjavic IB. Exercise training during normobaric hypoxic confinement does not alter hormonal appetite regulation. *PLoS One* 9, 2014.

77. Déry M-AC, Michaud MD, and Richard DE. Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators. *Int J Biochem Cell Biol* 37: 535–540, 2005.

78. Devries MC, Samjoo IA, Hamadeh MJ, and Tarnopolsky MA. Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and women. *Obesity (Silver Spring)* 16: 2281–2288,

2008.

79. Dewan NA, Nieto FJ, and Somers VK. Intermittent Hypoxemia and OSA. *Chest* 147: 266–274, 2015.

80. Díaz-Bulnes P, Saiz ML, López-Larrea C, and Rodríguez RM. Crosstalk Between Hypoxia and ER Stress Response: A Key Regulator of Macrophage Polarization. *Front Immunol* 10: 1–16, 2020.

81. Díaz-Gutiérrez J, Martínez-González MÁ, Pons Izquierdo JJ, González-Muniesa P, Martínez JA, and Bes-Rastrollo M. Living at Higher Altitude and Incidence of Overweight/Obesity: Prospective Analysis of the SUN Cohort. *PLoS One* 11: e0164483, 2016.

82. Dickinson JM, D'Lugos AC, Naymik MA, Siniard AL, Wolfe AJ, Curtis DP, Huentelman MJ, and Carroll CC. Transcriptome response of human skeletal muscle to divergent exercise stimuli. *J Appl Physiol*: japplphysiol.00014.2018, 2018.

83. Dimauro I, Paronetto MP, and Caporossi D. Exercise, redox homeostasis and the epigenetic landscape. *Redox Biol* 35: 101477, 2020.

84. Dobrosielski DA, Papandreou C, Patil SP, and Salas-Salvadó J. Diet and exercise in the management of obstructive sleep apnoea and cardiovascular disease risk. *Eur Respir Rev* 26, 2017.

85. Donath MY and Shoelson SE. Type 2 diabetes as an inflammatory disease. *Nat Rev Immunol* 11: 98–107, 2011.

86. Drager LF, Togeiro SM, Polotsky VY, and Lorenzi-Filho G. Obstructive Sleep Apnea. *J Am Coll Cardiol* 62: 569–576, 2013.

87. Dranka BP, Benavides GA, Diers AR, Giordano S, Zelickson BR, Reily C, Zou L, Chatham JC, Hill BG, Zhang J, Landar A, and Darley-Usmar VM. Assessing bioenergetic function in response to oxidative stress by metabolic profiling. *Free Radic Biol Med* 51: 1621–1635, 2011.

88. Duggan C, Xiao L, Terry MB, and McTiernan A. No effect of weight loss on LINE-1 methylation levels in peripheral blood leukocytes from postmenopausal overweight women. *Obesity* 22: 2091–2096, 2014.

89. Durán-Cantolla J, Aizpuru F, Martínez-Null C, and Barbé-Illa F. Obstructive sleep apnea/hypopnea and systemic hypertension. *Sleep Med Rev* 13: 323–331, 2009.

90. Egners A, Erdem M, and Cramer T. The Response of Macrophages and Neutrophils to Hypoxia in the Context of Cancer and Other Inflammatory Diseases. *Mediators Inflamm* 2016: 1–10, 2016.

91. El-Kadre LJ and Tinoco ACA. Interleukin-6 and obesity. *Curr Opin Clin Nutr Metab Care* 16: 1, 2013.

92. Eltzschig HK and Carmeliet P. Hypoxia and inflammation. *N Engl J Med* 364: 656–665, 2011.

93. Espinosa-Diez C, Miguel V, Mennerich D, Kietzmann T, Sánchez-Pérez P, Cadenas S, and Lamas S. Antioxidant responses and cellular adjustments to oxidative stress. *Redox Biol* 6: 183–197, 2015.

94. Essop MF. Cardiac metabolic adaptations in response to chronic hypoxia. *J Physiol* 584: 715–726, 2007.

95. Ezzati M, Horwitz ME, Thomas DS, Friedman AB, Roach R, Clark T, Murray CJ, and Honigman B. Altitude, life expectancy and mortality from ischaemic heart disease, stroke, COPD and cancers: national population-based analysis of US counties. *J Epidemiol Community Health* 66: e17, 2012.

96. Faeh D, Gutzwiller F, and Bopp M. Lower Mortality From Coronary Heart Disease and Stroke at Higher Altitudes in Switzerland. *Circulation* 120: 495–501, 2009.

97. Faeh D, Moser A, Panczak R, Bopp M, Roosli M, Spoerri A, and Group SNCS. Independent at heart: persistent association of altitude with ischaemic heart disease mortality after consideration of climate, topography and built environment. *J Epidemiol Community Health* 70: 798–806, 2016.

98. Farris AL, Rindone AN, and Grayson WL. Oxygen delivering biomaterials for tissue engineering. *J Mater Chem B* 4: 3422–3432, 2016.

99. Fathollahipour S, Patil PS, and Leipzig ND. Oxygen regulation in development: Lessons from embryogenesis towards tissue engineering. *Cells Tissues Organs* 205: 350–371, 2019.

100. Femminò S, Penna C, Bessone F, Caldera F, Dhakar N, Cau D, Pagliaro P, Cavalli R, and Trotta F. α-Cyclodextrin and α-Cyclodextrin Polymers as Oxygen Nanocarriers to Limit Hypoxia/Reoxygenation Injury: Implications from an In Vitro Model. *Polymers (Basel)* 10: 211, 2018.

101. Fischer WW, Hemp J, and Valentine JS. How did life survive Earth's great oxygenation? *Curr Opin Chem Biol* 31: 166–178, 2016.

102. Forsythe JA, Jiang BH, Iyer N V, Agani F, Leung SW, Koos RD, and Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. *Mol Cell Biol* 16: 4604–13, 1996.

103. Francis A and Baynosa R. Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms. *Diving Hyperb Med* 47: 110–117, 2017.

104. Franklin BA, Brinks J, Berra K, Lavie CJ, Gordon NF, and Sperling LS. Using Metabolic Equivalents in Clinical Practice. *Am J Cardiol* 121: 382–387, 2018.

105. Frayn KN. *Metabolic regulation: A Human Perspective*. 3rd ed., Wiley-Blackwell, 2010.

106. Fujisaka S, Usui I, Ikutani M, Aminuddin A, Takikawa A, Tsuneyama K, Mahmood A, Goda N, Nagai Y, Takatsu K, and Tobe K. Adipose tissue hypoxia induces inflammatory M1 polarity of macrophages in

an HIF-1α-dependent and HIF-1α-independent manner in obese mice. *Diabetologia* 56: 1403–1412, 2013.

107. Garcia-Lacarte M, Milagro FI, Zulet MA, Martinez JA, and Mansego ML. LINE-1 methylation levels, a biomarker of weight loss in obese subjects, are influenced by dietary antioxidant capacity. *Redox Rep* 21: 67–74, 2016.

108. Gatterer H, Haacke S, Burtscher M, Faulhaber M, Melmer A, Ebenbichler C, Strohl KP, Hogel J, and Netzer NC. Normobaric Intermittent Hypoxia over 8 Months Does Not Reduce Body Weight and Metabolic Risk Factors - a Randomized, Single Blind, Placebo-Controlled Study in Normobaric Hypoxia and Normobaric Sham Hypoxia. *Obes Facts* 8: 200–209, 2015.

109. St. George A, Bauman A, Johnston A, Farrell G, Chey T, and George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. *Hepatology* 50: 68–76, 2009.

110. Gerber PA and Rutter GA. The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus. *Antioxid Redox Signal* 26: 501–518, 2017.

111. Ghijsen MT, Lentsch GR, Gioux S, Brenner M, Durkin AJ, Choi B, and Tromberg BJ. Quantitative real-time optical imaging of the tissue metabolic rate of oxygen consumption. *J Biomed Opt* 23: 1, 2018.

112. Gholipourmalekabadi M, Zhao S, Harrison BS, Mozafari M, and Seifalian AM. Oxygen-Generating Biomaterials: A New, Viable Paradigm for Tissue Engineering? *Trends Biotechnol* 34: 1010–1021, 2016.

113. Al Ghouleh I, Khoo NKH, Knaus UG, Griendling KK, Touyz RM, Thannickal VJ, Barchowsky A, Nauseef WM, Kelley EE, Bauer PM, Darley-Usmar V, Shiva S, Cifuentes-Pagano E, Freeman BA, Gladwin MT, and Pagano PJ. Oxidases and peroxidases in cardiovascular and lung disease: New concepts in reactive oxygen species signaling. *Free Radic Biol Med* 51: 1271–1288, 2011.

114. Gimbrone MA and García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. *Circ Res* 118: 620–636, 2016.

115. Giordano L, Aneja MK, Sommer N, Alebrahimdehkordi N, Seraji A, Weissmann N, Rudolph C, Plank C, Jacobs HT, and Szibor M. Alternative oxidase encoded by sequence-optimized and chemically-modified RNA transfected into mammalian cells is catalytically active. *Gene Ther*, 2021.

116. Giordano L, Farnham A, Dhandapani PK, Salminen L, Bhaskaran J, Voswinckel R, Rauschkolb P, Scheibe S, Sommer N, Beisswenger C, Weissmann N, Braun T, Jacobs HT, Bals R, Herr C, and Szibor M. Alternative Oxidase Attenuates Cigarette Smoke–induced Lung Dysfunction and Tissue Damage. *Am J Respir Cell Mol Biol* 60: 515–522, 2019.

117. González-Muniesa P, Garcia-Gerique L, Quintero P, Arriaza S, Lopez-Pascual A, and Martinez JAA. Effects of Hyperoxia on Oxygen-Related Inflammation with a Focus on Obesity. *Oxid Med Cell Longev* 2016: 1–11, 2016.

118. González-Muniesa P, Lopez-Pascual A, de Andrés J, Lasa A, Portillo MP, Arós F, Durán J, Egea CJ, and Martinez JA. Impact of intermittent hypoxia and exercise on blood pressure and metabolic features from obese subjects suffering sleep apnea-hypopnea syndrome. *J Physiol Biochem* 71: 589–599, 2015.

119. González-Muniesa P, Mártinez-González M-A, Hu FB, Després J-P, Matsuzawa Y, Loos RJF, Moreno LA, Bray GA, and Martinez JA. Obesity. *Nat Rev Dis Prim* 3: 17034, 2017.

120. Gonzalez FJ, Xie C, and Jiang C. The role of hypoxia-inducible factors in metabolic diseases. *Nat Rev Endocrinol* 15: 21–32, 2019.

121. Goossens GH. The Metabolic Phenotype in Obesity: Fat Mass, Body Fat Distribution, and Adipose Tissue Function. *Obes Facts* 10: 207–215, 2017.

122. Goossens GH, Bizzarri A, Venteclef N, Essers Y, Cleutjens JP, Konings E, Jocken JW, Cajlakovic M, Ribitsch V, Clement K, and Blaak EE. Increased adipose tissue oxygen tension in obese compared with lean men is accompanied by insulin resistance, impaired adipose tissue capillarization, and inflammation. *Circulation* 124: 67–76, 2011.

123. Goossens GH and Blaak EE. Adipose tissue oxygen tension: implications for chronic metabolic and inflammatory diseases. *Curr Opin Clin Nutr Metab care* 15: 539, 2012.

124. Görgens SW, Benninghoff T, Eckardt K, Springer C, Chadt A, Melior A, Wefers J, Cramer A, Jensen J, Birkeland KI, Drevon CA, Al-Hasani H, and Eckel J. Hypoxia in Combination With Muscle Contraction Improves Insulin Action and Glucose Metabolism in Human Skeletal Muscle via the HIF-1α Pathway. *Diabetes* 66: 2800–2807, 2017.

125. Görlach A, Dimova EY, Petry A, Martínez-Ruiz A, Hernansanz-Agustín P, Rolo AP, Palmeira CM, and Kietzmann T. Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? *Redox Biol* 6: 372–385, 2015.

126. Görlach A, Klappa P, and Kietzmann DT. The Endoplasmic Reticulum: Folding, Calcium Homeostasis, Signaling, and Redox Control. *Antioxid Redox Signal* 8: 1391–1418, 2006.

127. Gowers IR, Walters K, Kiss-Toth E, Read RC, Duff GW, and Wilson AG. Age-related loss of CpG methylation in the tumour necrosis factor promoter. *Cytokine* 56: 792–797, 2011.

128. Greer SN, Metcalf JL, Wang Y, and Ohh M. The updated biology of hypoxia-inducible factor. *EMBO J* 31: 2448–2460, 2012.

129. Gregor MF and Hotamisligil GS. Inflammatory

57

Mechanisms in Obesity. *Annu Rev Immunol* 29: 415–445, 2011.

130. Greie S, Humpeler E, Gunga HC, Koralewski E, Klingler A, Mittermayr M, Fries D, Lechleitner M, Hoertnagl H, Hoffmann G, Strauss-Blasche G, and Schobersberger W. Improvement of metabolic syndrome markers through altitude specific hiking vacations. *J Endocrinol Invest* 29: 497–504, 2006.

131. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Spertus JA, and Costa F. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute scientific statement. *Circulation* 112: 2735–2752, 2005.

132. Guarrera S, Fiorito G, Onland-Moret NC, Russo A, Agnoli C, Allione A, Di Gaetano C, Mattiello A, Ricceri F, Chiodini P, Polidoro S, Frasca G, Verschuren MWM, Boer JMA, Iacoviello L, van der Schouw YT, Tumino R, Vineis P, Krogh V, Panico S, Sacerdote C, and Matullo G. Gene-specific DNA methylation profiles and LINE-1 hypomethylation are associated with myocardial infarction risk. *Clin Epigenetics* 7: 133, 2015.

133. Gutwenger I, Hofer G, Gutwenger AK, Sandri M, and Wiedermann CJ. Pilot study on the effects of a 2-week hiking vacation at moderate versus low altitude on plasma parameters of carbohydrate and lipid metabolism in patients with metabolic syndrome. *BMC Res Notes* 8: 103, 2015.

134. Haddad JJ and Land SC. A non-hypoxic, ROS-sensitive pathway mediates TNF-α-dependent regulation of HIF-1α. *FEBS Lett* 505: 269–274, 2001.

135. Hakkaart GAJ, Dassa EPEP, Jacobs HT, and Rustin P. Allotopic expression of a mitochondrial alternative oxidase confers cyanide resistance to human cell respiration. *EMBO Rep* 7: 341–345, 2006.

136. Hall JE and Guyton AC. *Textbook of Medical Physiology*. 13th ed., Elsevier Saunders, 2016.

137. Hanschmann EM, Godoy JR, Berndt C, Hudemann C, and Lillig CH. Thioredoxins, glutaredoxins, and peroxiredoxins-molecular mechanisms and health significance: From cofactors to antioxidants to redox signaling. *Antioxidants Redox Signal* 19: 1539–1605, 2013.

138. Hansson GK and Hermansson A. The immune system in atherosclerosis. *Nat Immunol* 12: 204–212, 2011.

139. Hara S, Hamada J, Kobayashi C, Kondo Y, and Imura N. Expression and characterization of hypoxia-inducible factor (HIF)-3alpha in human kidney: suppression of HIF-mediated gene expression by HIF-3alpha. *Biochem Biophys Res Commun* 287: 808–13, 2001.

140. Haslam DW and James WPT. Obesity. *Lancet* 366: 1197–1209, 2005.

141. Haufe S, Wiesner S, Engeli S, Luft FC, and Jordan J. Influences of normobaric hypoxia training on metabolic risk markers in human subjects. *Med Sci Sports Exerc* 40: 1939–1944, 2008.

142. Hayden MS and Ghosh S. Shared Principles in NF-κB Signaling. *Cell* 132: 344–362, 2008.

143. He Q, Gao Z, Yin J, Zhang J, Yun Z, and Ye J. Regulation of HIF-1{alpha} activity in adipose tissue by obesity-associated factors: adipogenesis, insulin, and hypoxia. *Am J Physiol Endocrinol Metab* 300: E877–E885, 2011.

144. Heckert EG, Karakoti AS, Seal S, and Self WT. The role of cerium redox state in the SOD mimetic activity of nanoceria. *Biomaterials* 29: 2705–2709, 2008.

145. Hermsdorff HH, Mansego ML, Campión J, Milagro FI, Zulet MA, and Martínez JA. TNF-alpha promoter methylation in peripheral white blood cells: Relationship with circulating TNFα, truncal fat and n-6 PUFA intake in young women. *Cytokine* 64: 265–271, 2013.

146. Hernansanz-Agustín P, Choya-Foces C, Carregal-Romero S, Ramos E, Oliva T, Villa-Piña T, Moreno L, Izquierdo-Álvarez A, Cabrera-García JD, Cortés A, Lechuga-Vieco AV, Jadiya P, Navarro E, Parada E, Palomino-Antolín A, Tello D, Acín-Pérez R, Rodríguez-Aguilera JC, Navas P, Cogolludo Á, López-Montero I, Martínez-del-Pozo Á, Egea J, López MG, Elrod JW, Ruíz-Cabello J, Bogdanova A, Enríquez JA, and Martínez-Ruiz A. Na+ controls hypoxic signalling by the mitochondrial respiratory chain. *Nature*: 1–5, 2020.

147. Hetherington MM and Cecil JE. Gene-Environment Interactions in Obesity. In: *Frontiers in Eating and Weight Regulation*. vol. 63Basel, KARGER, 2009, pp. 195–203.

148. Hirschler V. Cardiometabolic risk factors in native populations living at high altitudes. *Int J Clin Pract* 70: 113–118, 2016.

149. Hirst SM, Karakoti A, Singh S, Self W, Tyler R, Seal S, and Reilly CM. Bio-distribution and in vivo antioxidant effects of cerium oxide nanoparticles in mice. *Environ Toxicol* 28: 107–118, 2013.

150. Hirst SM, Karakoti AS, Tyler RD, Sriranganathan N, Seal S, and Reilly CM. Anti-inflammatory properties of cerium oxide nanoparticles. *Small* 5: 2848–2856, 2009.

151. Hodson EJ, Nicholls LG, Turner PJ, Llyr R, Fielding JW, Douglas G, Ratnayaka I, Robbins PA, Pugh CW, Buckler KJ, Ratcliffe PJ, and Bishop T. Regulation of ventilatory sensitivity and carotid body proliferation in hypoxia by the PHD2/HIF-2 pathway. *J Physiol* 594: 1179–1195, 2016.

152. Hold GL and El-Omar EM. Genetic aspects of inflammation and cancer. *Biochem J* 410: 225–35, 2008.

153. Hopkins BL and Neumann CA. Redoxins as gatekeepers of the transcriptional oxidative stress

response. *Redox Biol* 21: 101104, 2019.

154. Hopkins PN. Molecular Biology of Atherosclerosis. *Physiol Rev* 93: 1317–1542, 2013.

155. Hosogai N, Fukuhara A, Oshima K, Miyata Y, Tanaka S, Segawa K, Furukawa S, Tochino Y, Komuro R, Matsuda M, and Shimomura I. Adipose Tissue Hypoxia in Obesity and Its Impact on Adipocytokine Dysregulation. *Diabetes* 56: 901–911, 2007.

156. Hotamisligil GS. Inflammation and metabolic disorders. *Nature* 444: 860, 2006.

157. Hotamisligil GS. Inflammation, metaflammation and immunometabolic disorders. *Nature* 542: 177–185, 2017.

158. Huang J, Song D, Flores A, Zhao Q, Mooney SM, Shaw LM, and Lee FS. IOP1, a novel hydrogenase-like protein that modulates hypoxia-inducible factor-1alpha activity. *Biochem J* 401: 341–52, 2007.

159. Huerta-Sánchez E, Degiorgio M, Pagani L, Tarekegn A, Ekong R, Antao T, Cardona A, Montgomery HE, Cavalleri GL, Robbins PA, Weale ME, Bradman N, Bekele E, Kivisild T, Tyler-Smith C, Nielsen R, Huerta-Sanchez E, Degiorgio M, Pagani L, Tarekegn A, Ekong R, Antao T, Cardona A, Montgomery HE, Cavalleri GL, Robbins PA, Weale ME, Bradman N, Bekele E, Kivisild T, Tyler-Smith C, and Nielsen R. Genetic Signatures Reveal High-Altitude Adaptation in a Set of Ethiopian Populations. *Mol Biol Evol* 30: 1877–1888, 2013.

160. Hussain S, Al-Nsour F, Rice AB, Marshburn J, Yingling B, Ji Z, Zink JI, Walker NJ, and Garantziotis S. Cerium Dioxide Nanoparticles Induce Apoptosis and Autophagy in Human Peripheral Blood Monocytes. *ACS Nano* 6: 5820–5829, 2012.

161. Hussain S, Al-Nsour, Rice, Marshburn, Ji, Zink, Yingling, Walker, and Garantziotis. Cerium dioxide nanoparticles do not modulate the lipopolysaccharide-induced inflammatory response in human monocytes. *Int J Nanomedicine* 7: 1387, 2012.

162. Hussain S, Kodavanti PP, Marshburn JD, Janoshazi A, Marinakos SM, George M, Rice A, Wiesner MR, and Garantziotis S. Decreased Uptake and Enhanced Mitochondrial Protection Underlie Reduced Toxicity of Nanoceria in Human Monocyte-Derived Macrophages. *J Biomed Nanotechnol* 12: 2139–2150, 2016.

163. Iliopoulos O, Levy AP, Jiang C, Kaelin WG, and Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. *Proc Natl Acad Sci* 93: 10595–10599, 1996.

164. Iommarini L, Porcelli AM, Gasparre G, and Kurelac I. Non-Canonical Mechanisms Regulating Hypoxia-Inducible Factor 1 Alpha in Cancer. *Front Oncol* 7: 1–9, 2017.

165. Ismail I, Keating SE, Baker MK, and Johnson NA. A systematic review and meta-analysis of the effect of aerobic vs. resistance exercise training on visceral fat.

Obes Rev 13: 68–91, 2012.

166. Italiani P and Boraschi D. From Monocytes to M1/M2 Macrophages: Phenotypical vs. Functional Differentiation. *Front Immunol* 5: 1–22, 2014.

167. Jaakkola P, Mole DR, Tian Y-M, Wilson MI, Gielbert J, Gaskell SJ, Kriegsheim A v., Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation. *Science (80-)* 292: 468–472, 2001.

168. Jafari M, Ghadami E, Dadkhah T, and Akhavan-Niaki H. PI3k/AKT signaling pathway: Erythropoiesis and beyond. *J Cell Physiol* 234: 2373–2385, 2019.

169. Jain IH, Calvo SE, Markhard AL, Skinner OS, To TL, Ast T, Mootha VK, Zazzeron L, Goli R, Alexa K, Schatzman-Bone S, Dhillon H, Goldberger O, Peng J, Shalem O, Sanjana NE, Zhang F, Goessling W, Zapol WM, Mootha VK, Calvo SE, Markhard AL, Skinner OS, To TL, Ast T, and Mootha VK. Genetic Screen for Cell Fitness in High or Low Oxygen Highlights Mitochondrial and Lipid Metabolism. *Cell* 181: 716-727.e11, 2020.

170. Jain IH, Zazzeron L, Goli R, Alexa K, Schatzman-Bone S, Dhillon H, Goldberger O, Peng J, Shalem O, Sanjana NE, Zhang F, Goessling W, Zapol WM, and Mootha VK. Hypoxia as a therapy for mitochondrial disease. *Science (80-)* 352: 54–61, 2016.

171. Jang DH, Shofer FS, Weiss SL, and Becker LB. Impairment of mitochondrial respiration following ex vivo cyanide exposure in peripheral blood mononuclear cells. *Clin Toxicol* 54: 303–307, 2016.

172. Jette M, Sidney K, and Blumchen G. Metabolic equivalents (METS) in exercise testing, exercise prescription, and evaluation of functional capacity. *Clin Cardiol* 13: 555–565, 1990.

173. Jia Y, Duan L, and Li J. Hemoglobin-Based Nanoarchitectonic Assemblies as Oxygen Carriers. *Adv Mater* 28: 1312–1318, 2016.

174. Jiang C, Qu A, Matsubara T, Chanturiya T, Jou W, Gavrilova O, Shah YM, and Gonzalez FJ. Disruption of Hypoxia-Inducible Factor 1 in Adipocytes Improves Insulin Sensitivity and Decreases Adiposity in High-Fat Diet-Fed Mice. *Diabetes* 60: 2484–2495, 2011.

175. Joyce KE, Weaver SR, and Lucas SJE. Geographic components of SARS-CoV-2 expansion: a hypothesis. *J Appl Physiol*: 257–262, 2020.

176. Jun JC, Devera R, Unnikrishnan D, Shin MK, Bevans-Fonti S, Yao Q, Rathore A, Younas H, Halberg N, Scherer PE, and Polotsky VY. Adipose HIF-1a causes obesity by suppressing brown adipose tissue thermogenesis. *J Mol Med* 95: 287–297, 2017.

177. Jung Y-J, Isaacs JS, Lee S, Trepel J, and Neckers L. IL-1beta-mediated up-regulation of HIF-1alpha via an NFKappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis.

FASEB J 17: 2115–7, 2003.

178. Kahn SE, Cooper ME, and Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. *Lancet* 383: 1068–1083, 2014.

179. Kaludercic N, Mialet-Perez J, Paolocci N, Parini A, and Di Lisa F. Monoamine oxidases as sources of oxidants in the heart. *J Mol Cell Cardiol* 73: 34–42, 2014.

180. Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, Ibbs M, Bliźniak R, Łuczewski Ł, and Lamperska K. 2D and 3D cell cultures – a comparison of different types of cancer cell cultures. *Arch Med Sci* 14: 910–919, 2016.

181. Karar J and Maity A. PI3K/AKT/mTOR Pathway in Angiogenesis. *Front Mol Neurosci* 4: 1–8, 2011.

182. Kayser B and Verges S. Hypoxia, energy balance and obesity: from pathophysiological mechanisms to new treatment strategies. *Obes Rev* 14: 579–592, 2013.

183. Keith B, Johnson RS, and Simon MC. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. *Nat Rev Cancer* 12: 9–22, 2011.

184. Khatri P, Sirota M, and Butte AJ. Ten Years of Pathway Analysis: Current Approaches and Outstanding Challenges. *PLoS Comput Biol* 8: e1002375, 2012.

185. Kheirandish-Gozal L, Khalyfa A, Gozal D, Bhattacharjee R, and Wang Y. Endothelial dysfunction in children with obstructive sleep apnea is associated with epigenetic changes in the eNOS gene. *Chest* 143: 971–977, 2013.

186. Kietzmann T and Görlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. *Semin Cell Dev Biol* 16: 474–486, 2005.

187. Kihira Y, Miyake M, Hirata M, Hoshina Y, Kato K, Shirakawa H, Sakaue H, Yamano N, Izawa-Ishizawa Y, Ishizawa K, Ikeda Y, Tsuchiya K, Tamaki T, and Tomita S. Deletion of Hypoxia-Inducible Factor-1α in Adipocytes Enhances Glucagon-Like Peptide-1 Secretion and Reduces Adipose Tissue Inflammation. *PLoS One* 9: e93856, 2014.

188. Kim J, Bhattacharjee R, Khalyfa A, Kheirandish-Gozal L, Capdevila OS, Wang Y, and Gozal D. DNA Methylation in Inflammatory Genes among Children with Obstructive Sleep Apnea. *Am J Respir Crit Care Med* 185: 330–338, 2012.

189. Kimlin L, Kassis J, and Virador V. 3D in vitro tissue models and their potential for drug screening. *Expert Opin Drug Discov* 8: 1455–1466, 2013.

190. Kirchner H, Nylen C, Laber S, Barrès R, Yan J, Krook A, Zierath JR, and Näslund E. Altered promoter methylation of PDK4, IL1 B, IL6, and TNF after Roux-en Y gastric bypass. *Surg Obes Relat Dis* 10: 671–678, 2014.

191. Kong Z, Zang Y, and Hu Y. Normobaric hypoxia training causes more weight loss than normoxia training after a 4-week residential camp for obese young adults. *Sleep Breath* 18: 591–597, 2013.

192. Krauss S, Zhang CY, and Lowell BB. The mitochondrial uncoupling-protein homologues. *Nat Rev Mol Cell Biol* 6: 248–261, 2005.

193. Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J, Memmert K, Naegeli H-U, Petersen F, Eck MJ, Bair KW, Wood AW, and Livingston DM. Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. *Cancer Cell* 6: 33–43, 2004.

194. Kyosseva S V., Chen L, Seal S, and McGinnis JF. Nanoceria inhibit expression of genes associated with inflammation and angiogenesis in the retina of Vldlr null mice. *Exp Eye Res* 116: 63–74, 2013.

195. Lam YY and Ravussin E. Indirect calorimetry: an indispensable tool to understand and predict obesity. *Eur J Clin Nutr* 71: 318–322, 2017.

196. Lassègue B, San Martín A, and Griendling KK. Biochemistry, Physiology, and Pathophysiology of NADPH Oxidases in the Cardiovascular System. *Circ Res* 110: 1364–1390, 2012.

197. Leal V de O and Mafra D. Adipokines in obesity. *Clin Chim Acta* 419: 87–94, 2013.

198. Lecoultre V, Boss A, Tappy L, Borrani F, Tran C, Schneiter P, and Schutz Y. Training in hypoxia fails to further enhance endurance performance and lactate clearance in well-trained men and impairs glucose metabolism during prolonged exercise. *Exp Physiol* 95: 315–330, 2010.

199. Lecoultre V, Peterson CM, Covington JD, Ebenezer PJ, Frost EA, Schwarz J-M, and Ravussin E. Ten Nights of Moderate Hypoxia Improves Insulin Sensitivity in Obese Humans. *Diabetes Care* 36: e197–e198, 2013.

200. Lee K, Roth RA, and LaPres JJ. Hypoxia, drug therapy and toxicity. *Pharmacol Ther* 113: 229–246, 2007.

201. Lee S-H, Jee J-G, Bae J-S, Liu K-H, and Lee YM. A Group of Novel HIF-1α Inhibitors, Glyceollins, Blocks HIF-1α Synthesis and Decreases Its Stability via Inhibition of the PI3K/AKT/mTOR Pathway and Hsp90 Binding. *J Cell Physiol* 230: 853–862, 2015.

202. Lee YS, Kim JW, Osborne O, Oh da Y, Sasik R, Schenk S, Chen A, Chung H, Murphy A, Watkins SM, Quehenberger O, Johnson RS, and Olefsky JM. Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity. *Cell* 157: 1339–1352, 2014.

203. Lefere S, Van Steenkiste C, Verhelst X, Van Vlierberghe H, Devisscher L, and Geerts A. Hypoxia-regulated mechanisms in the pathogenesis of obesity and non-alcoholic fatty liver disease. *Cell Mol Life Sci* 73: 3419–3431, 2016.

204. De Lemos ML, De La Torre AV, Petrov D, Brox S, Folch J, Pallàs M, Lazarowski A, Beas-Zarate C, Auladell C, and Camins A. Evaluation of hypoxia inducible factor expression in inflammatory and neurodegenerative brain models. *Int J Biochem Cell Biol* 45: 1377–1388, 2013.

205. Lempesis IG, van Meijel RLJ, Manolopoulos KN, and Goossens GH. Oxygenation of adipose tissue: A human perspective. *Acta Physiol* 228: 1–17, 2020.

206. Lenton TM. The coupled evolution of life and atmospheric oxygen. In: *Evolution on Planet Earth*. Elsevier, 2003, pp. 35–53.

207. Li B, Qiu B, Lee DSM, Walton ZE, Ochocki JD, Mathew LK, Mancuso A, Gade TPF, Keith B, Nissim I, and Simon MC. Fructose-1,6-bisphosphatase opposes renal carcinoma progression. *Nature* 513: 251–5, 2014.

208. Li E and Zhang Y. DNA methylation in mammals. *Cold Spring Harb Perspect Biol* 6: a019133, 2014.

209. Li F, Li Y, Duan Y, Hu CAA, Tang Y, and Yin Y. Myokines and adipokines: Involvement in the crosstalk between skeletal muscle and adipose tissue. *Cytokine Growth Factor Rev* 33: 73–82, 2017.

210. Li Q, Pan H, Guan L, Su D, and Ma X. CITED2 mutation links congenital heart defects to dysregulation of the cardiac gene VEGF and PITX2C expression. *Biochem Biophys Res Commun* 423: 895–9, 2012.

211. Li Y, Lim S, Hoffman D, Aspenstrom P, Federoff HJ, and Rempe DA. HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and transport. *J Cell Biol* 185: 1065–81, 2009.

212. Li Z, Lai Z, Ya K, Fang D, Ho YW, Lei Y, and Ming QZ. Correlation between the expression of divalent metal transporter 1 and the content of hypoxia-inducible factor-1 in hypoxic HepG2 cells. *J Cell Mol Med* 12: 569–79, 2008.

213. Libby P. Mechanisms of Acute Coronary Syndromes and Their Implications for Therapy. *N Engl J Med* 368: 2004–2013, 2013.

214. Lin C-H, Su W-H, Chen Y-C, Feng P-H, Shen W-C, Ong J-R, Wu M-Y, and Wong CS. Treatment with normobaric or hyperbaric oxygen and its effect on neuropsychometric dysfunction after carbon monoxide poisoning. *Medicine (Baltimore)* 97: e12456, 2018.

215. Lindahl SGE. Oxygen and Life on Earth. *Anesthesiology* 109: 7–13, 2008.

216. Lindgärde F, Ercilla MB, Correa LR, and Ahrén B. Body Adiposity, Insulin, and Leptin in Subgroups of Peruvian Amerindians. *High Alt Med Biol* 5: 27–31, 2004.

217. Lippl FJ, Neubauer S, Schipfer S, Lichter N, Tufman A, Otto B, and Fischer R. Hypobaric Hypoxia Causes Body Weight Reduction in Obese Subjects. *Obesity* 18: 675–681, 2010.

218. Liu L, Wise DR, Diehl JA, and Simon MC. Hypoxic

Reactive Oxygen Species Regulate the Integrated Stress Response and Cell Survival. *J Biol Chem* 283: 31153–31162, 2008.

219. Liu Y, Nie H, Zhang K, Ma D, Yang G, Zheng Z, Liu K, Yu B, Zhai C, and Yang S. A feedback regulatory loop between HIF-1α and miR-21 in response to hypoxia in cardiomyocytes. *FEBS Lett* 588: 3137–46, 2014.

220. Lopez-Legarrea P, Mansego ML, Zulet MA, and Martinez JA. SERPINE1, PAI-1 protein coding gene, methylation levels and epigenetic relationships with adiposity changes in obese subjects with metabolic syndrome features under dietary restriction. *J Clin Biochem Nutr* 53: 139–144, 2013.

221. Lopez-Pascual A, Arévalo J, Martínez JA, and González-Muniesa P. Inverse Association Between Metabolic Syndrome and Altitude: A Cross-Sectional Study in an Adult Population of Ecuador. *Front Endocrinol (Lausanne)* 9: 1–8, 2018.

222. Lopez-Pascual A, Bes-Rastrollo M, Sayón-Orea C, Perez-Cornago A, Díaz-Gutiérrez J, Pons JJJJ, Martínez-González MAMA, González-Muniesa P, Alfredo Martínez J, and Martínez JA. Living at a Geographically Higher Elevation Is Associated with Lower Risk of Metabolic Syndrome: Prospective Analysis of the SUN Cohort. *Front Physiol* 7: 1–9, 2017.

223. Lopez-Pascual A, Lasa A, Portillo MPMP, Arós F, Mansego MLML, González-Muniesa P, and Martinez JAA. Low Oxygen Consumption is Related to a Hypomethylation and an Increased Secretion of IL-6 in Obese Subjects with Sleep Apnea-Hypopnea Syndrome. *Ann Nutr Metab* 71: 16–25, 2017.

224. Lopez-Pascual A, Lorente-Cebrián S, Moreno-Aliaga MJMJMJ, Martinez JAA, and González-Muniesa P. Inflammation stimulates hypoxia-inducible factor-1α regulatory activity in 3T3-L1 adipocytes with conditioned medium from lipopolysaccharide-activated RAW 264.7 macrophages. *J Cell Physiol* 234: 550–560, 2019.

225. Lopez-Pascual A, Urrutia-Sarratea A, Lorente-Cebrián S, Martinez JA, and González-Muniesa P. Cerium Oxide Nanoparticles Regulate Insulin Sensitivity and Oxidative Markers in 3T3-L1 Adipocytes and C2C12 Myotubes. *Oxid Med Cell Longev* 2019: 1–10, 2019.

226. Lou Y-R and Leung AW. Next generation organoids for biomedical research and applications. *Biotechnol Adv* 36: 132–149, 2018.

227. Mackenzie R, Maxwell N, Castle P, Brickley G, and Watt P. Acute hypoxia and exercise improve insulin sensitivity (SI2*) in individuals with type 2 diabetes. *Diabetes Metab Res Rev* 27: 94–101, 2011.

228. Mackenzie R, Maxwell N, Castle P, Elliott B, Brickley G, and Watt P. Intermittent Exercise with and without Hypoxia Improves Insulin Sensitivity in Individuals with Type 2 Diabetes. *J Clin Endocrinol Metab* 97: E546–E555, 2012.

229. Majmundar AJ, Wong WJ, and Simon MC. Hypoxia-Inducible Factors and the Response to Hypoxic Stress. *Mol Cell* 40: 294–309, 2010.

230. Makrecka-Kuka M, Krumschnabel G, and Gnaiger E. High-resolution respirometry for simultaneous measurement of oxygen and hydrogen peroxide fluxes in permeabilized cells, tissue homogenate and isolated mitochondria. *Biomolecules* 5: 1319–1338, 2015.

231. Mansego ML, Milagro FI, Zulet MA, Moreno-Aliaga MJ, and Martinez JA. Differential DNA Methylation in Relation to Age and Health Risks of Obesity. *Int J Mol Sci* 16: 16816–16832, 2015.

232. María Martín-Núñez G, Rubio-Martín E, Cabrera-Mulero R, Rojo-Martínez G, Olveira G, Valdés S, Soriguer F, Castaño L, and Morcillo S. Type 2 diabetes mellitus in relation to global LINE-1 DNA methylation in peripheral blood: A cohort study. *Epigenetics* 9: 1322–1328, 2014.

233. Marin JM, Artal J, Martin T, Carrizo SJ, Andres M, Martin-Burriel I, Bolea R, Sanz A, Varona L, Godino J, Gallego B, Garcia-Erce JA, Villar I, Gil V, Forner M, Cubero JP, and Ros L. Epigenetics modifications and Subclinical Atherosclerosis in Obstructive Sleep Apnea: The EPIOSA study. *BMC Pulm Med* 14: 114, 2014.

234. Marques-Rocha JL, Milagro FI, Mansego ML, Mourão DM, Martínez JA, and Bressan J. LINE-1 methylation is positively associated with healthier lifestyle but inversely related to body fat mass in healthy young individuals. *Epigenetics* 11: 49–60, 2016.

235. Martínez JA, Milagro FI, Claycombe KJ, and Schalinske KL. Epigenetics in Adipose Tissue, Obesity, Weight Loss, and Diabetes. *Adv Nutr* 5: 71–81, 2014.

236. Mateika JH, El-Chami M, Shaheen D, and Ivers B. Intermittent hypoxia: a low-risk research tool with therapeutic value in humans. *J Appl Physiol* 118: 520–532, 2015.

237. Mateika JH and Komnenov D. Intermittent hypoxia initiated plasticity in humans: A multipronged therapeutic approach to treat sleep apnea and overlapping co-morbidities. *Exp Neurol* 287: 113–129, 2017.

238. Mathieu D, Marroni A, and Kot J. Tenth european consensus conference on hyperbaric medicine: Recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. *Diving Hyperb Med* 47: 24–31, 2017.

239. Matsuura H, Ichiki T, Inoue E, Nomura M, Miyazaki R, Hashimoto T, Ikeda J, Takayanagi R, Fong GH, and Sunagawa K. Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance. *Circulation* 127: 2078–2087, 2013.

240. McElroy MK, Gerard a, Powell FL, Prisk GK, Sentse N, Holverda S, and West JB. Nocturnal O2 enrichment of room air at high altitude increases daytime O2 saturation without changing control of ventilation. *High Alt Med Biol* 1: 197–206, 2000.

241. McGettrick AF and O'Neill LAJ. The Role of HIF in Immunity and Inflammation. *Cell Metab* 32: 524–536, 2020.

242. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response. *Br J Radiol* 87: 20130676, 2014.

243. Medzhitov R. Origin and physiological roles of inflammation. *Nature* 454: 428–435, 2008.

244. Merico D, Isserlin R, Stueker O, Emili A, and Bader GD. Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation. *PLoS One* 5: e13984, 2010.

245. Michailidou Z, Morton NM, Navarrete JMM, West CC, Stewart KJ, Fernández-Real JM, Schofield CJ, Seckl JR, and Ratcliffe PJ. Adipocyte pseudohypoxia suppresses lipolysis and facilitates benign adipose tissue expansion. *Diabetes* 64: 733–745, 2015.

246. Milagro FI, Mansego ML, De Miguel C, and Martinez JA. Dietary factors, epigenetic modifications and obesity outcomes: progresses and perspectives. *Mol Aspects Med* 34: 782–812, 2013.

247. Milano G, Abruzzo PM, Bolotta A, Marini M, Terraneo L, Ravara B, Gorza L, Vitadello M, Burattini S, Curzi D, Falcieri E, von Segesser LK, and Samaja M. Impact of the Phosphatidylinositide 3-Kinase Signaling Pathway on the Cardioprotection Induced by Intermittent Hypoxia. *PLoS One* 8: 1–14, 2013.

248. Miles AL, Burr SP, Grice GL, and Nathan JA. The vacuolar-ATPase complex and assembly factors, TMEM199 and CCDC115, control HIF1α prolyl hydroxylation by regulating cellular iron levels. *Elife* 6, 2017.

249. Millet GP, Debevec T, Brocherie F, Malatesta D, and Girard O. Therapeutic Use of Exercising in Hypoxia: Promises and Limitations. *Front Physiol* 7: 224, 2016.

250. Mirrakhimov AE and Polotsky VY. Obstructive Sleep Apnea and Non-Alcoholic Fatty Liver Disease: Is the Liver Another Target? *Front Neurol* 3: 1–12, 2012.

251. Mittal S and Pandey AK. Cerium oxide nanoparticles induced toxicity in human lung cells: Role of ROS mediated DNA damage and apoptosis. *Biomed Res Int* 2014, 2014.

252. Mizukami Y, Iwamatsu A, Aki T, Kimura M, Nakamura K, Nao T, Okusa T, Matsuzaki M, Yoshida K-I, and Kobayashi S. ERK1/2 regulates intracellular ATP levels through alpha-enolase expression in cardiomyocytes exposed to ischemic hypoxia and reoxygenation. *J Biol Chem* 279: 50120–31, 2004.

253. Mochly-Rosen D, Das K, and Grimes K V. Protein kinase C, an elusive therapeutic target? *Nat Rev Drug Discov* 11: 937–957, 2012.

254. Mole DR, Blancher C, Copley RR, Pollard PJ, Gleadle JM, Ragousis J, and Ratcliffe PJ. Genome-wide

association of hypoxia-inducible factor (HIF)-1α and HIF-2α DNA binding with expression profiling of hypoxia-inducible transcripts. *J Biol Chem* 284: 16767–16775, 2009.

255. Molica F, Morel S, Kwak BR, Rohner-Jeanrenaud F, and Steffens S. Adipokines at the crossroad between obesity and cardiovascular disease. *Thromb Haemost* 113: 553–566, 2015.

256. Mortensen CR. Hyperbaric oxygen therapy. *Curr Anaesth Crit Care* 19: 333–337, 2008.

257. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, and Eisenberg MJ. The Metabolic Syndrome and Cardiovascular Risk. *J Am Coll Cardiol* 56: 1113–1132, 2010.

258. Movafagh S, Crook S, and Vo K. Regulation of Hypoxia-Inducible Factor-1a by Reactive Oxygen Species : New Developments in an Old Debate. *J Cell Biochem* 116: 696–703, 2015.

259. Muñoz-Garach A, Cornejo-Pareja I, and Tinahones F. Does Metabolically Healthy Obesity Exist? *Nutrients* 8: 320, 2016.

260. Murphy MP. How mitochondria produce reactive oxygen species. *Biochem J* 417: 1–13, 2009.

261. Na YK, Hong HS, Lee WK, Kim YH, and Kim DS. Increased methylation of interleukin 6 gene is associated with obesity in Korean women. *Mol Cells* 38: 452–456, 2015.

262. Nathan DM. Diabetes. *JAMA* 314: 1052, 2015.

263. Navarrete-Opazo A and Mitchell GS. Therapeutic potential of intermittent hypoxia: a matter of dose. *Am J Physiol Integr Comp Physiol* 307: R1181–R1197, 2014.

264. Navarro E, Funtikova AN, Fito M, and Schroder H. Can Metabolically Healthy Obesity be explained by diet, genetics and inflammation? *Mol Nutr Food Res*, 2014.

265. Nemmar A, Yuvaraju P, Beegam S, Fahim MA, and Ali BH. Cerium Oxide Nanoparticles in Lung Acutely Induce Oxidative Stress, Inflammation, and DNA Damage in Various Organs of Mice. *Oxid Med Cell Longev* 2017: 1–12, 2017.

266. Netzer NC, Chytra R, and Küpper T. Low intense physical exercise in normobaric hypoxia leads to more weight loss in obese people than low intense physical exercise in normobaric sham hypoxia. *Sleep Breath* 12: 129–134, 2008.

267. Neumayr G, Fries D, Mittermayer M, Humpeler E, Klingler A, Schobersberger W, Spiesberger R, Pokan R, Schmid P, and Berent R. Effects of hiking at moderate and low altitude on cardiovascular parameters in male patients with metabolic syndrome: Austrian Moderate Altitude Study. *Wilderness Environ Med* 25: 329–334, 2014.

268. Ni Y-N, Wang Y-M, Liang B-M, and Liang Z-A. The effect of hyperoxia on mortality in critically ill

patients: a systematic review and meta analysis. *BMC Pulm Med* 19: 53, 2019.

269. Nicoletti CF, Nonino CB, de Oliveira BAP, Pinhel MA de S, Mansego ML, Milagro FI, Zulet MA, and Martinez JA. DNA Methylation and Hydroxymethylation Levels in Relation to Two Weight Loss Strategies: Energy-Restricted Diet or Bariatric Surgery. *Obes Surg* 26: 603–611, 2016.

270. Nielsen HB. Arterial desaturation during exercise in man: implication for O2 uptake and work capacity. *Scand J Med Sci Sports* 13: 339–358, 2003.

271. Nishi K, Oda T, Takabuchi S, Oda S, Fukuda K, Adachi T, Semenza GL, Shingu K, and Hirota K. LPS Induces Hypoxia-Inducible Factor 1 Activation in Macrophage-Differentiated Cells in a Reactive Oxygen Species–Dependent Manner. *Antioxid Redox Signal* 10: 983–996, 2008.

272. Nishiwaki M, Kawakami R, Saito K, Tamaki H, and Ogita F. The effects of exercise training under mild hypoxic conditions on body composition and circulating adiponectin in postmenopausal women. *Clin Physiol Funct Imaging* 36: 468–475, 2016.

273. Niu J, Azfer A, Rogers LM, Wang X, and Kolattukudy PE. Cardioprotective effects of cerium oxide nanoparticles in a transgenic murine model of cardiomyopathy. *Cardiovasc Res* 73: 549–559, 2007.

274. Niu J, Wang K, and Kolattukudy PE. Cerium Oxide Nanoparticles Inhibits Oxidative Stress and Nuclear Factor- B Activation in H9c2 Cardiomyocytes Exposed to Cigarette Smoke Extract. *J Pharmacol Exp Ther* 338: 53–61, 2011.

275. Norboo T, Stobdan T, Tsering N, Angchuk N, Tsering P, Ahmed I, Chorol T, Kumar Sharma V, Reddy P, Singh SB, Kimura Y, Sakamoto R, Fukutomi E, Ishikawa M, Suwa K, Kosaka Y, Nose M, Yamaguchi T, Tsukihara T, Matsubayashi K, Otsuka K, and Okumiya K. Prevalence of hypertension at high altitude: cross-sectional survey in Ladakh, Northern India 2007-2011. *BMJ Open* 5: e007026-2014–007026, 2015.

276. Norouzirad R, González-Muniesa P, and Ghasemi A. Hypoxia in Obesity and Diabetes: Potential Therapeutic Effects of Hyperoxia and Nitrate. *Oxid Med Cell Longev* 2017: 1–14, 2017.

277. O'Neill S and O'Driscoll L. Metabolic syndrome: a closer look at the growing epidemic and its associated pathologies. *Obes Rev* 16: 1–12, 2015.

278. Ochoa CD, Wu RF, and Terada LS. ROS signaling and ER stress in cardiovascular disease. *Mol Aspects Med* 63: 18–29, 2018.

279. Oh JG and Ishikawa K. Experimental Models of Cardiovascular Diseases: Overview. In: *Methods in Molecular Biology*. vol. 1816, 2018, pp. 3–14.

280. Olson N and van der Vliet A. Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease. *Nitric Oxide* 25:

125–137, 2011.

281. Osborn O and Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. *Nat Med* 18: 363–374, 2012.

282. Ottolenghi S, Maria Rubino F, Sabbatini G, Coppola S, Veronese A, Chiumello D, and Paroni R. Oxidative stress markers to investigate the effects of hyperoxia in anesthesia. *Int J Mol Sci* 20: 1–12, 2019.

283. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH, and Hotamisligil GS. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. *Science* 306: 457–461, 2004.

284. Pagé EL, Robitaille GA, Pouysségur J, and Richard DE. Induction of hypoxia-inducible factor-1α by transcriptional and translational mechanisms. *J Biol Chem* 277: 48403–48409, 2002.

285. Palmer BF and Clegg DJ. Ascent to altitude as a weight loss method: the good and bad of hypoxia inducible factor activation. *Obesity (Silver Spring)* 22: 311–317, 2014.

286. Papandreou I, Cairns RA, Fontana L, Lim AL, and Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. *Cell Metab* 3: 187–197, 2006.

287. Park YS, David AE, Huang Y, Park JB, He H, Byun Y, and Yang VC. In vivo delivery of cell-permeable antisense hypoxia-inducible factor 1α oligonucleotide to adipose tissue reduces adiposity in obese mice. *J Control Release* 161: 1–9, 2012.

288. Parsanejad M, Zhang Y, Qu D, Irrcher I, Rousseaux MWC, Aleyasin H, Kamkar F, Callaghan S, Slack RS, Mak TW, Lee S, Figeys D, and Park DS. Regulation of the VHL/HIF-1 pathway by DJ-1. *J Neurosci* 34: 8043–50, 2014.

289. Paşca SP. The rise of three-dimensional human brain cultures. *Nature* 553: 437–445, 2018.

290. Paschos NK, Brown WE, Eswaramoorthy R, Hu JC, and Athanasiou KA. Advances in tissue engineering through stem cell-based co-culture. *J Tissue Eng Regen Med* 9: 488–503, 2015.

291. Pasha Q and Pandey P. Oxidative stress at high altitude: genotype-phenotype correlations. *Adv Genomics Genet* 4: 29, 2014.

292. Patnaik MM and Tefferi A. The complete evaluation of erythrocytosis: congenital and acquired. *Leukemia* 23: 834–844, 2009.

293. Patti M-E and Corvera S. The Role of Mitochondria in the Pathogenesis of Type 2 Diabetes. *Endocr Rev* 31: 364–395, 2010.

294. Pawelec G, Goldeck D, and Derhovanessian E. Inflammation, ageing and chronic disease. *Curr Opin Immunol* 29: 23–28, 2014.

295. Pereira-Lancha LO, Campos-Ferraz PL, and Lancha AH. Obesity: Considerations about etiology, metabolism, and the use of experimental models. *Diabetes, Metab Syndr Obes Targets Ther* 5: 75–87, 2012.

296. Picón-Reátegui E. Intravenous Glucose Tolerance Test at Sea Level and at High Altitudes. *J Clin Endocrinol Metab* 21: 1177–1180, 1966.

297. Pinheiro-Castro N, Silva LBAR, Novaes GM, and Ong TP. Hypercaloric Diet-Induced Obesity and Obesity-Related Metabolic Disorders in Experimental Models. vol. 1134, 2019, pp. 149–161.

298. Piras AM, Dessy A, Chiellini F, Chiellini E, Farina C, Ramelli M, and Della Valle E. Polymeric nanoparticles for hemoglobin-based oxygen carriers. *Biochim Biophys Acta - Proteins Proteomics* 1784: 1454–1461, 2008.

299. Pittman RN. *Regulation of Tissue Oxygenation Second Edition*. 2nd ed., Morgan & Claypool, 2016.

300. Piyathilake CJ, Badiga S, Alvarez RD, Partridge EE, and Johanning GL. A Lower Degree of PBMC L1 Methylation Is Associated with Excess Body Weight and Higher HOMA-IR in the Presence of Lower Concentrations of Plasma Folate. *PLoS One* 8: e54544, 2013.

301. Poff AM, Kernagis D, and D'Agostino DP. Hyperbaric Environment: Oxygen and Cellular Damage versus Protection. In: *Comprehensive Physiology*. vol. 7Hoboken, NJ, USA, John Wiley & Sons, Inc., 2016, pp. 213–234.

302. Pouysségur J, Dayan F, and Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. *Nature* 441: 437–443, 2006.

303. Prommer N, Heinicke K, Viola T, Cajigal J, Behn C, and Schmidt WF. Long-term intermittent hypoxia increases O2-transport capacity but not VO2max. *High Alt Med Biol* 8: 225–235, 2007.

304. Pugh CW, O'Rourke JF, Nagao M, Gleadle JM, and Ratcliffe PJ. Activation of Hypoxia-inducible Factor-1; Definition of Regulatory Domains within the α Subunit. *J Biol Chem* 272: 11205–11214, 1997.

305. Pundir CS, Narwal V, and Batra B. Determination of lactic acid with special emphasis on biosensing methods: A review. *Biosens Bioelectron* 86: 777–790, 2016.

306. Qiu C and Fratiglioni L. A major role for cardiovascular burden in age-related cognitive decline. *Nat Rev Cardiol* 12: 267–277, 2015.

307. Querido JS, Sheel AW, Cheema R, Van Eeden S, Mulgrew AT, and Ayas NT. Effects of 10 days of modest intermittent hypoxia on circulating measures of inflammation in healthy humans. *Sleep Breath* 16: 657–662, 2012.

308. Quintero P, Milagro FI, Campión J, and Martínez JA. Impact of oxygen availability on body weight management. *Med Hypotheses* 74: 901–907, 2010.

309. Rabinovitch RC, Samborska B, Faubert B, Ma EH, Gravel S-P, Andrzejewski S, Raissi TC, Pause A, St.-Pierre J, and Jones RG. AMPK Maintains Cellular Metabolic Homeostasis through Regulation of Mitochondrial Reactive Oxygen Species. *Cell Rep* 21: 1–9, 2017.

310. Radad K, Rausch WD, and Gille G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. *Neurochem Int* 49: 379–386, 2006.

311. Radak Z, Zhao Z, Koltai E, Ohno H, and Atalay M. Oxygen Consumption and Usage During Physical Exercise: The Balance Between Oxidative Stress and ROS-Dependent Adaptive Signaling. *Antioxid Redox Signal* 18: 1208–1246, 2013.

312. Rahtu-Korpela L, Karsikas S, Horkko S, Blanco Sequeiros R, Lammentausta E, Makela KA, Herzig K-H, Walkinshaw G, Kivirikko KI, Myllyharju J, Serpi R, and Koivunen P. HIF Prolyl 4-Hydroxylase-2 Inhibition Improves Glucose and Lipid Metabolism and Protects Against Obesity and Metabolic Dysfunction. *Diabetes* 63: 3324–3333, 2014.

313. Rains JL and Jain SK. Oxidative stress, insulin signaling, and diabetes. *Free Radic Biol Med* 50: 567–575, 2011.

314. Ratcliffe P, Koivunen P, Myllyharju J, Ragoussis J, Bovée J, Batinic-Haberle I, Vinatier C, Trichet V, Robriquet F, Oliver L, and Gardie B. Update on hypoxia-inducible factors and hydroxylases in oxygen regulatory pathways: from physiology to therapeutics. *Hypoxia* Volume 5: 11–20, 2017.

315. Rausch ME, Weisberg S, Vardhana P, and Tortoriello D V. Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration. *Int J Obes* 32: 451–463, 2008.

316. Ray PD, Huang B-W, and Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. *Cell Signal* 24: 981–990, 2012.

317. Regazzetti C, Peraldi P, Grémeaux T, Najem-Lendom R, Ben-Sahra I, Cormont M, Bost F, Le Marchand-Brustel Y, Tanti JF, and Giorgetti-Peraldi S. Hypoxia decreases insulin signaling pathways in adipocytes. *Diabetes* 58: 95, 2009.

318. Reilly SM and Saltiel AR. Adapting to obesity with adipose tissue inflammation. *Nat Rev Endocrinol* 13: 633–643, 2017.

319. Relton CL, Groom A, St Pourcain B, Sayers AE, Swan DC, Embleton ND, Pearce MS, Ring SM, Northstone K, Tobias JH, Trakalo J, Ness AR, Shaheen SO, and Davey Smith G. DNA methylation patterns in cord blood DNA and body size in childhood. *PLoS One* 7: e31821, 2012.

320. Ribarič S. Diet and Aging. *Oxid Med Cell Longev* 2012: 1–20, 2012.

321. Richard DE, Berra E, and Pouyssegur J. Nonhypoxic pathway mediates the induction of hypoxia-inducible factor 1alpha in vascular smooth muscle cells. *J Biol Chem* 275: 26765–71, 2000.

322. Robson-Doucette CA, Sultan S, Allister EM, Wikstrom JD, Koshkin V, Bhatacharjee A, Prentice KJ, Sereda SB, Shirihai OS, and Wheeler MB. B-Cell Uncoupling Protein 2 Regulates Reactive Oxygen Species Production, Which Influences Both Insulin and Glucagon Secretion. *Diabetes* 60: 2710–2719, 2011.

323. Rocca A, Mattoli V, Mazzolai B, and Ciofani G. Cerium oxide nanoparticles inhibit adipogenesis in rat mesenchymal stem cells: Potential therapeutic implications. *Pharm Res* 31: 2952–2962, 2014.

324. Rocca A, Moscato S, Ronca F, Nitti S, Mattoli V, Giorgi M, and Ciofani G. Pilot in vivo investigation of cerium oxide nanoparticles as a novel anti-obesity pharmaceutical formulation. *Nanomedicine Nanotechnology, Biol Med* 11: 1725–1734, 2015.

325. da Rocha EEM, Alves VGF, and da Fonseca RB V. Indirect calorimetry: methodology, instruments and clinical application. *Curr Opin Clin Nutr Metab Care* 9: 247–256, 2006.

326. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, Alla F, Alvis-Guzman N, Amrock S, Ansari H, Ärnlöv J, Asayesh H, Atey TM, Avila-Burgos L, Awasthi A, Banerjee A, Barac A, Bärnighausen T, Barregard L, Bedi N, Belay Ketema E, Bennett D, Berhe G, Bhutta Z, Bitew S, Carapetis J, Carrero JJ, Malta DC, Castañeda-Orjuela CA, Castillo-Rivas J, Catalá-López F, Choi J-Y, Christensen H, Cirillo M, Cooper L, Criqui M, Cundiff D, Damasceno A, Dandona L, Dandona R, Davletov K, Dharmaratne S, Dorairaj P, Dubey M, Ehrenkranz R, El Sayed Zaki M, Faraon EJA, Esteghamati A, Farid T, Farvid M, Feigin V, Ding EL, Fowkes G, Gebrehiwot T, Gillum R, Gold A, Gona P, Gupta R, Habtewold TD, Hafezi-Nejad N, Hailu T, Hailu GB, Hankey G, Hassen HY, Abate KH, Havmoeller R, Hay SI, Horino M, Hotez PJ, Jacobsen K, James S, Javanbakht M, Jeemon P, John D, Jonas J, Kalkonde Y, Karimkhani C, Kasaeian A, Khader Y, Khan A, Khang Y-H, Khera S, Khoja AT, Khubchandani J, Kim D, Kolte D, Kosen S, Krohn KJ, Kumar GA, Kwan GF, Lal DK, Larsson A, Linn S, Lopez A, Lotufo PA, El Razek HMA, Malekzadeh R, Mazidi M, Meier T, Meles KG, Mensah G, Meretoja A, Mezgebe H, Miller T, Mirrakhimov E, Mohammed S, Moran AE, Musa KI, Narula J, Neal B, Ngalesoni F, Nguyen G, Obermeyer CM, Owolabi M, Patton G, Pedro J, Qato D, Qorbani M, Rahimi K, Rai RK, Rawaf S, Ribeiro A, Safiri S, Salomon JA, Santos I, Santric Milicevic M, Sartorius B, Schutte A, Sepanlou S, Shaikh MA, Shin M-J, Shishehbor M, Shore H, Silva DAS, Sobngwi E, Stranges S, Swaminathan S, Tabarés-Seisdedos R, Tadele Atnafu N, Tesfay F, Thakur JS, Thrift A, Topor-Madry R, Truelsen T, Tyrovolas S, Ukwaja KN, Uthman O, Vasankari T, Vlassov V, Vollset SE, Wakayo T, Watkins D, Weintraub R, Werdecker A, Westerman R, Wiysonge

CS, Wolfe C, Workicho A, Xu G, Yano Y, Yip P, Yonemoto N, Younis M, Yu C, Vos T, Naghavi M, and Murray C. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. *J Am Coll Cardiol* 70: 1–25, 2017.

327. SACK M. Mitochondrial depolarization and the role of uncoupling proteins in ischemia tolerance. *Cardiovasc Res* 72: 210–219, 2006.

328. Sack M, Alili L, Karaman E, Das S, Gupta A, Seal S, and Brenneisen P. Combination of Conventional Chemotherapeutics with Redox-Active Cerium Oxide Nanoparticles--A Novel Aspect in Cancer Therapy. *Mol Cancer Ther* 13: 1740–1749, 2014.

329. Salas-Pérez F, Ramos-Lopez O, Mansego ML, Milagro FI, Santos JL, Riezu-Boj JI, and Martínez JA. DNA methylation in genes of longevity-regulating pathways: association with obesity and metabolic complications. *Aging (Albany NY)* 11: 1874–1899, 2019.

330. Salminen A, Kauppinen A, and Kaarniranta K. 2-Oxoglutarate-dependent dioxygenases are sensors of energy metabolism, oxygen availability, and iron homeostasis: Potential role in the regulation of aging process. *Cell Mol Life Sci* 72: 3897–3914, 2015.

331. Salord N, Gasa M, Mayos M, Fortuna-Gutierrez AM, Montserrat JM, Sánchez-de-la-Torre M, Barceló A, Barbé F, Vilarrasa N, and Monasterio C. Impact of OSA on Biological Markers in Morbid Obesity and Metabolic Syndrome. *J Clin Sleep Med* 10: 263–70, 2014.

332. Samblas M, Milagro FI, and Martínez A. DNA methylation markers in obesity, metabolic syndrome, and weight loss. *Epigenetics* 14: 421–444, 2019.

333. Samoylenko A, Hossain J Al, Mennerich D, Kellokumpu S, Hiltunen JK, and Kietzmann T. Nutritional Countermeasures Targeting Reactive Oxygen Species in Cancer: From Mechanisms to Biomarkers and Clinical Evidence. *Antioxid Redox Signal* 19: 2157–2196, 2013.

334. Sano R and Reed JC. ER stress-induced cell death mechanisms. *Biochim Biophys Acta - Mol Cell Res* 1833: 3460–3470, 2013.

335. De Santis V and Singer M. Tissue oxygen tension monitoring of organ perfusion: Rationale, methodologies, and literature review. *Br J Anaesth* 115: 357–365, 2015.

336. Santos AL, Sinha S, and Lindner AB. The Good, the Bad, and the Ugly of ROS: New Insights on Aging and Aging-Related Diseases from Eukaryotic and Prokaryotic Model Organisms. *Oxid Med Cell Longev* 2018: 1941285, 2018.

337. Sanz-Rubio D, Sanz A, Varona L, Bolea R, Forner M, Gil A V., Cubero P, Marin-Oto M, Martin-Burriel I, and Marin JM. Forkhead Box P3 Methylation and Expression in Men with Obstructive Sleep Apnea. *Int J Mol Sci* 21: 2233, 2020.

338. Sasayama S, Izumi T, Seino Y, Ueshima K, and Asanoi H. Effects of nocturnal oxygen therapy on outcome measures in patients with chronic heart failure and cheyne-stokes respiration. *Circ J* 70: 1–7, 2006.

339. Sauaia A, Moore EE, and Banerjee A. Hemoglobin-based blood substitutes and risk of myocardial infarction and death. *JAMA - J Am Med Assoc* 300: 1297, 2008.

340. Scheller J, Chalaris A, Schmidt-Arras D, and Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta - Mol Cell Res* 1813: 878–888, 2011.

341. Schett G and Neurath MF. Resolution of chronic inflammatory disease: universal and tissue-specific concepts. *Nat Commun* 9: 3261, 2018.

342. Schobersberger W, Schmid P, Lechleitner M, von Duvillard SP, Hortnagl H, Gunga HC, Klingler A, Fries D, Kirsch K, Spiesberger R, Pokan R, Hofmann P, Hoppichler F, Riedmann G, Baumgartner H, and Humpeler E. Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome. *Eur J Appl Physiol* 88: 506–514, 2003.

343. Semenza GL. Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1. *J Clin Invest* 106: 809–812, 2000.

344. Semenza GL. Hypoxia-inducible factor 1: Regulator of mitochondrial metabolism and mediator of ischemic preconditioning. *Biochim Biophys Acta - Mol Cell Res* 1813: 1263–1268, 2011.

345. Semenza GL. Oxygen Sensing, Homeostasis, and Disease. *N Engl J Med* 365: 537–547, 2011.

346. Semenza GL. Hypoxia-Inducible Factors in Physiology and Medicine. *Cell* 148: 399–408, 2012.

347. Semenza GL. Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology. *Annu Rev Pathol Mech Dis* 9: 47–71, 2014.

348. Semenza GL. Hypoxia-Inducible Factor 1 and Cardiovascular Disease. *Annu Rev Physiol* 76: 39–56, 2014.

349. Semenza GL, Roth PH, Fang HM, and Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. *J Biol Chem* 269: 23757–63, 1994.

350. Semenza GL and Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. *Mol Cell Biol* 12: 5447–54, 1992.

351. Sen A, Ren S, Lerchenmüller C, Sun J, Weiss N, Most P, and Peppel K. MicroRNA-138 regulates hypoxia-induced endothelial cell dysfunction by targeting S100A1. *PLoS One* 8: e78684, 2013.

352. Sena LA and Chandel NS. Physiological roles of mitochondrial reactive oxygen species. *Mol Cell* 48:

66

158–167, 2012.

353. Sena LA, Chandel NS, Jiang D, Gao F, Zhang Y, Wong DSH, Li Q, Tse HF, Xu G, Yu Z, and Lian Q. Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage. *Cell Death Dis* 7: e2467-10, 2016.

354. Sepehrvand N and Ezekowitz JA. Oxygen Therapy in Patients With Acute Heart Failure. *JACC Hear Fail* 4: 783–790, 2016.

355. Serebrovska T V., Portnychenko AG, Drevytska TI, Portnichenko VI, Xi L, Egorov E, Gavalko A V., Naskalova S, Chizhova V, and Shatylo VB. Intermittent hypoxia training in prediabetes patients: Beneficial effects on glucose homeostasis, hypoxia tolerance and gene expression. *Exp Biol Med* 242: 1542–1552, 2017.

356. Serebrovska T V., Portnychenko AG, Portnichenko VI, Xi L, Egorov E, Antoniuk-Shcheglova I, Naskalova S, and Shatylo VB. Effects of intermittent hypoxia training on leukocyte pyruvate dehydrogenase kinase 1 (PDK-1) mRNA expression and blood insulin level in prediabetes patients. *Eur J Appl Physiol* 119: 813–823, 2019.

357. Shekhar S, Cunningham MW, Pabbidi MR, Wang S, Booz GW, and Fan F. Targeting vascular inflammation in ischemic stroke: Recent developments on novel immunomodulatory approaches. *Eur J Pharmacol* 833: 531–544, 2018.

358. Sherpa LY, Deji, Stigum H, Chongsuvivatwong V, Thelle DS, and Bjertness E. Obesity in Tibetans aged 30-70 living at different altitudes under the North and South faces of Mt. Everest. *Int J Environ Res Public Health* 7: 1670–1680, 2010.

359. Shih VF-S, Tsui R, Caldwell A, and Hoffmann A. A single NFκB system for both canonical and non-canonical signaling. *Cell Res* 21: 86–102, 2011.

360. Shin MK, Drager LF, Yao Q, Bevans-Fonti S, Yoo DY, Jun JC, Aja S, Bhanot S, and Polotsky VY. Metabolic Consequences of High-Fat Diet Are Attenuated by Suppression of HIF-1α. *PLoS One* 7: 1–10, 2012.

361. Siemieniuk RAC, Chu DK, Kim LHY, Güell-Rous MR, Alhazzani W, Soccal PM, Karanicolas PJ, Farhoumand PD, Siemieniuk JLK, Satia I, Irusen EM, Refaat MM, Stephen Mikita J, Smith M, Cohen DN, Vandvik PO, Agoritsas T, Lytvyn L, and Guyatt GH. Oxygen therapy for acutely ill medical patients: A clinical practice guideline. *BMJ* 363: 1–10, 2018.

362. Sies H and Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. *Nat Rev Mol Cell Biol* 21: 363–383, 2020.

363. Silva AM and Oliveira PJ. Evaluation of Respiration with Clark-Type Electrode in Isolated Mitochondria and Permeabilized Animal Cells. In: *Methods in Molecular Biology*. vol. 1782, 2018, pp. 7–29.

364. Sjöberg F and Singer M. The medical use of oxygen: A time for critical reappraisal. *J Intern Med* 274: 505–528, 2013.

365. Snow JB, Kitzis V, Norton CE, Torres SN, Johnson KD, Kanagy NL, Walker BR, and Resta TC. Differential effects of chronic hypoxia and intermittent hypocapnic and eucapnic hypoxia on pulmonary vasoreactivity. *J Appl Physiol* 104: 110–118, 2008.

366. Sommer N, Alebrahimdehkordi N, Pak O, Knoepp F, Strielkov I, Scheibe S, Dufour E, Andjelković A, Sydykov A, Saraji A, Petrovic A, Quanz K, Hecker M, Kumar M, Wahl J, Kraut S, Seeger W, Schermuly RT, Ghofrani HA, Ramser K, Braun T, Jacobs HT, Weissmann N, and Szibor M. Bypassing mitochondrial complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. *Sci Adv* 6: eaba0694, 2020.

367. Soni S and Padwad YS. HIF-1 in cancer therapy: two decade long story of a transcription factor. *Acta Oncol (Madr)* 56: 503–515, 2017.

368. Spindel ON, World C, and Berk BC. Thioredoxin interacting protein: Redox dependent and independent regulatory mechanisms. *Antioxidants Redox Signal* 16: 587–596, 2012.

369. Stamati K, Mudera V, and Cheema U. Evolution of oxygen utilization in multicellular organisms and implications for cell signalling in tissue engineering. *J Tissue Eng* 2: 1–12, 2011.

370. Steegenga WT, Boekschoten M V, Lute C, Hooiveld GJ, de Groot PJ, Morris TJ, Teschendorff AE, Butcher LM, Beck S, and Müller M. Genome-wide age-related changes in DNA methylation and gene expression in human PBMCs. *Age (Omaha)* 36: 9648, 2014.

371. Straznicky NE, Lambert EA, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, Masuo K, Chopra R, Sari CI, Dixon JB, Tilbrook AJ, and Lambert GW. The effects of dietary weight loss with or without exercise training on liver enzymes in obese metabolic syndrome subjects. *Diabetes, Obes Metab* 14: 139–148, 2012.

372. Stuart Wood I, Wang B, Lorente-Cebrián S, and Trayhurn P. Hypoxia increases expression of selective facilitative glucose transporters (GLUT) and 2-deoxy-d-glucose uptake in human adipocytes. *Biochem Biophys Res Commun* 361: 468–473, 2007.

373. Sun K, Halberg N, Khan M, Magalang UJ, and Scherer PE. Selective Inhibition of HIF1α Ameliorates Adipose Tissue Dysfunction. *Mol Cell Biol* 33: 904–917, 2012.

374. Swartz HM. Using EPR to Measure a Critical but Often Unmeasured Component of Oxidative Damage: Oxygen. *Antioxidants Redox Signal* 6: 677–686, 2004.

375. Szibor M, Dhandapani PK, Dufour E, Holmström KM, Zhuang Y, Salwig I, Wittig I, Heidler J, Gizatullina Z, Gainutdinov T, Fuchs H, Gailus-Durner V, Hrabê De Angelis M, Nandania J, Velagapudi V, Wietelmann A, Rustin P, Gellerich FN, Jacobs HT, and Braun T. Broad AOX expression in a genetically tractable

mouse model does not disturb normal physiology. *DMM Dis Model Mech* 10: 163–171, 2017.

376. Taniyama Y and Griendling KK. Reactive Oxygen Species in the Vasculature. *Hypertension* 42: 1075–1081, 2003.

377. Thalmann S and Meier CA. Local adipose tissue depots as cardiovascular risk factors. *Cardiovasc Res* 75: 690–701, 2007.

378. The Lancet Public Health. Tackling obesity seriously: the time has come. *Lancet Public Heal* 3: e153, 2018.

379. Thiele RH. Subcellular Energetics and Metabolism. *Anesth Analg* 124: 1872–1885, 2017.

380. Tibbles PM and Edelsberg JS. Hyperbaric-Oxygen Therapy. *N Engl J Med* 334: 1642–1648, 1996.

381. Togeiro SM, Carneiro G, Ribeiro Filho FF, Zanella MT, Santos-Silva R, Taddei JA, Bittencourt LRA, and Tufik S. Consequences of obstructive sleep apnea on metabolic profile: A Population-Based Survey. *Obesity* 21: 847–851, 2013.

382. Toyama T, Seki R, Kasama S, Isobe N, Sakurai S, Adachi H, Hoshizaki H, Oshima S, and Taniguchi K. Effectiveness of Nocturnal Home Oxygen Therapy to Improve Exercise Capacity, Cardiac Function and Cardiac Sympathetic Nerve Activity in Patients With Chronic Heart Failure and Central Sleep Apnea. *Circ J* 73: 299–304, 2009.

383. Trayhurn P. Hypoxia and Adipose Tissue Function and Dysfunction in Obesity. *Physiol Rev* 93: 1–21, 2013.

384. Trayhurn P. Hypoxia and adipocyte physiology: implications for adipose tissue dysfunction in obesity. *Annu Rev Nutr* 34: 207–236, 2014.

385. Trayhurn P. Oxygen – the forgotten nutrient. *J Nutr Sci* 6: e47, 2017.

386. Trayhurn P. Oxygen—A Critical, but Overlooked, Nutrient. *Front Nutr* 6, 2019.

387. Trayhurn P and Alomar SY. Oxygen deprivation and the cellular response to hypoxia in adipocytes - Perspectives on white and brown adipose tissues in obesity. *Front Endocrinol (Lausanne)* 6: 1–8, 2015.

388. Trayhurn P, de Heredia FP, Wang B, de Oliveira C, Gonzalez-Muniesa P, and Wood IS. Cellular Hypoxia: a Key Modulator of Adipocyte Function in Obesity? *Adipobiology* 1: 19–26, 2009.

389. Treins C, Giorgetti-Peraldi S, Murdaca J, Semenza GL, and Van Obberghen E. Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway. *J Biol Chem* 277: 27975–27981, 2002.

390. Trzepizur W, Boursier J, Mansour Y, Le Vaillant M, Chollet S, Pigeanne T, Bizieux-Thaminy A, Humeau MP, Alizon C, Goupil F, Meslier N, Priou P, Calès P, Gagnadoux F, Person C, Molinier O, Paris A, Caby I, Bellier M, Langelot-Richard M, Leclair-Visonneau L, Jaffre S, Corne F, de la Tranchade MN, Rouault B,

Racineux JL, Gosselin C, and Pelletier-Fleury N. Association Between Severity of Obstructive Sleep Apnea and Blood Markers of Liver Injury. *Clin Gastroenterol Hepatol* 14: 1657–1661, 2016.

391. Tuomilehto H, Seppä J, and Uusitupa M. Obesity and obstructive sleep apnea - Clinical significance of weight loss. *Sleep Med Rev* 17: 321–329, 2013.

392. Turcot V, Tchernof A, Deshaies Y, Perusse L, Belisle A, Marceau S, Biron S, Lescelleur O, Biertho L, and Vohl MC. LINE-1 methylation in visceral adipose tissue of severely obese individuals is associated with metabolic syndrome status and related phenotypes. *Clin Epigenetics* 4: 10, 2012.

393. Ulrich C, Toriola A, Koepl L, Sandifer T, Poole E, Duggan C, McTiernan A, and Issa J-PJ. Metabolic, hormonal and immunological associations with global DNA methylation among postmenopausal women. *Epigenetics* 7: 1020–1028, 2012.

394. Urdampilleta A, Gonzalez-Muniesa P, Portillo M, and Martinez J. Usefulness of combining intermittent hypoxia and physical exercise in the treatment of obesity. *J Physiol Biochem* 68: 289, 2012.

395. Valdes S, Maldonado-Araque C, Garcia-Torres F, Goday A, Bosch-Comas A, Bordiu E, Calle-Pascual A, Carmena R, Casamitjana R, Castano L, Castell C, Catala M, Delgado E, Franch J, Gaztambide S, Girbes J, Gomis R, Gutierrez G, Lopez-Alba A, Martinez-Larrad M, Menendez E, Mora-Peces I, Ortega E, Pascual-Manich G, Serrano-Rios M, Urrutia I, Vazquez JA, Vendrell J, Soriguer F, and Rojo-Martinez G. Ambient temperature and prevalence of obesity in the Spanish population: The Di@bet.es study. *Obesity (Silver Spring)* 22: 2328–2332, 2014.

396. Valtin H. "Drink at least eight glasses of water a day." Really? Is there scientific evidence for "8 × 8"? *Am J Physiol Integr Comp Physiol* 283: R993–R1004, 2002.

397. Valverde G, Zhou H, Lippold S, de Filippo C, Tang K, Lopez Herraez D, Li J, and Stoneking M. A novel candidate region for genetic adaptation to high altitude in Andean populations. *PLoS One* 10: e0125444, 2015.

398. van Uden P, Kenneth NS, and Rocha S. Regulation of hypoxia-inducible factor-1α by NF-κB. *Biochem J* 412: 477–484, 2008.

399. Varela-Guruceaga M, Milagro FI, Martínez JA, and de Miguel C. Effect of hypoxia on caveolae-related protein expression and insulin signaling in adipocytes. *Mol Cell Endocrinol*, 2018.

400. Vats P, Ray K, Majumadar D, Amitabh, Joseph DA, Bayen S, Akunov A, Sarbaev A, and Singh SB. Changes in cardiovascular functions, lipid profile, and body composition at high altitude in two different ethnic groups. *High Alt Med Biol* 14: 45–52, 2013.

401. Villanueva C and Kross RD. Antioxidant-Induced Stress. *Int J Mol Sci* 13: 2091–2109, 2012.

402. Vink RG, Roumans NJ, Cajlakovic M, Cleutjens JPM, Boekschoten M V, Fazelzadeh P, Vogel MAA, Blaak

EE, Mariman EC, van Baak MA, and Goossens GH. Diet-induced weight loss decreases adipose tissue oxygen tension with parallel changes in adipose tissue phenotype and insulin sensitivity in overweight humans. *Int J Obes* 41: 722–728, 2017.

403. Vinnakota KC, Cha CY, Rorsman P, Balaban RS, La Gerche A, Wade-Martins R, Beard DA, and Jeneson JAL. Improving the physiological realism of experimental models. *Interface Focus* 6: 20150076, 2016.

404. Viollet S, Monot C, and Cristofari G. L1 retrotransposition: The snap-velcro model and its consequences. *Mob Genet Elements* 4: e28907, 2014.

405. Voss JD, Allison DB, Webber BJ, Otto JL, and Clark LL. Lower obesity rate during residence at high altitude among a military population with frequent migration: a quasi experimental model for investigating spatial causation. *PLoS One* 9: e93493, 2014.

406. Voss JD, Masuoka P, Webber BJ, Scher AI, and Atkinson RL. Association of elevation, urbanization and ambient temperature with obesity prevalence in the United States. *Int J Obes (Lond)* 37: 1407–1412, 2013.

407. Wang GL, Jiang BH, Rue EA, and Semenza GL. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. *Proc Natl Acad Sci U S A* 92: 5510–4, 1995.

408. Wang GL and Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. *Proc Natl Acad Sci U S A* 90: 4304–8, 1993.

409. Wang Y, Branicky R, Noë A, and Hekimi S. Superoxide dismutases: Dual roles in controlling ROS damage and regulating ROS signaling. *J Cell Biol* 217: 1915–1928, 2018.

410. Wegner A, Meiser J, Weindl D, and Hiller K. How metabolites modulate metabolic flux. *Curr Opin Biotechnol* 34: 16–22, 2015.

411. Weichhart T, Hengstschläger M, and Linke M. Regulation of innate immune cell function by mTOR. *Nat Rev Immunol* 15: 599–614, 2015.

412. West JB. Commuting to high altitude: value of oxygen enrichment of room air. *High Alt Med Biol* 3: 223–235, 2002.

413. WESTRA J, BROUWER E, BOS R, POSTHUMUS MD, DOORNBOS-VAN DER MEER B, KALLENBERG CGM, and LIMBURG PC. Regulation of Cytokine-Induced HIF-1 Expression in Rheumatoid Synovial Fibroblasts. *Ann N Y Acad Sci* 1108: 340–348, 2007.

414. Wiesner S, Haufe S, Engeli S, Mutschler H, Haas U, Luft FC, and Jordan J. Influences of normobaric hypoxia training on physical fitness and metabolic risk markers in overweight to obese subjects. *Obesity* 18: 116–120, 2010.

415. Wilms B, Ernst B, Thurnheer M, Weisser B, and Schultes B. Correction factors for the calculation of metabolic equivalents (MET) in overweight to extremely obese subjects. *Int J Obes (Lond)* 38: 1383–1387, 2014.

416. Wilson JL, Burchell J, and Grimshaw MJ. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1. *Cancer Res* 66: 11802–7, 2006.

417. Wilson PW, D'Agostino RB, Parise H, Sullivan L, and Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. *Circulation* 112: 3066–3072, 2005.

418. Wolfbeis OS. Luminescent sensing and imaging of oxygen: Fierce competition to the Clark electrode. *BioEssays* 37: 921–928, 2015.

419. Wong RW and Hagen T. Mechanistic target of rapamycin (mTOR) dependent regulation of thioredoxin interacting protein (TXNIP) transcription in hypoxia. *Biochem Biophys Res Commun* 433: 40–46, 2013.

420. Wood DM, Alsahaf H, Streete P, Dargan PI, and Jones AL. Fatality after deliberate ingestion of the pesticide rotenone: a case report. *Crit Care* 9: 280–284, 2005.

421. Woods SL and Whitelaw ML. Differential activities of murine single minded 1 (SIM1) and SIM2 on a hypoxic response element. Cross-talk between basic helix-loop-helix/per-Arnt-Sim homology transcription factors. *J Biol Chem* 277: 10236–43, 2002.

422. Woolcott OO, Ader M, and Bergman RN. Glucose Homeostasis During Short-term and Prolonged Exposure to High Altitudes. *Endocr Rev* 36: 149–173, 2015.

423. Woolcott OO, Castillo OA, Gutierrez C, Elashoff RM, Stefanovski D, and Bergman RN. Inverse association between diabetes and altitude: A cross-sectional study in the adult population of the United States. *Obesity* 22: 2080–2090, 2014.

424. Woolcott OO, Gutierrez C, Castillo OA, Elashoff RM, Stefanovski D, and Bergman RN. Inverse association between altitude and obesity: A prevalence study among andean and low-altitude adult individuals of Peru. *Obesity* 24: 929–937, 2016.

425. Wouters BG and Koritzinsky M. Hypoxia signalling through mTOR and the unfolded protein response in cancer. *Nat Rev Cancer* 8: 851–864, 2008.

426. Xia J, Ozaki I, Matsuhashi S, Kuwashiro T, Takahashi H, Anzai K, and Mizuta T. Mechanisms of PKC-Mediated Enhancement of HIF-1α Activity and its Inhibition by Vitamin K2 in Hepatocellular Carcinoma Cells. *Int J Mol Sci* 20: 1022, 2019.

427. Xiao W, Wang R-S, Handy DE, and Loscalzo J. NAD(H) and NADP(H) Redox Couples and Cellular Energy Metabolism. *Antioxid Redox Signal* 28: 251–272, 2018.

428. Xie S, Chen M, Yan B, He X, Chen X, and Li D. Identification of a Role for the PI3K/AKT/mTOR Signaling Pathway in Innate Immune Cells. *PLoS One* 9: e94496, 2014.

429. Xu C and Qu X. Cerium oxide nanoparticle: a remarkably versatile rare earth nanomaterial for biological applications. *NPG Asia Mater* 6: e90, 2014.

430. Xu D, Yao Y, Lu L, Costa M, and Dai W. Plk3 functions as an essential component of the hypoxia regulatory pathway by direct phosphorylation of HIF-1alpha. *J Biol Chem* 285: 38944–50, 2010.

431. Yang HK, Han K, Cho J-H, Yoon K-H, Cha B-Y, and Lee S-H. Ambient Temperature and Prevalence of Obesity: A Nationwide Population-Based Study in Korea. *PLoS One* 10: e0141724, 2015.

432. Yin J, Gao Z, He Q, Zhou D, Guo Z, and Ye J. Role of hypoxia in obesity-induced disorders of glucose and lipid metabolism in adipose tissue. *Am J Physiol Metab* 296: E333-42, 2009.

433. Yokel RA, Au TC, MacPhail R, Hardas SS, Butterfield DA, Sultana R, Goodman M, Tseng MT, Dan M, Haghnazar H, Unrine JM, Graham UM, Wu P, and Grulke EA. Distribution, elimination, and biopersistence to 90 days of a systemically introduced 30 nm ceria-engineered nanomaterial in rats. *Toxicol Sci* 127: 256–268, 2012.

434. Yu J, Li J, Zhang S, Xu X, Zheng M, Jiang G, and Li F. IGF-1 induces hypoxia-inducible factor 1α-mediated GLUT3 expression through PI3K/Akt/mTOR dependent pathways in PC12 cells. *Brain Res* 1430: 18–24, 2012.

435. Zhai J, Wu Y, Wang X, Cao Y, Xu K, Xu L, and Guo Y. Antioxidation of Cerium Oxide Nanoparticles to Several Series of Oxidative Damage Related to Type II Diabetes Mellitus In Vitro. *Med Sci Monit* 22: 3792–3797, 2016.

436. Zhang FF, Cardarelli R, Carroll J, Fulda KG, Kaur M, Gonzalez K, Vishwanatha JK, Santella RM, and Morabia A. Significant differences in global genomic DNA methylation by gender and race/ethnicity in peripheral blood. *Epigenetics* 6: 623–629, 2011.

437. Zhang FF, Santella RM, Wolff M, Kappil MA, Markowitz SB, and Morabia A. White blood cell global methylation and IL-6 promoter methylation in association with diet and lifestyle risk factors in a cancer-free population. *Epigenetics* 7: 606–614, 2012.

438. Zhang H, Akman HO, Smith ELP, Zhao J, Murphy-Ullrich JE, and Batuman OA. Cellular response to hypoxia involves signaling via Smad proteins. *Blood* 101: 2253–60, 2003.

439. Zhang H and Barralet JE. Mimicking oxygen delivery and waste removal functions of blood. *Adv Drug Deliv Rev* 122: 84–104, 2017.

440. Zhang J, Wang X, Vikash V, Ye Q, Wu D, Liu Y, and Dong W. ROS and ROS-Mediated Cellular Signaling. *Oxid Med Cell Longev* 2016, 2016.

441. Zhou Y, Li X-H, Zhang C-C, Wang M-J, Xue W-L, Wu D-D, Ma F-F, Li W-W, Tao B-B, and Zhu Y-C. Hydrogen sulfide promotes angiogenesis by downregulating miR-640 via the VEGFR2/mTOR pathway. *Am J Physiol Cell Physiol* 310: C305-17, 2016.

442. Ziello JE, Jovin IS, and Huang Y. Hypoxia-Inducible Factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. *Yale J Biol Med* 80: 51–60, 2007.

443. Zoncu R, Efeyan A, and Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol* 12: 21–35, 2011.

List of Abbreviations

ABCB1, adenosine triphosphate binding cassette subfamily B member 1

ABCB1, adenosine triphosphate binding cassette subfamily B member 1

ABCG2, adenosine triphosphate binding cassette subfamily G member 2 (Junior blood group)

ACAN, aggrecan

ADIPOQ, adiponectin

ADM, adrenomedullin

ADORA2A, adenosine A2a receptor

AFP, alpha fetoprotein

AGR2, anterior gradient 2, protein disulphide isomerase family member

AGT, angiotensinogen

AHA/NHLBI, American heart association/national heart, lung, and blood institute

AK1, adenylate kinase 1

AKT1, Akt serine/threonine kinase 1

ANG, angiogenin

ANGPT1, angiopoietin 1

ANGPT2, angiopoietin 2

ANGPTL4, angiopoietin like 4

AOX, alternative oxidase

APEX1, apurinic/apyrimidinic endodeoxyribonuclease 1

APOE, apolipoprotein E

AQP4, aquaporin 4

ARG1, arginase 1

ATA, atmosphere absolute

ATF6, activating transcription factor 6

ATG5, autophagy protein 5

ATP, adenosine triphosphate

ATPIII, adult treatment panel III

AURKA, aurora kinase A

AXL, Axl receptor tyrosine kinase

BAT, brown adipose tissue

BAX, B-cell lymphoma 2 associated X, apoptosis regulator

BBC3, B-cell lymphoma 2 binding component 3

BCL2, B-cell lymphoma 2 apoptosis regulator

BCL2L1, B-cell lymphoma 2 like 1

BHLHE40, basic helix-loop-helix family member e40

BHLHE41, basic helix-loop-helix family member e41

BIRC5, baculoviral inhibition of apoptosis repeat containing 5

BMI, body mass index

BNIP3, B-cell lymphoma 2 interacting protein 3

BNIP3L, B-cell lymphoma 2 interacting protein 3 like

BSG, basigin (Ok blood group)

BTG2, B-cell translocation gene family anti-proliferation factor 2

CA9, carbonic anhydrase 9

CALCRL, calcitonin receptor like receptor

CASP3, caspase 3

CBP p300, cAMP response element-binding (CREB)-binding protein and p300 complex

CCL2, C-C motif chemokine ligand 2 (MCP-1)

CCL4, C-C motif chemokine ligand 4

CCL5, C-C motif chemokine ligand 5

CCN1, cellular communication network factor 1

CCN2, cellular communication network factor 2

CCND1, cyclin D1

CCR1, C-C motif chemokine receptor 1

CCR5, C-C motif chemokine receptor 5 (gene/pseudogene)

CD44, cluster of differentiation 44 molecule (Indian blood group)

CDH1, cadherin 1

CDH2, cadherin 2

CDKN1A, cyclin dependent kinase inhibitor 1A

CEBPA, CCAAT enhancer binding protein alpha

CeO$_2$ NPs, Cerium oxide nanoparticles

c-HDL, high-density lipoprotein cholesterol levels

c-LDL, low-density lipoprotein cholesterol

COL1A1, collagen type I alpha 1 chain

COMMD1, copper metabolism domain containing 1

COPS5, constitutive photomorphogenesis 9 signalosome subunit 5

COX4I2, cytochrome c oxidase subunit 4I2

CP, ceruloplasmin

CPEB2, cytoplasmic polyadenylation element binding protein 2

CPT1A, carnitine palmitoyltransferase 1A

CREB3L1, cyclic adenosine monophosphate responsive element binding protein 3 like 1

CTNNB1, catenin beta 1

CTSD, cathepsin D

CUL2, cullin 2

CVD, cardiovascular disease

CXCL12, C-X-C motif chemokine ligand 12

CXCL8, C-X-C motif chemokine ligand 8

CXCR1, C-X-C motif chemokine receptor 1

CXCR2, C-X-C motif chemokine receptor 2

CXCR4, C-X-C motif chemokine receptor 4

CYBB, cytochrome b-245 beta chain

DCUN1D1, defective in cullin neddylation 1 domain containing 1

DDIT4, DNA damage inducible transcript 4

DLL4, delta like canonical Notch ligand 4

DNAJB1, DnaJ heat shock protein family (Hsp40) member B1

E2F7, E2 factor transcription factor 7

E2F8, E2 factor transcription factor 8

EAF2, eleven-nineteen lysine-rich leukemia associated factor 2

ECHM, European Committee for Hyperbaric Medicine

EDN1, endothelin 1

EDN2, endothelin 2

EDNRB, endothelin receptor type B

EGLN1, endoglucanase-9 family hypoxia inducible factor 1

EGLN3, endoglucanase-9 family hypoxia inducible factor 3

EIF4EBP1, eukaryotic translation initiation factor 4E binding protein 1

ELL, elongation factor for RNA polymerase II

ELOB, elongin B

ELOC, elongin C
ENTPD1, ectonucleoside triphosphate diphosphohydrolase 1
EPO, erythropoietin
EPR, electron paramagnetic resonance spectroscopy
ER, endoplasmic reticulum
ESR1, estrogen receptor 1
ESR2, estrogen receptor 2
ESRRG, estrogen related receptor gamma
EZH2, enhancer of zeste 2 polycomb repressive complex 2 subunit
FABP4, fatty acid binding protein 4
FAM162A, family with sequence similarity 162 member A
FASN, fatty acid synthase
FBXO32, F-box protein 32
FBXW7, F-box and tryptophan-aspartic acid (WD) repeat domain containing 7
FDA, Food and Drug Administration
FGF2, fibroblast growth factor 2
FIH, factor inhibiting HIF-1
FLT1, macrophage colony-stimulating factor related tyrosine kinase 1
FLT4, macrophage colony-stimulating factor related tyrosine kinase 4
FN1, fibronectin 1
FOXM1, forkhead box M1
FOXO3, forkhead box O3
FOXP3, Forkhead box P3
FTCD, formimidoyltransferase cyclodeaminase
GAPDH, glyceraldehyde-3-phosphate dehydrogenase
GO, Gene Ontology
HBOT, hyperbaric oxygen therapy
HDAC2, histone deacetylase 2
HDAC4, histone deacetylase 4
HDAC5, histone deacetylase 5
HDAC6, histone deacetylase 6
HDAC7, histone deacetylase 7
HEXIM1, hexamthylene bis-acetamide inducible 1 (HEXIM) - positive transcription elongation factor b (p-TEFb) complex subunit 1
HEY1, hes related family basic helix-loop-helix transcription factor with YRPW motif 1
HEY2, hes related family basic helix-loop-helix transcription factor with YRPW motif 2
HIF-1, hypoxia inducible factor-1
HIF1AN, hypoxia inducible factor 1 subunit alpha inhibitor
HIF3A, hypoxia inducible factor 3 subunit alpha
HK2, hexokinase 2
HMOX1, heme oxygenase 1
HNF4A, hepatocyte nuclear factor 4 alpha
HOTAIR, homeobox transcript antisense RNA
HR, hazard ratio
HRE, hypoxia-response element
HSP90AA1, heat shock protein 90 alpha family class A member 1
HSP90AB1, heat shock protein 90 alpha family class B member 1
HSPA1L, heat shock protein family A (Hsp70) member 1 like

HSPA4, heat shock protein family A (Hsp70) member 4
HSPA8, heat shock protein family A (Hsp70) member 8
IC, inferred by curator
ICAM-1, intracellular cell adhesion molecule 1
ID1, inhibitor of DNA binding 1, helix-loop-helix protein
IDA, inferred from direct assay
IDF, international diabetes federation
IDF-AHA/NHLBI, harmonized definition of IDF and AHA/NHLBI
IEP, inferred from expression pattern
IFNG, interferon gamma
IGF2, insulin like growth factor 2
IGFBP1, insulin like growth factor binding protein 1
IGFBP3, insulin like growth factor binding protein 3
IH, intermittent hypoxia
IKBKG, inhibitor of nuclear factor kappa B kinase regulatory subunit gamma
IL10, interleukin 10
IL1B, interleukin 1 beta (IL-1β)
IL22, interleukin 22
IL4, interleukin 4
IL6, interleukin 6 (IL-6)
IMP, inferred from mutant phenotype
INHA, inhibin subunit alpha
IRE1, inositol requiring enzyme 1
IRF1, interferon regulatory factor 1
JAG1, jagged canonical Notch ligand 1
JUN, Jun proto-oncogene, activating protein-1 transcription factor subunit
KAT2B, lysine acetyltransferase 2B
KAT5, lysine acetyltransferase 5
KDM3A, lysine demethylase 3A
KDM4B, lysine demethylase 4B
KDM4C, lysine demethylase 4C
KDR, kinase insert domain receptor
KITLG, Kit ligand
KLK3, kallikrein related peptidase 3
KRT18, keratin 18
KRT19, keratin 19
LDHA, lactate dehydrogenase A
LEP, leptin
LGALS3, galectin 3
LIFR, leukemia inhibitory factor receptor subunit alpha
LINC01139, long intergenic non-protein coding RNA 1139
LINE1, long interspersed nucleotide element 1
LOX, lysyl oxidase
LOXL2, lysyl oxidase like 2
LRRK2, leucine rich repeat kinase 2
MAFG, musculoaponeurotic fibrosarcoma basic leucine-zipper domain transcription factor G
MALAT1, metastasis associated lung adenocarcinoma transcript 1
MAPK1, mitogen-activated protein kinase 1
MAPK3, mitogen-activated protein kinase 3
MCL1, myeloid cell leukemia sequence 1 apoptosis regulator, B-cell lymphoma 2 family member
MCM3, minichromosome maintenance complex component 3

MCM7, minichromosome maintenance complex component 7

MCP-1, monocyte chemotactic protein 1

MDK, midkine

MDM2, mouse double minute 2 proto-oncogene

MetS, metabolic syndrome

MHO, metabolically healthy obese

MIF, macrophage migration inhibitory factor

MIR, microRNA

mmHg, millimeters of mercury

MMP1, matrix metallopeptidase 1

MMP14, matrix metallopeptidase 14

MMP2, matrix metallopeptidase 2

MMP28, matrix metallopeptidase 28

MMP3, matrix metallopeptidase 3

MMP9, matrix metallopeptidase 9

MRI, magnetic resonance imaging

MTA1, metastasis associated 1

MTDH, metadherin

MTF1, metal regulatory transcription factor 1

mTOR, mechanistic target of rapamycin kinase

MXI1, myelocytomatosis associated factor X interactor 1, dimerization protein

MYC, myelocytomatosis proto-oncogene, basic helix-loop-helix transcription factor

NAA10, N(alpha)-acetyltransferase 10, NatA catalytic subunit

NAFLD, non-alcoholic fatty liver disease

NBN, nibrin

NBOT, normobaric oxygen therapy

NCOA1, nuclear receptor coactivator 1

NCOA2, nuclear receptor coactivator 2

NDN, necdin, melanoma-associated antigen gene family member

NDRG1, N- myelocytomatosis downstream regulated 1

NEDD8, neural precursor cell expressed, developmentally down-regulated 8 ubiquitin like modifier

NEUROG3, neurogenin 3

NFAT5, nuclear factor of activated T cells 5

NFKB1, nuclear factor kappa B (NF-κB) subunit 1

NO, nitric oxide

NOS, nitric oxide synthase

NOS2, nitric oxide synthase 2

NOS3, nitric oxide synthase 3

NOTCH1, notch receptor 1

NOTCH3, notch receptor 3

NOTCH4, notch receptor 4

NOX4, NADPH oxidase 4

NQO1, NAD(P)H quinone dehydrogenase 1

NT5E, 5'-nucleotidase ecto

OCLN, occludin

OR, odds ratio

OS9, OS9 endoplasmic reticulum lectin

OTUD7B, OTU deubiquitinase 7B

PAI-1, plasminogen activator inhibitor 1

PARP1, poly (adenosine diphosphate-ribose) polymerase 1

PCGF2, polycomb group ring finger 2

PCNA, proliferating cell nuclear antigen

PDGFC, platelet derived growth factor C

PDK1, pyruvate dehydrogenase kinase I

PER1, period circadian regulator 1

PERK, protein kinase R-like like endoplasmic reticulum kinase

PET, positron emission tomography

PFKP, phosphofructokinase, platelet

PGF, placental growth factor

PGK1, phosphoglycerate kinase 1

PHD, prolyl hydroxylase domain proteins

PI3K, phosphatidylinositol 3-kinase

PIAS3, protein inhibitor of activated signal transducer and activator of transcription 3

PIN1, peptidylprolyl cis/trans isomerase, never in mitosis gene-interacting 1

PKC, protein kinase C

PKM, pyruvate kinase M1/2

PLAU, plasminogen activator, urokinase

PLAUR, plasminogen activator, urokinase receptor

PLD1, phospholipase D1

PLD2, phospholipase D2

PLIN2, perilipin 2

PNMT, phenylethanolamine N-methyltransferase

pO_2, oxygen partial pressure

POU5F1, pituitary specific 1-octamer transcription factor-uncoordinated 86 (Pit-Oct-Unc) class 5 homeobox 1

PPARA, peroxisome proliferator activated receptor alpha

PPARG, peroxisome proliferator activated receptor gamma

PRKDC, protein kinase, DNA-activated, catalytic subunit

PRKN, parkin ring-between-ring E3 ubiquitin protein ligase

PROM1, prominin 1

PROX1, prospero homeobox 1

PSMA7, proteasome 20S subunit alpha 7

PSMC3, proteasome 26S subunit, ATPase 3

PSMD10, proteasome 26S subunit, non-ATPase 10

PTBP1, polypyrimidine tract binding protein 1

PTGS2, prostaglandin-endoperoxide synthase 2

PTK6, protein tyrosine kinase 6

PTPRB, protein tyrosine phosphatase receptor type B

RAC1, Rac family small guanosine triphosphatase 1

RACGAP1, Rac guanosine triphosphatase activating protein 1

RACK1, receptor for activated C kinase 1

RB1, RB transcriptional corepressor 1

RBM38, RNA binding motif protein 38

RELA, reticuloendotheliosis viral homolog A proto-oncogene, NF-kB subunit

RHBDF1, rhomboid 5 homolog 1

RHOBTB3, Rho related broad complex-tramtrack-bric a brac domain containing 3

RNS, reactive nitrogen species

RORC, retinoic acid-related related orphan receptor C

ROS, reactive oxygen species

RPTOR, regulatory associated protein of MTOR complex 1

RUNX1, Runt-related transcription factor family transcription factor 1

RWDD3, ring finger and tryptophan-aspartic acid (WD) domain containing 3

SAHS, sleep apnea-hypopnea syndrome

SAT1, spermidine/spermine N1-acetyltransferase 1

SAT2, spermidine/spermine N1-acetyltransferase family member 2
SENP1, SUMO specific peptidase 1
SENP3, SUMO specific peptidase 3
SERPINE1, serpin family E member 1 (PAI-1)
SHC1, Schmidt-Ruppin homology 2 domain-containing adaptor protein 1
SLC2A1, solute carrier family 2 member 1
SLC2A3, solute carrier family 2 member 3
SLC2A4, solute carrier family 2 member 4
SMAD3, mothers against decapentaplegic homolog family member 3
SMAD4, mothers against decapentaplegic homolog family member 4
SMARCA2, switch/sucrose non-fermentable related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
SMARCA4, switch/sucrose non-fermentable related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4
SNAI1, snail family transcriptional repressor 1
SNAI2, snail family transcriptional repressor 2
sO_2, saturation of oxygen
SOCS3, suppressor of cytokine signaling 3
SOD2, superoxide dismutase 2
SOST, sclerostin
SOX2, sex-determining region Y-box transcription factor 2
SOX9, sex-determining region Y-box transcription factor 9
SP1, specificity protein 1 transcription factor
SP7, specificity protein 7 transcription factor
SPHK1, sphingosine kinase 1
SQSTM1, sequestosome 1
SRC, SRC proto-oncogene, non-receptor tyrosine kinase
SREBF1, sterol regulatory element binding transcription factor 1
STAT3, signal transducer and activator of transcription 3
STC1, stanniocalcin 1
STIM1, stromal interaction molecule 1
STUB1, stress-induced-phosphoprotein 1 homology and U-box containing protein 1
SUMO1, small ubiquitin like modifier 1
T2D, type 2 diabetes
TAS, traceable author statement
TERT, telomerase reverse transcriptase
TET1, tet methylcytosine dioxygenase 1
TF, transcription factor
TFRC, transferrin receptor
TGFB1, transforming growth factor beta 1
TGM2, transglutaminase 2
TH, tyrosine hydroxylase
TIMP1, tissue inhibitor of metallopeptidase 1
TLR4, toll like receptor 4
TNF, tumor necrosis factor
TNFAIP6, tumor necrosis factor alpha induced protein 6
TNFRSF12A, tumor necrosis factor receptor superfamily member 12A
TNF-α, tumor necrosis factor alpha
TP53, tumor protein p53
TP63, tumor protein p63
TRAF6, tumor necrosis factor receptor associated factor 6

TRIM63, tripartite motif containing 63
TSGA10, testis specific 10
TWIST1, twist family basic helix-loop-helix transcription factor 1
TXNIP, thioredoxin interacting protein
Ub, ubiquitin
UBXN7, ubiquitin regulatory X domain protein 7
UCPs, uncoupling proteins
UPR, unfolded protein response
USP19, ubiquitin specific peptidase 19
USP20, ubiquitin specific peptidase 20
USP7, ubiquitin specific peptidase 7
VCAM-1, vascular cell adhesion molecule 1
VEGFA, vascular endothelial growth factor A
VEGFC, vascular endothelial growth factor C
VHL, von Hippel-Lindau tumor suppressor
VHLL, von Hippel-Lindau like
VIM, vimentin
VLDLR, very low-density lipoprotein receptor
WAT, white adipose tissue
WC, waist circumference
WWOX, tryptophan-tryptophan (WW) domain containing oxidoreductase
XPO1, exportin 1
ZC3H12A, zinc finger cysteine-cysteine-cysteine-histidine (CCCH) type containing 12A
ZEB1, zinc finger E-box binding homeobox 1
ZEB2, zinc finger E-box binding homeobox 2
ZNF197, zinc finger protein 197